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Introduction 
 
Acute Kidney injury (AKI) in the ICU set up has been a rising problem with the past few 
decades showing a change in the profile of patients getting admitted to the ICU‘s. They 
are more severely ill as compared to 10-15 years back and often have multiple organ 
involvement and associated sepsis and other comorbidities.[1] AKI in ICU has  a 
significant effect on patient outcome and recently has been equated to other two 
syndromes of Severe sepsis and Acute lung injury that determine patient prognosis in 
ICU. 
An understanding of  factors affecting renal recovery might improve overall outcome. 
The current study is undertaken to study the profile of AKI and factors which predict its 
outcome in the ICU set up. Recently a number of novel biomarkers have not only been 
shown to predict AKI but also its outcome. Neutrophil gelatinase associated Lipocalin is 
one such biomarker that has also been called as the Renal Troponin due to its excellent 
performance in predicting AKI prior to rise of serum creatinine but also in predicting 
outcome. Few studies from South India have validated the utility of NGAL in AKI 
.Present study also aims to look into the utility of urinary NGAL in predicting AKI 
outcomes as a Pilot project in view of the costs incurred. 
The Medical Intensive Care unit in CMC, Vellore has a monthly average admission rate 
of 80-90 patients from all medical specialties. Hence the study is undertaken with an 
intention to look into the causes of AKI as well as into the factors affecting the renal 
2 
 
outcome in the ICU of this tertiary care hospital of South India. Simultaneously the study 
of urinary NGAL in predicting the outcomes shall be done as a PILOT project.  
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REVIEW OF LITERATURE 
 
ACUTE KIDNEY INJURY: Acute kidney injury (AKI) is one of the common clinical 
syndromes in Nephrology with a host of underlying etiologic factors. It commonly occurs 
in the in-hospital setting with increasing frequency as the admission place changes to the 
Intensive Care Unit (ICU) 
[1]
. It causes significant morbidity including increased length 
of hospital stay, progression  to Chronic kidney disease (CKD) as well as being 
associated with in hospital mortality.
[1,2]
 In fact with the requirement of Renal 
replacement therapy mortality rates can go as high as 60%. In the ICU setting AKI has 
emerged as a powerful clinical syndrome besides Sepsis and Acute Respiratory Distress 
Syndrome (ARDS) to predict patient outcome 
[3]
. 
DEFINITIONS OF ACUTE KIDNEY INJURY: 
Until 2004 there was no standard definition of Acute Kidney Injury .In fact when applied 
to the same cohort, different definitions resulted in different incidence and prevalence 
rates for AKI thus adding to confusion. It was in 2004 when Acute Dialysis Quality 
Initiative (ADQI) group came up with the RIFLE classification of AKI with an aim to 
standardize its definition for clinical and research purposes 
[4]
. As depicted in Fig.1 
RIFLE includes three AKI severity classes i.e. ‗Risk‘, ‗Injury‘ and ‗Failure‘ in increasing 
order of severity and two outcome classes : ‗Loss‘ and ‗End stage kidney disease‘.  The 
severity classes are based on changes in urine output, serum creatinine and Glomerular 
Filtration rate with the worst of the variables defining severity. The outcome classes Loss 
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and End stage kidney disease depend on the duration of loss of renal function viz. 4 
weeks and 3 months respectively. 
 
 
Fig.1 RIFLE Criteria for Acute Kidney Injury (from Reference 4) 
GFR: Glomerular Filtration RATE; ESRD: End Stage Renal Disease 
AKIN STAGING : While the RIFLE criteria was a significant  advancement towards 
standardization of the definition of Acute Kidney Injury ,it had certain drawbacks .First, 
the Risk class definition of increase in serum creatinine to 1.5 times of baseline was 
considered as too conservative as even smaller increases in creatinine were shown to 
affect outcome. In fact Chertow et al 
[5]
 showed that even 0.3 mg% increase in serum 
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creatinine was associated with increased morbidity and mortality. Second the RIFLE 
classification does not consider the requirement of Renal Replacement Therapy (RRT) in 
defining the severity of AKI. Considering these drawbacks, in 2007 the AKIN group 
suggested modifications in the RIFLE classification. These included broadening the 
‗Risk‘ class to include an increase in serum creatinine of 0.3 mg% occurring within 48 
hours and adding the need of RRT irrespective of serum creatinine to the ‗Failure‘ class. 
Finally the RIFLE classes Risk‘, ‗Injury‘ and ‗Failure‘ have been replaced by AKIN 
stage 1, 2 and 3 respectively 
6
 [Table 1], In fact modification of ‗Risk‘ class has increased 
the sensitivity for diagnosis of AKI further. 
 
Table 1: AKIN vs.  RIFLE Classification 
KDIGO STAGING: In 2012 Kidney Disease: Improving Global Outcomes introduced 
the composite AKI staging which is almost the same as the AKIN staging except for in 
patients younger than 18 years a decrease in GFR to less than 35ml/min/1.73m
2
 is also 
included in the stage 3 
[7]
 . 
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EPIDEMIOLOGY OF ACUTE KIDNEY INJURY: Since the first publication of 
RIFLE in 2004 numerous studies have been done in different settings to validate it. 
Accordingly the incidence of AKI varies depending on the cohort studied. Table 2 
illustrates the incidence of AKI in different patient population along with the maximum 
RIFLE class attained in each. 
First Author 
(Reference No.) 
Cohort Patients 
n 
AKI% Risk% Injury% Failure, 
% 
        Cruz (20) ICU 2,164 10.8 2.1 3.8 4.9 
Heringlakeb (29) CS-ICU 29,623 16 9 5 2 
Uchinob (10) Hospital 20,126 18 9.1 5.2 3.7 
Kuitunen (30) CS-ICU 813 19.1 10.8 3.4 4.9 
Lopes (16) BMT 140 33.5 13.5 10 14.3 
Lopesb (15) Burn 126 35.7 14.3 8.7 12.7 
Ostermann (22) ICU 41,972 35.8 17.2 11 7.6 
O’Riordan (13) Liver Tx 359 35.9 NA 10.9 25.1 
Lopes (17) Sepsis 182 37.4 6.0 11.5 19.8 
Lopes (28) HIV-ICU 97 47.4 12.4 9.6 25.8 
Ahlstrom (31) ICU 685 52.0 25.5 15.2 11.2 
Guitard (14) Liver Tx 94 63.8 NA 41.5 22.3 
Hoste (27) ICU 5,383 67 12.4 26.5 28.1 
Lin (32) ICU-ECMO 46 78.2 15.2 39.1 23.9 
Abosaif (21) ICU-AKI 183 86.9 32.8 30.6 23.5 
Bell (33) ICU-RRT 207 90.8 8.2 24.2 58.5 
Maccariello (34) ICU-RRT 214 100 25.0 27.0 48.0 
 
Table 2: Different Studies in Acute Kidney Injury 
ICU, intensive care unit; CS-ICU, cardiac surgery ICU; BMT, bone marrow transplant patients; 
Burn, burn unit patients; Liver Tx, liver transplant patients; NA, not assessed; HIV-ICU, patients 
with human immunodeficiency virus infection admitted to the ICU; ICU-ECMO, ICU patients 
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treated with extracorporeal membrane oxygenation for acute renal failure; ICU-AKI,ICU 
patients with AKI;ICU-RRT,ICU patients requiring renal replacement therapy 
 
Population based studies : Few studies have looked at the incidence of AKI in general 
population .One of such studies was done in Northern Scotland by Ali et al 
[8]
 using the 
RIFLE criteria and included a population base of 523,390.The annual incidence of AKI 
was 2147 per million population with sepsis being the commonest etiology of renal 
dysfunction. Another study done by Hsu et al 
[9]
 in Northern California from 1996-2003, 
reported the incidence of AKI to be 4085 per million population (pmp) although it used 
somewhat different criteria than RIFLE for diagnosis of AKI. They also reported an 
increase in the use of acute RRT from 195 pmp/yr in the period 1996–1997 to 295 
pmp/yr in the period 2002–2003.  
Hospital Studies: Uchino et al. 
[10]
 studied AKI using the RIFLE classification in a 
cohort of 20,126 patients admitted to a teaching hospital for more than 24 hour over a 
period of 3 years. Overall incidence of AKI was 18%. The maximum RIFLE class 
achieved was Risk in 9.1%, Injury in 5.2 % and Failure in 3.7% of patients. In 
multivariate logistic regression analysis ‗R‘ carried an odds ratio of in- hospital mortality 
of 2.5, class ‗I‘ of 5.4, and class ‗F‘ of 10.1. Similarly Fang et al. [11] studied 176,155 
patients from a tertiary hospital in Eastern China over a 4 year period. Using the AKIN 
staging the incidence of AKI was 3.19% and higher AKIN stages had greater association 
with in –hospital mortality. Recently Murugan et al [12] in a prospective multicenter trial 
estimated  the incidence of AKI using the RIFLE criteria in 1836 patients  admitted  in 28 
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different hospitals in USA for Community Acquired  Pneumonia .Overall incidence of 
AKI was 34% , with 58% occurring in patients with severe sepsis and 24% in patients 
without severe sepsis. 
O‘Riordan et al  [13] and Guitard at al [14]  studied the incidence of AKI in Liver transplant 
in 359 and 94 patients and found the incidence to be 35.9% and 63.8% respectively .Of 
note all the patients were in RIFLE class I or F. 
Lopes et al has studied AKI in specific population groups including Burns 
[15]
, Bone 
marrow Transplant 
[16]
 and Sepsis 
[17]
 and has found the incidence to be 33.5%, 35.7%, 
37.4% respectively. 
Acute Kidney Injury In ICU Set Up: 
In different ICU studies AKI occurs in up to two thirds of patients. Approximately, 5% of 
ICU patients develop AKI severe enough to require RRT 
[18, 19]
. Also mortality in these 
ICU patients requiring RRT is heavily dependent on other organ dysfunction and 
comorbidities amounting to 50-60% 
[18,19]
. 
NEiPHROS-AKI was a prospective multicenter AKI study, carried out in 19 ICUs in 
northeastern Italy over a 3-month period 
[20]. 
Using the RIFLE criteria, 234 (10.8%) out of 
2164 patients developed AKI of which 19% were in R class, 35% in I, and 46% were in F 
class. Overall mortality was 20%, 29.3% and 49.5% in R, I and F class respectively 
.Similarly in 2005, Abosaif et al 
[21] 
found that RIFLE class predicted mortality: 74.5% in 
Failure, 50% in Injury and 38.3% in Risk category. 
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 Ostermann and Chang 
[22]
 in 2007 retrospectively analyzed the incidence of AKI in 
41,972 patients admitted between 1989 and 1999 to 22 ICUs in UK and Germany. AKI 
as defined by the creatinine criteria of RIFLE, occurred in 15, 019 (35.8%) patients. Of 
these AKI patients 7207 (48 %) were in R, 4613 (30.7%) had I, and 3199 (21.3%) were 
in F class. In - hospital mortality rates were highest in F (56.8%), followed by I (45.6%) 
and 20.9% in R class as compared to 8.4% in non AKI patients .Similarly, from January 
2000 to December 2005, Bagshaw et al.
 [23]
, studied AKI by RIFLE using only creatinine 
in 120, 123 patients admitted in 57 intensive care units across Australia for at least 24 h 
period. Category wise AKI class was R in 16.3%, I in 13.6%, and F in 6.3% patients, 
cumulating to 36.1% overall. In  multivariate analysis, each RIFLE category had  
independent  association  with hospital mortality with  Odds Ratio of  1.58, 2.54, and  
3.22 for R,I,F classes respectively. 
In one of the largest ICU studies Thakar et al. 
[24]
 retrospectively analysed the data of 191 
ICU‘S comprising 323, 395 patients across USA and used the AKIN staging (Modified 
RIFLE) for the diagnosis of AKI. He found the overall incidence of AKI to be 22% 
(71,486 patients) after excluding many cases of community acquired AKI. Of these 
17.5% had stage 1, 2.4% had Stage 2 and 2% had stage 3 AKI. The odds ratio of 
mortality after adjusting for severity of illness was 2.2 for stage 1, 6.1 for stage 2 and 8.6 
for stage 3. In 2009 Joannidis et al. 
[25]
 compared the RIFLE criteria with and without the 
modification of 0.3 mg/dl increase in serum creatinine within 48 h as proposed by AKIN 
in 16,784 patients admitted across 330 ICUs in Austria. They found that using the AKIN 
staging resulted in increase in AKI incidence by 3% while at the same time they also 
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showed that by excluding the patients who met the RIFLE criteria of 1.5 times increase in 
serum creatinine compared to baseline but did not exhibit an increase of serum creatinine 
of at least 0.3 mg/dl over 48 h or less, they would not be able to diagnose AKI in 10% of 
patients. Thus a combination of both change from baseline creatinine and an absolute rise 
of 0.3 mg% in less than 48 hours is the best combination for the diagnosis of AKI. 
NEFROINT 
[26]
 was a prospective observational multicenter study to evaluate the profile 
of AKI in incident patients admitted to 10 ICU‘s in Italy. It studied 576 patients (25 
patients with End stage renal disease were excluded) of which 42.7% (246) had AKI at 
admission while 133 developed new AKI during stay. RIFLE-initial class was Risk in 
54.1% (205) patients, Injury in 26.1% (99) and Failure in 19.8% (75) patients.AKI further 
progressed to higher class in 30.8% (114) patients. Forty eight patients (8.3%) required 
renal replacement therapy of which significant patients had sepsis. AKI patients had 
significantly higher mortality (28.8%) vs. non AKI patients (8.1%) with 
P<0.001.Complete renal recovery occurred in 205(59.7%) of AKI, partial recovery in 51 
(13.5%) while 103 (27.2%) did not recover renal function at ICU discharge/ death. In 
another study Hoste et al 
[27]
 studied 5383 critically ill patients in 7 ICU‘s with AKI 
occurring in 67% of them. Of these 12% achieved a maximum of R class, 27% reached I 
class and 28% attained F class. Patients with no AKI had 5.5% mortality while those with 
R had 8.8%, I had 11.4% and those in F class had 26.3% mortality rate.  
Lopes et al studied 97 HIV patients admitted to ICU and found the incidence of AKI to 
be 47.4%, not much different from general population 
[28]
. Heringlake et al 
[29]
 and 
Kuitunen et al 
[30]
 studied AKI in Cardiac Surgery ICU in 29,623 and 813 patients with 
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incidence of 16% and 19.1% respectively .In both studies more than 50% of patients were 
in Risk class (Table 2)  
 
 
RECOVERY FROM ACUTE KIDNEY INJURY: 
 
 
Besides the increased risk of in hospital mortality, AKI can cause persistent loss of renal 
function including a dialysis dependant state. This includes both development of 
progressive Chronic Kidney Disease (CKD) and increased rate of progression of pre-
existing CKD. (Fig.2)  
Recent studies have associated AKI survival to subsequent CKD or end-stage renal 
disease (ESRD) development.  Chawla et al 
[35]
 assessed 11,589 patients for AKI and 
evaluated the risk for CKD progression in AKI patients. A total of 5351 patients had AKI 
of which14% (728) entered stage 4 CKD. Patients with more severe AKI especially those 
requiring RRT and subsequently recovered were at higher risk for progression to CKD. 
 
Acute Renal Failure Trials Network (ATN) study of intensity of dialytic support only 
53% of surviving patients had complete or partial recovery of renal function by 28 days 
while by day 60 only 16% could be discharged off dialysis 
[36]
. It is possible that the renal 
recovery in AKI survivors is dependent on a number of factors including the underlying 
etiology of kidney disease and AKI severity (Fig. 2).  
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Fig .2: Renal outcomes of AKI (Amdur R etal KI 2009)  
 
A large study by Ishani et al in 2009 in U.S. cohort of medical beneficiaries (age ≥ 67 
years) without prior evidence of CKD found that an AKI episode resulted in an eightfold 
increased risk of CKD G5.
37
 To estimate the risk of progressive CKD in known CKD 
population Hsu et al studied patients with preadmission baseline eGFR < 45 ml/min/1.73 
m
2
 and found that those who developed an episode of AKI requiring dialysis had very 
high risk of developing CKD 5G
[38]
.Another U.S. study evaluated the risk of progressive 
CKD after AKI in patients with a baseline eGFR more than 45 ml/min/1.73 m
2 [39]
. 
Patients who required dialytic support for AKI but became dialysis independent within 30 
days of discharge had a 28-fold increased risk of progressing to CKD G4 or worse. 
 
Coca SG et al in 2012 did a meta-analysis of 13 cohort AKI studies and reported 
that the cumulative incidences of CKD and CKD G5 after Acute Kidney Injury were 25.8 
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and 8.6 per 100 person-years, respectively 
[40]
. Pooled adjusted relative risks in these AKI 
patients for subsequent CKD and CKD G5 compared to those without AKI were 8.8 
(95% CI 3.1-25.5) and 3.1 (95% CI 1.9- 5.0) respectively. Depending on the severity of 
AKI older adults have 2-13 times the risk for development of ESRD after a single 
episode of AKI. Also after a single AKI episode the annual absolute risk of CKD G5 
ranges from 0.6% to 1.2% in those who experience mild AKI and up to 9% in those with 
preexisting CKD 
[41].
 
Age, unmeasured comorbidity and fraility might be confounding factors for the 
association between AKI and subsequent CKD. However CKD development has been 
linked to AKI in pediatric patients who are generally not affected by these confounding 
factors. In this regard126 critically ill pediatric AKI survivors who had completely 
recovered their kidney function were studied 
[42]
 .This study revealed that overall 10% 
patients developed CKD over 3 years of follow up (albumin to creatinine ratio less than 
or equal to 30mg/g or eGFR less than 60ml /min /m2) .Also it is noteworthy that 38% of 
cohort had mildly decreased eGFR 60-90 ml/min and 3.2% had hypertension both being 
risk factors for future CKD)  
Link between AKI and CKD: Incomplete repair or pathological transition of the repair 
process can result in renal non recovery and progression to CKD. Nath et al 
[43]
 in his 
work on rats showed that repeated cutaneous glycerol injection would result in recurrent 
AKI with reversible decrease in creatinine clearance but subsequently it led to  slow loss 
of renal reserve with increased Transforming Growth Factor β (TGF β) expression and 
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interstitial fibrosis. In ischemia/ reperfusion and cisplatin induced AKI in rats chronic 
reductions in concentrating ability have been observed even after single episode of insult 
[44,45]
 .Following a single bout of ischemia reperfusion in rats the proximal tubule repair 
usually is complete by 4-6 weeks while increased expression of TGF β also normalizes in 
4 weeks .In case where the repair process is delayed to 16-40 weeks ,features of CKD 
including proteinuria, interstitial fibrosis manifest along with secondary increase in TGF 
β [45].In case AKI occurs in the presence of reduced renal mass there are greater chances 
of incomplete repair and progression to CKD 
[38]
 . Patgulanan et al. did morphometric 
analysis of ultra thin serial sections in AKI patients to show that an AKI episode resulted 
in nephron dropout which was presumed to be due to loss of contact between the tubule 
and the parent glomerulus 
[46]
. AKI in reduced renal mass models has been associated 
with dilated tubules which contain differentiated  cells expressing profibrotic factors like 
Platelet Derived Growth Factor which may initially help in physiological repair, however 
with sustained expression may cause fibrosis 
[47]
.Also renal vascular epithelium repair 
seems to be reduced as compared to tubular epithelium as capillary microfill experiments 
show a reduction in capillary density of 30-50% most pronounced in inner stripe of outer 
medulla following recovery from AKI
[45]
.The role of inflammatory cells and immune 
system in progression to CKD has been demonstrated in several studies. Forbes et al, 
showed that blockade of ED-1 positive macrophages by treating with an endothelin 
antagonist early decreased the late complications of acute kidney injury 
[48]
. The role for 
T cells in CKD development was demonstrated by Chandrakar et al, who showed that 
blockade of the B7 costimulatory pathway after one month of unilateral I/R injury with 
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reduced renal mass, resulted in a substantial decrease in progressive proteinuria and 
interstitial fibrosis with recovery occurring in up to 6 months
 [49]
. Burne-Taney et al 
demonstrated that splenocytes from injured mice transferred to non injured recipients 
promoted proteinuria within 12 weeks of injury, suggesting the role of immune responses 
in CKD progression 
[50]
. Finally, in a study by Pechman et al, it was shown that blocking 
the lymphocyte function with mycophenolate mofetil from 5 weeks after recovery from 
I/R injury prevented the building up of hypertension and interstitial fibrosis associated 
with elevated sodium intake 
[51]
 
 
PATHOPHYSIOLOGY OFACUTE KIDNEY INJURY: 
Pathophysiologic classification of AKI broadly divides it into pre-renal, intrinsic renal 
and post renal mechanisms. 
[52]
 While post renal AKI accounts for about 10% of cases 
secondary to intrinsic or extrinsic obstruction the remainder is taken care of by Pre-renal 
and intrinsic renal mechanisms. Post renal AKI is characterized by acute obstruction to 
urinary flow and rise in intratubular pressures and decrease in glomerular filtration rate 
(GFR). It can also cause reduction in renal blood flow as well as trigger inflammatory 
processes resulting in further reduction in GFR 
[53, 54]
. Pre-renal AKI occurs secondary to 
a reduction in renal perfusion and a fall in Glomerular filtration rate thus resulting in a 
‗functional‘ decline without any histopathological evidence of renal injury [55].The 
various causes of such decline include decreased cardiac output ,systemic vasodilation 
,volume depletion ,afferent arteriolar constriction and efferent arteriolar vasodilation. 
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Since the tubular function is maintained hence conservation of Sodium and water results 
to maintain intravascular volume and renal perfusion in low urinary sodium and high 
urine osmolarities 
[56]
. 
As compared to the pre-renal AKI, intrinsic AKI may affect different compartments of 
the kidney which include the glomeruli, tubules, interstitium and the vascular 
compartment. Hence it may manifest in acute tubular necrosis or intratubular obstruction, 
acute interstitial nephritis ,acute glomerulonephritis or may involve the renal 
micro/macrovasculature causing thrombotic microangiopathies and vascular 
thrombosis/embolism respectively.  
Most cases of hospital acquired AKI are secondary to Acute tubular necrosis (ATN) 
which occurs due to ischemic or nephrotoxic insult. The etiology of AKI in the ICU is 
again a combination of decreased renal perfusion, sepsis and nephrotoxic agents resulting 
in prerenal injury to frank ATN. The S3 segment of proximal tubule followed by the 
medullary thick ascending limb of  loop of Henle have been considered to be the most 
important sites of injury in ATN. This is due to the chronic low Oxygen concentration in 
the medullary region as well as high metabolic rates 
[57]
. 
Clinically ATN can be divided into initiation, extension, maintenance, and recovery 
phases. The initiation phase starts with reduction in renal blood flow severe enough to 
cause ATP depletion and cellular injury. This sublethal injury of tubular cells results in 
disruption of the filamentous actin architecture 
[58]
 and translocation of the Sodium-
Potassium ATPase and other proteins from basolateral to apical surface .As a result there 
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is decreased salt and water retention in the proximal tubule which activates the 
tubuloglomerular feedback. Recent evidence shows that  there may be activation of 
epithelial and possibly endothelial cells resulting in upregulation of inflammatory 
cytokines 
[59]
. 
The extension phase is characterized by continued hypoxia and inflammatory response 
both of which are predominant at the corticomedullary junction and outer medulla. The 
cells in the outer medulla predominantly continue to undergo injury and death via 
necrosis and apoptosis 
[60]
 .Cellular detachment leads to intraluminal cast formation and 
obstruction resulting in further fall in GFR. There is further amplification of the 
inflammatory cascade due to production of chemokines and cytokines 
[61]
.Fig .3 shows 
the interplay between inflammation and   tubular and vascular injury in the extension 
phase of ATN.  
During the maintenance phase to maintain tubular integrity the cells undergo 
proliferation, migration, apoptosis and repair with the GFR remaining stable at a level 
determined by the severity of initial insult. Lin et al. used a transgenic cre-lox approach 
to label renal tubular epithelial cells and track their progeny following I/R injury. They 
were able to demonstrate that Bromodeoxyuridine (BrdU) localized in Cre-induced 
transgene expressing dedifferentiated cells signifying that the source of regenerating cells 
could be  resident, non lethally injured tubular epithelial cells 
[62]
.Other groups have also 
confirmed that the primary source of regenerating new cells in repair is sublethally 
damaged  renal tubule cells 
[63]
. Slowly the maintenance phase gives way to recovery 
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phase characterized by increased cell proliferation , restoration of polarity and return of 
organ function 
[64]
. 
 
 
 
 
 
 
 
 
 
 
 
Fig.3: Extension Phase of AKI 
The hemodynamic changes in ATN consist of sustained increase in renal vascular 
resistance caused by number of mediators including increased sympathetic nervous 
system activity 
[65]
, ,endothelin
 [66]
, Platelet activated factor
[67]
, adenosine as well as direct 
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injury to vessel walls leading to decreased vascular responsiveness. In fact alteration in 
vascular responsiveness  has been shown to occur even one week after recovery from 
Ischemia/Reperfusion injury when total renal blood flow has returned to normal
[68]
.  
Role of inflammatory cells and cytokines: A variety of cells including neutrophils , T 
cells, macrophages and dendritic cells have been implicated to play important role in the 
inflammatory cascade in AKI. While the role of neutrophils is unclear as they are not 
prominent in biopsies of patients with AKI, recent evidence suggests that T cells may 
play important role in ATN. While T cells are found in the medullary vasa recta region in 
animal models of AKI and also in biopsies of patients with AKI 
[69, 70] 
, there role in 
pathogenesis has been supported by studies which have demonstrated that depleting the T 
cells using the antibody neutralizing 
[71] 
or genetic approach 
[72] 
results in reducing the I/R 
injury. However the fact that CD4+ T cells are cells of antigen specific adaptive 
immunity and require 2-4 days of processing puts their role in ATN to question. 
However, natural killer T (NKT) cells express both the TCR (T cell receptor) and the 
marker NK1.1 thus representing a unique smaller  subset of CD4+ cells. These cells are 
capable of producing large amounts of cytokines both Th1 type such as Interferon γ 
(IFNγ) and Tumor Necrosis Factor (TNF) or Th2 type like  IL-4 and IL13. In fact , NKT 
producing IFNγ are present within 3 hours in the post-I/R kidney injury [73]. Blockade of 
activation of  NKT cell with the anti-CD1d mAb or NKT cell depletion with anti-NK1.1 
mAb in wild-type mice, or use of iNKT cell deficient mice (Jα18−/−) inhibits the 
accumulation of IFN-γ-producing neutrophils after I/R injury  and  prevented AKI [73]. 
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Macrophages are found to  infiltrate the injured kidney within 1 hour of ischemia 
reperfusion in response to expression of fractalkine (CX3CL1) by injured endothelial 
cells which is  a potent chemoattractant and adhesion molecule for them . Blockade of 
CX3C receptor-1 on macrophages by specific antibody reduces the severity AKI in mice 
[74]
. In the setting of Acute kidney injury, macrophages are most abundant during the 
repair  phase  with a  distinct population, referred to as M2 macrophages being active . 
These M2 macrophages secrete anti inflammatory cytokines  such as IL-10 and TGF-β 
and  may help  in tissue repair by secreting potential trophic growth factors  and 
angiogenic factors 
[75,76]
.  Wang et al., demonstrated that ex vivo programming of 
macrophages to  an M2 phenotype would  reduce chronic renal inflammation 
[77]
.Also 
administration of macrophages during the repair phase of ATN hastens recovery 
[78]
.Dendritic cell activation has been suggested to lead to TNF α production in ischemic 
AKI 
[79]
, but there are few functional studies to support it. That dendritic cells may have a 
protective role was supported by a study which showed that ablation of CD11c + 
Dendritic cells increased the sensitivity to cisplatin induced injury 
[80]
. 
Both tubular cells and leukocytes produce a number of inflammatory mediators to 
promote postitive feedback loop of inflammation producing further kidney injury. 
Tubular epithelial cells can  produce IL-1, IL-6, IL-8, TNF-α, Monocyte Chemotactant 
Protein 1 (MCP-1) ,Transforming   Growth factor β  (TGF-β), ENA78, RANTES and 
fractalkines  while leukocytes may produce IL-1, IL8, MCP-1, reactive oxygen species 
(ROS) and eicosanoids.  
[81]
. 
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IL1β is a chemotactic factor that recruits leukocytes to injured areas.The blockade 
of IL-1β decreases the infiltration of neutrophils following ischemic injury, but does not 
improve the consequent  loss of renal function 
[82]
. IL-18 is increased in AKI and is 
considered an early biomarker of acute tubular  injury 
[83]
.Injured proximal tubules 
activate the expression of IL-6 on infiltrating macrophages and IL6 is elevated in mice 
following AKI 
[84]
. Other systems which have been implicated in AKI are the Toll like 
receptors (TLR‘s) and complement system. In fact TLR 4 is expressed on capillaries of 
vasa recta within 4 hours of ischemia reperfusion injury with secondary increases 
occurring within 24 hours on the proximal tubular cells 
[85]
.There is evidence that 
alternate pathway of complement may be active during ischemia reperfusion 
[86]
 with C3a 
and C5a contributing to injury with activation of apoptosis and impairment of recovery 
responses. 
Repair and Regeneration: 
Renal stress respone: Acute kidney injury activates cytoprotective pathways which can 
be broadly divided in three broad categories: 
1.Heme Oxygenase (Inducible HO) and anti-oxidant genes: Heme Oxygenase is the 
rate limiting step in the heme catabolism producing biliverdin, iron, and carbon monoxide 
(CO).The enzyme occurs in two isoforms : the inducible HO1 and the constitutive 
HO2
[87]
.In animal studies HO1 is rapidly induced following nephrotoxic 
[88]
, glycerol-
rhabdomyolysis 
[89]
, and  ischemia/reperfusion 
[90]
 injury.HO-1 reduces oxidant stress by 
degradation of heme , a toxic pro-oxidant, as well as by generation of bilrubin which is a 
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peroxy radical scavenger that prevents lipid peroxidation. Besides CO can  have potential  
vasodilatory effect resulting in improvement of renal blood flow.   Mice with a HO-1 null 
mutation suffer  from more severe AKI and have  increased mortality in ischemia 
reperfusion 
[91]
, glycerol 
[89]
, and LPS 
[92]
 AKI models while induction of HO-1 
expression  by viral delivery of HO-1 gene or by intravenous infusion of hemoglobin  
prior to injury protects from AKI
 [93, 94]
. 
2. Heat shock proteins (HSP): They belong to multigene protein family ranging in size 
from 10–150 kDa and are found in all major cellular compartments [95].The protective 
properties of HSPs is widely ascribed to their activity as "molecular chaperones," which 
are considered to aid in the assembly and repair of newly synthesized or degenerated  
proteins 
[96]
. An important  role of HSPs is linked to the stabilization and revival of 
cytoskeletal structure following AKI. During recovery after ischemia/reperfusion , the 
Na, K, ATPase gets reincorporated in the  cytoskeleton which is aided by HSP 70 
[97]
. 
Emami et al in one of the earliest reports suggested the role of  heat shock proteins in 
protection from acute kidney injury. Exposure to transient minimal ischemia of 15 min 
resulted in upregulation of  heat shock protein72 (HSP72), which resulted in protection 
from later ischemia/reperfusion injury 
[98]
.Since then many more  members HSP family 
have been found. It is now clear that not only HSP 72, but also other members including 
HSP10, HSP 25/27, HSP47, HSP70 , HSP90 as well as αβ-crystallin play important role 
in diverse models of AKI including ischemia reperfusion, cisplatin toxicity and unilateral 
ureteral obstruction 
[99, 100, 101]
. 
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HSP-chaperone activity may also aid in cytoprotection by manipulation of the 
biochemical pathways leading toward cell death i.e. apoptosis or necrosis 
[102]
. Heat 
Shock Proteins may also be having role as cellular antioxidants. In MDCK cells exposed 
to oxidant stress, HSP-70 controlled the superoxide production by increasing the activity 
of enzymes  glutathione reductase and glutathione peroxidase  
[103]
. 
Recently, Kim et al., confirmed that increased expression of HSP-27 in proximal tubules 
conferred protection  from ischemic AKI 
[104]
. Also higher basal levels of HSP-72 and 
HSP-27 have been  reported in Brown Norway rats which are more resistant to AKI than 
the commonly utilized Sprague Dawley rats 
[105]
 . 
3. Stress activated protein kinases : Cellular stress results in activation of  two related 
parts of the mitogen-activated protein kinase (MAPKs) signaling pathway- the 
extracellular-regulated protein kinases (ERKs), and the stress-activated protein kinase 
(SAPK), also identified as Jun N-terminal kinase (JNK and p38).Both of these kinases 
are activated in response to tubular stress /AKI 
[106]
 .Following  ischemic injury JNK 
activation occurs in both proximal and distal tubule 
[107]
while its down regulation has 
been shown to reduce the peroxide induced proximal tubular injury 
[108]
. Inhibition of 
ERK activity in proximal tubules of opossum has been shown to block apoptosis 
associated with cisplatin nephrotoxicity 
[109]
.  
Regeneration:  
The restoration of structure and function of proximal tubule following renal injury 
requires complex and coordinated cellular activity and not just proliferation 
[110] 
. The 
newly proliferative cells are dedifferentiated, smaller in size with loss of epithelial 
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markers and express vimentin 
[111]
. They rapidly realign the denuded proximal tubule 
basement membrane, undergo hyperplasia and differentiation with a decrease in cellular 
number per cross sectional area towards normal. Concomitantly there  is a wave of 
apoptosis that restores tubular cell density to normal and  may last from between one 
week to several months of recovery 
[112]
. 
Proximal tubule cells can proliferate on exposure to a variety of mitogens like 
insulin-like growth factor-I (IGF-1)
 [113]
, epidermal growth factor (EGF) 
[114]
, hepatocyte 
growth factor (HGF) 
[115] 
, and fibroblast growth factor  (FGFs) 
[116]
.However not all of 
them have been shown to play important roles in the regeneration process. While IGF 1 
has been shown to be expressed in regenerating tubular cells 
[117]
 and HGF levels are 
increased in urine of AKI patients 
[118]
, there is no definite evidence of their role in renal 
repair. Recently Bone Morphogenic Protein 7 (BMP 7) has been found to have significant 
potential of stimulating tubular cell proliferation and also acting as anti- fibrotic agent in 
CKD. Exogenously administered BMP 7 helps in early recovery from AKI 
[119].
 
EGF is expression is decreased in multiple forms of AKI 
[120]
, still it is expressed and may 
help in renal repair. Also different members of  FGF family are increased after the 
induction of ischemic and nephrotoxic injury. 
Discovered by Serhan et al 
[121]
 Resolvins (Rv) and protectins (PD) are two novel families 
of n–3 fatty acid docosahexaenoic acid metabolites shown to play important role in 
resolution of AKI. Mouse kidneys have been shown to produce D series resolvins (RvDs) 
and PD1 
[122]
 in response to I/R injury .Also the administration of these metabolites  prior 
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to and after the injury has been shown to have protective effect on kidney by decreasing 
inflammation as well as it reduces the resulting interstitial fibrosis. 
 
BIO MARKERS OF ACUTE KIDNEY INJURY: 
Biomarker-Definition: As per the NIH Biomarkers Definitions Working Group, a 
biological marker (biomarker) is defined as ―A characteristic that is measured objectively 
and is evaluated as an indicator of normal biological processes, pathogenic processes or 
pharmacologic responses to a therapeutic intervention.‖ [123] 
Characteristics of Ideal Biomarker: Although it is impossible to find a biomarker with 
all the characteristics as mentioned below still an approximation of them is desired 
[123,124]
. 
(1)It should be non invasive and easily measured, inexpensive and produce quick results;  
(2) It should be tested from easily available sources, such as blood or urine; 
 (3) The biomarker should have a high sensitivity, allowing for early detection of disease, 
without overlap between diseased patients and healthy controls;  
(4) It should have a high specificity, being greatly affected in the diseased samples 
specifically and not by comorbid conditions; 
 (5) The levels of biomarker should change quickly in response to treatment; 
 (6) Biomarker levels should help in risk stratification and provide prognostic information 
regarding outcomes;  
 (7) It should be biologically plausible and should help to understand the disease 
mechanism 
26 
 
The receiver operating characteristic (ROC) curve depends on both sensitivity and 
specificity and the area under the ROC curve (AUC) for a biomarker at  specific cut off is 
a good measure of its validity. While an AUC of 1 means a perfect biomarker but it is not 
practically possible.An AUC of 0.75 represents a good biomarker while that of 0.9 is 
considered excellent for all practical purposes 
[124]
. 
Need for Biomarker in AKI: While serum creatinine and urine output have been 
established markers of renal damage since long time, serum creatinine cannot be 
considered as a sensitive/specific marker for AKI. This is because of the presence of a 
‗Window period‘ of 8- 48 hours when AKI continues without manifesting as increase in 
serum creatinine which occurs later only
[125]
 .In fact serum creatinine may show upward 
trend only once about 50% of renal function has been lost .Also the production of 
creatinine from muscle is decreased in AKI due  to sepsis, thus  rise in creatinine may not 
be according to decline in GFR 
[126]
.Besides several non-renal factors can affect 
creatinine levels  irrespective of renal function - age, gender, race, nutritional status, 
muscle  mass, infection, total parenteral nutrition and certain drugs. In fact trimethoprim, 
cimetidine and salicylates are known to alter the tubular secretion of creatinine causing 
changes in its level independent of GFR 
[127]
.Fig.4 shows the window period where novel 
biomarkers may have a potential role in early diagnosis and intervention. 
Novel  Biomarkers of AKI 
1. Interleukin 18: Interleukin 18 is a proinflammatory cytokine produced by variety of 
cells in the body including mononuclear cells , dendritic cells ,renal epithelial cells etc.It 
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has been implicated in the pathogenesis of a number of conditions including arthritis, 
ischemic AKI, Acute coronary syndrome and others. Caspase 1 is the enzyme which 
activates both IL-18 and IL-1 β [128]. In freshly isolated mice proximal tubules it was 
shown that hypoxic tubules expressed  high levels of IL-18 [129].Thereafter another 
study demonstrated increased urine IL 18 in mice with ischemic AKI than sham operated 
controls 
[128]
.Subsequently urine IL 18 was found to be raised in humans with ATN than  
normal controls, patients with prerenal azotemia, urinary tract infection nephrotic 
syndrome ,and chronic kidney disease.
[130]
 
A nested case control study was performed within the ARDS network trial to determine 
the utility of IL-18 in predicting AKI in ICU patients. Urine IL- 18 had an area under the 
receiver operated characteristic (ROC) curve of 0.73 as a  predictor of  AKI in the next 24 
hours thus establishing as a good biomarker 
[131]
. In a pediatric cohort of 137 children 
with an average age of 6.5 years (47% female) the peak IL-18 levels significantly 
correlated with the severity of AKI as defined by the pediatric RIFLE (pRIFLE) 
classification. Urinary IL-18 rose 2 days prior to significant increase in serum creatinine 
in critically ill non septic AKI patients and were independent predictor of mortality. 
Besides they were also increased in sepsis 
[132]
.In 55 children who underwent 
cardiopulmonary bypass urinary IL-18 started increasing at 4-6 hours of procedure in 
those who developed AKI. It peaked to almost 25 times at 12 hours and consistently 
remained elevated upto 48 hours post procedure. In comparison serum creatinine 
increased only 48-72 hours after the procedure in the AKI patients.
[133]
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Haiyan he et al studied  IL-18 in 180 patients who underwent coronary intervention and 
received low osmolal contrast. Contrast induced nephropathy (CIN) as defined by 
increase in serum creatinine by 0.5 mg% or ≥25% increase over baseline within 24-48 
hours of procedure occurred in 16 (8.9%) patients.IL-18 levels increased in these patients 
even after 2 hours of procedure though not significantly , but the rise became significant 
at 6,12,24 and 48 hours as compared to pre procedural levels. Serum creatinine did not 
show significant difference between pre procedure values and 24 hours after procedure. 
The area under the ROC curve for IL-18 for predicting CIN was 0.811. 
[134]
 
Recently in a meta-analysis of 18 studies,  IL-18 level predicted  AKI with a sensitivity 
and specificity of 0.58 and 0.75, respectively. Also the  area under the ROC curve for IL-
18 for predicting AKI was 0.70 (95% CI, 0.66-0.74)
[135]
. 
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Fig. 4: Timing Diagram of Acute Kidney injury (From Ref. 125) 
 
2. Kidney Injury Molecule 1: 
Kidney injury molecule 1 (KIM 1) is a recognized epithelial cell adhesion molecule 
which contains an immunoglobulin domain. In fact normal kidney expresses KIM 1 
mRNA and protein at a low level in but its levels increase rapidly in  ischemic AKI 
[136]
Urinary KIM 1 have been showed to be elevated significantly in both  cisplatin 
induced and ischemic AKI in rats.
[137]
 In a small study of 32 patients with various acute 
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and chronic kidney diseases, and eight normal controls urinary KIM 1 levels were 
significantly higher in patients with ischemic ATN as compared to other 
patients/controls.In all six patients with renal biopsy proven ATN there was widespread 
expression of KIM 1 in proximal tubule cells 
[138] 
.
 
In a study involving  90 patients 
undergoing cardiac surgery ,urinary KIM 1, N acetyl beta (D) glucosaminidase (NAG) 
and Neutrophil gelatinase associated lipocalin (NGAL) were measured immediately and 
3 hours post surgery. Thirty six patients (40%) had AKI within 72 h of surgery. The area 
under ROC curve for KIM 1 to predict AKI  immediately and 3 h after surgery was 0.68 
and 0.65 respectively. A combination of the three biomarkers, KIM 1, NAG and NGAL, 
improved the sensitivity for early detection of AKI at 0 and 3 hours of procedure to 0.75 
and 0.78 respectively 
[139]
. 
            In a meta-analysis of 11 studies involving a total of 2979 patients, urinary KIM-1 
had a sensitivity of 74.0% and a specificity of 86.0% for the diagnosis of AKI. The area 
under the ROC curve for KIM 1 to predict AKI was 0.86 (95% CI, 0.83–0.89). [140] 
3. Cystatin C:Cystatin C is produced by all nucleated cells of the body .It is a 
polypeptide containing 120 amino acid residues .Its completely reabsorbed in the 
proximal tubules and is not secreted anywhere in the nephron 
[141]
. 
In 127 patients undergoing cardiac catheterization, Artunc et al studied serum creatinine, 
serum cystatin C and the clearance of the iodinated contrast iopromide  (reference 
standard for GFR ). Serum cystatin C had a higher correlation (0.805) to the iopromide 
clearance compared to serum creatinine (0.652).Also serum cystatin C levels of more 
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than 1.3 mg/L confirmed renal failure with a sensitivity of 88%and 96% specificity as 
defined by an iopromide clearance of less than 80 mL/min/m2.
[142]
  
Rosenthal studied cystatin C and creatinine in live renal donors before and after 
uninephrectomy. Serum cystatin C rose 1 day after uninephrectomy as compared to 
serum creatinine that increased after 2 days of  procedure
[143]
 . Orlando et al studied 
Inulin, serum cystatin C and creatinine clearances in 36 patients with decompensated 
cirrhosis and 56 non cirrhotic controls .Plasma cystatin C and not serum creatinine or 
creatinine clearance was an accurate marker of GFR in the cirrhotic patients. In fact 
plasma creatinine  and calculated creatinine clearance, varied with the severity of the 
liver disease and did not correlate with GFR
[144]
. 
Cystatin C was compared to creatinine in detecting AKI as defined by the  the RIFLE 
classification in 85 high risk patients .Serum cystatin C rose by more than 50% at an 
average of 0.6 days earlier than the increase in serum creatinine thus concluding that 
serum cystatin C is a better marker for the detection of AKI than creatinine 
[145]
.To study 
the use of urinary cystatin C for the early identification of AKI, plasma and urine samples 
were collected from 72 adults undergoing elective cardiac surgery 
[146]
. While plasma 
NGAL and cystatin C levels did not predict  AKI within the first 6 h of procedure but  
urinary cystatin C and NGAL were elevated in 34 patients who later developed AKI, 
compared to patients with no AKI. With urinary Cystatin C  being the most useful at 6 
hours to predict AKI. 
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Thus it is possible that Cystatin C may be an ideal endogenous marker as all nucleated 
cells produce it at a constant rate, its levels are unaffected by changes in  height, gender, 
age and muscle mass, nutrition and is neither secreted nordegraded by renal tubules. In 
fact in Germany in 2002 ,at a multinational meeting it was concluded that cystatin C was 
equal if not superior marker of GFR than creatinine. It may actually be of benefit to use it 
as a marker in children ,elderly people and reduced muscle mass patients 
[147]
. 
 
4. Liver fatty acid binding protein (L-FABP): It acts as a carrier protein for fatty acids 
and other lipophilic substances like ecosanoids and retinoids .Some of the FABPs help in 
transportation of lipophilic molecules from outer cell membrane to intracellular receptors 
like PPAR and also in transportation of fatty acids between extra and intracellular 
membrane. 
In a model of Folic acid induced kidney injury in mice L FABP levels in both kidney and 
urine was found to have a major correlation with the degree of tubulointerstitial damage 
[148]
.In live related human renal transplants ,renal peritubular blood flow and ischemia 
time had a significant correlation with the urinary L-FABP levels 
[149]
. 
40 pediatric patients were assessed for urine L-FABP levels just before undergoing 
cardio-pulmonary bypass surgery .Following surgery 21 patients developed AKI . 
Enzyme linked immunosorbent assay analysis in these patients revealed increased L-
FABP levels of about 94 and 45 fold at 4 hrs and 12hrs, respectively which was 
confirmed by western blot analysis. This study showed urine L-FABP to be a sensitive 
and predictive early biomarker of AKI following cardiac surgery 
[150]
. 
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Further in a study of  80 critically ill patients it was shown that urine L-FABP levels were 
higher in patients with septic shock as compared to patients with severe sepsis alone 
[151]
. 
To summarise , urine L-FABP is increased in patients with AKI. Also, it is the urinary 
LFABP levels and not serum L-FABP levels that is increased in patients with septic 
shock. L-FABP is also a biomarker for progression of chronic kidney disease. 
5. IL-6 and IL-8:IL6 which is a proinflammatory cytokine plays an importrant role in 
immune response and haematopoesis .It is basically found in endothelium , macrophages 
and fibroblast . IL8 is also a proinflammatory cytokine .It functions by activating and 
recruiting the neutrophils .In a mouse model of AKI IL8, IL6 and IL12 levels were 
significantly raised early after onset of ischaemia. Serum and urine levels of IL 8 were 
highest after 3 hour of  induction of ischemia and before occurrence of significant rise in 
serum creatinine. There was a significant fall in the levels of IL1 , IL2,IL4 and IFN γ 
after AKI while IL 1b, IL 3, IL 5, IL 10, IL 12 (p70), IL 17, GM CSF and RANTES did 
not show any change as compared to no AKI group 
[152]
  . 
In renal allograft recipients, urine IL 8 was found to be markedly elevated in patients who 
had delayed graft function as compared to patients with immediate graft function 
[153]
.                                                                                      
In the PROWESS (Prospective Recombinant Human Activated Protein-C Worldwide 
Evaluation in Severe Sepsis) trial, of the 547 patients from the placebo group 127 
developed AKI . In a multivariable Cox regression model log IL 6 and APACHE II score 
were important predictors of AKI 
[154]
. 
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NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN (NGAL): 
 
NGAL, also known as Lipocalin 2/Siderocalin  is a 25 kDa glycosylated polypeptide 
member of lipocalin superfamily of proteins. Human NGAL is made up of 178 amino 
acid residues linked by a single disulfide bond and can exist as monomer with molecular 
weight (MW) of 25kDa ,homodimer with MW of 35kDa or as heterodimer complexed 
with Matrix Metalloproteinase 9 (MMP 9) 
[155]
. In neutrophils it is present chiefly as 
homodimer and  small percent occurs as monomer or heterodimer while renal epithelium 
secretes mainly monomers when under stress. 
[156,157]
.This is supported by the observation 
that patients with urinary tract infection have raised homodimeric NGAL while those 
with AKI have predominant monomeric molecule 
[157,158]
.  
NGAL has capacity to bind siderophores and thus is involved in iron traffic to and 
fro between cells. Because iron is important for bacterial proliferation and can also cause 
tissue injury by free radical generation , hence by sequestering iron NGAL can act as 
bacteriostatic agent as well as protect from inflammation associated injury 
[159,160]
.It has 
also been shown to promote iron dependant differentiation of mesenchymal progenitors 
into nephrons during renal development 
[161]
. 
NGAL is expressed at very low concentrations in other human tissue like trachea ,colon, 
lung, kidney etc. and its levels increase in stimulated epithelia due to inflammation 
[156]
.It 
is also expressed in adenomas and inflamed bowel epithelium
[162]
, adenocarcinoma 
breast
[163]
, urothelial cancers 
[164]
.Being a small peptide and due to resistance to protease 
35 
 
degradation NGAL is freely excreted in the urine both in free and complex form with 
MMP 9.Thus urinary levels correlate with plasma levels, but specifically high NGAL 
levels in urine can be found when released from ischemic tubules 
[165]
. While both urinary 
and plasma NGAL have been shown to be elevated in different forms of AKI including 
post cardio-pulmonary bypass, Contrast induced Nephropathy, critically ill patients etc. 
urinary NGAL may be better in characterizing AKI as has been suggested  by study by 
Mårtensson, Bell et al. They showed that mean plasma NGAL levels were more elevated 
in patients with sepsis than without sepsis irrespective of GFR. They studied peak levels 
of plasma NGAL (a) and urinary NGAL (b) in non-AKI patients (N=27) with SIRS, 
severe sepsis, and septic shock and in AKI patients with septic shock (N=18).Plasma 
NGAL (pNGAL) were elevated in all four groups as shown in Fig.5 and was not 
significantly different between Septic shock with and without AKI groups. Urinary 
NGAL (uNGAL) was less confounded by sepsis being significantly elevated in AKI 
patients with septic shock .It was good predictor of AKI in next 12 hours (AUC ROC of 
0.86) as compared to pNGAL with an area under ROC curve of only 0.67
 [166]
.  
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Fig.5 Urinary NGAL Vs. Plasma NGAL (from Reference 166) 
Study by Mishra et al showed that NGAL mRNA and protein was produced in cultured 
human proximal tubule cells within 1 hour of ATP depletion due to Ischemia/reperfusion 
injury. This confirmed that the source of urinary NGAL was kidney proximal tubule cells 
and not merely activated neutrophils which are found to accumulate in ischemic AKI at 
around 4 hours and peak at 12 hours of insult. Also these neutrophils have not been found 
to express the NGAL mRNA in the renal tissue 
[167]
. 
A large number of studies have analysed the utility of both plasma and urinary NGAL in 
post Cardiopulmonary bypass AKI in both children and adults. In children urine and 
plasma NGAL at 2 hours of surgery predicted AKI and plasma NGAL was also 
associated with the duration of AKI and mortality 
[168, 169]
.Similarly in adults mean 
urinary NGAL levels were significantly elevated at 3 and 18 hours after cardiac surgery 
than non AKI patients 
[170]
. Hasse et al studied plasma NGAL and cystatin C in 100 
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patients after cardiac surgery and found it to be independent predictor of AKI ,its 
duration and severity as well as length of ICU stay 
[171,172]
. 
In studies of Contrast induced nephropathy in both children and adults uNGAL and 
pNGAL significantly rose much earlier i.e. 2-4 hours of cardiac catheterization than 
serum creatinine which was found to increase at only 6-24 hours of procedure 
[173,174]
. 
Urinary NGAL was studied in 140 critically ill children who were on mechanical 
ventilation. The levels of uNGAL rose 48 hours before a rise in creatinine of 50% or 
more occurred and they correlated well with worsening Pediatric RIFLE class. The area 
under the ROC curve for development of AKI for uNGAL was 0.78 while its levels were 
also predictors for AKI duration of more than 48 hours 
[175]
. Hilde R et al studied 632 
ICU patients of which 171 (27%) developed AKI. Plasma and urinary NGAL at 
admission were significantly related to severity of Aki as determined by RIFLE scores. 
Also NGAL was an independent predictor of RIFLE ‗F‘ class in multivariate logistic 
regression model 
[176]
. 
In a cohort of 635 patients admitted to the Emergency Department ,a single urinary 
measurement of NGAL had high sensitivity and specificity in detecting AKI . In fact a 
cutoff value of 130 μg/G creatinine had a sensitivity of 90% and specificity of 99.5% for 
detecting AKI , which was much higher than N acetyl beta (D) glucosaminidase, 
fractional excretion of sodium (FeNa) and serum creatinine. In regression analysis 
uNGAL predicted requirement of dialysis and admission to ICU. Since only 6% of the 
patients of the cohort were subsequently admitted to the ICU, the possibility of sepsis 
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acting as a source of extrarenal NGAL and thus confounding measurements of uNGAL is 
low 
[177]
. 
Lately quite a few studies have investigated the role of NGAL in differentiating pre-renal 
and intrinsic AKI and predicting its severity and outcome 
[178,179,180]
.Singer et al studied 
147 hospitalized patients and found that a cutoff level of uNGAL of more than 104 ng/ml 
predicted intrinsic AKI (Odds ratio 5.97) while a level of less than 47 ng/ml was in 
favour of prerenal injury 
[178]
.Comparing different biomarkers -NGAL, KIM-1, IL-18 and 
Cystatin C, Nejat et al showed that uNGAL is best in differentiating Pre-renal from 
persistent AKI where pre-renal AKI was defined as renal recovery within 48 hours and 
Fractional excretion of Sodium < 1% 
[179]
. 
NGAL rises significantly in AKI patients but not in controls 
[180]
. NGAL levels on the 
day of transplant predicts delayed graft function and dialysis requirement 
[181]
. 
Limitations of NGAL: 
Measurements may be influenced by coexisting variables such as pre-existing renal 
disease, urinary tract infections, malignancy etc .Serum NGAL may be produced in 
several non renal sites in septic patients with multi-organ failure, leukocytosis, chronic 
Inflammatory disorders and cancer. Both urine and serum NGAL are elevated in CKD 
patients and correlate with the severity of CKD stage and predict progression of CKD. 
Also the relative increase in NGAL is less when such individuals suffer acute injury  
[182]
 
. 
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In critically ill patients NGAL‘s performance in predicting AKIN 1/RIFLE ‗R‘ as 
determined by area under ROC curve has been inconsistent with results ranging from 
0.50 to 0.93 after cardiac surgery and from 0.54 to 0.99 in general ICU patients 
[183]
.This 
may partly be related to different timings of biomarker measurement and concomitant 
different sources of NGAL besides the renal tissue. Any inflammatory stimulus like 
SIRS, surgical stress will cause neutrophils to degranulate besides increasing the 
synthesis of NGAL in other tissues like lungs and liver 
[156,160]
. This shall increase the 
filtered load of NGAL which shall appear in urine irrespective of renal damage. Support 
for this comes from studies that demonstrate increased plasma and urinary levels of 
NGAL after cardiac surgery without post procedure AKI . Also the urinary NGAL in 
these patients were found to be homodimeric reflecting their source to be neutrophils 
[184,185]
.Finally the current NGAL assays do not differentiate between the monomeric, 
dimeric and heterodimeric forms of NGAL and thus are not specific for the monomeric 
tubular cell specific monomer. 
COMBINATION OF BIOMARKERS: 
 
Koyner et al 
[186]
 studied patients undergoing cardiac surgery and showed that while 
Urinary cystatin C predicted AKI immediately afterward procedure , Neutrophil 
gelatinase-associated lipocalin had good predictive value within the first 6 hrs post 
procedure. Similaly Parikh et al measured urinary NGAL and IL 18 in children with post 
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cardiopulmonary bypass (CPB) AKI .While urinary NGAL rose to 25 fold within 2 h of 
operation and decreased to normal within 6 h , in comparison, urine IL 18 started 
increasing after 4 to 6 hours of CPB, peaked with an increase of almost 25 times at 12 h, 
and remained consistently high even after 48 hours of surgery.
[187 ]
 
This suggests that for diagnosis of AKI with adequate sensitivity and specificity a panel 
of biomarkers may be better than single biomarker. In fact to put the idea to test nine 
urinary biomarkers : KIM 1, NGAL, IL 18, cystatin C,  NAG, hepatocyte growth factor 
(HGF), vascular endothelial growth factor (VEGF), chemokine interferon inducible 
protein 10 and total  protein were  studied in a heterogenous  cohort of 204 patients with 
or without AKI. It consisted of  healthy volunteers, patients undergoing cardiac 
catheterization and ICU patients.
[188 ]
 In logistic regression model, the area under the 
ROC curve for AKI prediction for the combination of biomarkers  was 0.94 which was 
consistently greater than for any individual biomarker.  
In a systematic metanalysis of 31 studies of AKI biomarkers , Parikh et al reported the 
qualities of different biomarkers in AKI diagnosis. Twenty one urine and serum 
biomarkers of AKI were evaluated from  studies reported on MEDLINE and EMBASE 
databases between 2000 and 2006.
[189] 
Urine IL 18, KIM 1and NAG were found to be the 
best for diagnosing established AKI ,while serum cystatin C, urine NGAL, IL 18 and 
brush border enzyme glutathione S transferase scored in the early diagnosis of AKI. 
Finally KIM 1 and IL 18 were the best predictors of mortality risk in patients with AKI. 
To summarize a panel of AKI biomarkers and serum markers of GFR like cystatin C may 
result in a greater potential to identify AKI earlier than we currently can . 
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AIMS AND OBJECTIVES 
 
AIM: 
• To study the clinical profile of incident and prevalent Acute Kidney Injury (AKI) 
patients in a Medical ICU at a tertiary care centre. 
 
OBJECTIVE:  
• To study the Renal outcome and Mortality  at day 7 of follow up of these patients. 
• To study the utility of urinary Neutrophil Gelatinase associated Lipocalin in 
predicting the severity and outcome of acute kidney injury. 
• To distinguish between the characteristics of Transient and Persistent AKI. 
• To study the characteristics of patients requiring RRT in this cohort. 
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MATERIALS AND METHODS 
Type of study: Prospective observational cohort study approved by the Institutional  
review board 
Setting and location: Departments of Nephrology, Critical care medicine, Christian 
Medical College, Vellore-632004. 
Study Period: June – November 2014 
Participants: 
 One hundred and three consecutive patients who had AKI at the time of ICU 
admission or who developed AKI during ICU stay were recruited in the study over 
a period of 6 months. 
A) For studying clinical profile: 
Inclusion criteria: 
• Incident /prevalent AKI patients > 18 year in ICU as per AKIN criteria. 
Exclusion Criteria  
• Pregnant women and children. 
• Patients in whom baseline serum creatinine cannot be found prospectively or 
retrospectively. 
• Chronic Kidney Disease patients eGFR < 60 ml/min/m2 BSA prior to current 
illness. 
 
B) For studying urinary NGAL 
Inclusion criteria 
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Patients with eGFR > 60 ml/min/ m
2
 BSA 
Exclusion criteria 
1. Patients in whom baseline serum creatinine cannot be found prospectively 
or retrospectively 
2. Patients with obstructive uropathy. 
3. Suspected Urinary tract infection. 
4. Patients with CKD i.e .eGFR < 60 ml/min/m2 BSA prior to current illness 
5. Pregnant women and children 
 
Data Sources/measurement:  
 
History and treatment details were noted from the chart records.Baseline creatinine was 
retrieved from prior records within 3 months. If no previous records were available and if 
the lowest creatinine attained in the hospital  corresponded to GFR >60ml/min/1.73m
2
,it 
was considered as baseline creatinine . 
Blood pressure, height, weight, BMI, age, gender and other demographic details were 
noted from the chart records. Serum creatinine, urea, total leukocyte counts, differential 
counts, liver function test, Urine analysis & microscopy, urine osmolarity and other 
investigations were noted from electronic records. Fractional excretion of  Sodium was 
calculated as per formula – (Urine Sodium X Plasma Creat)/(Urine creat X Plasma 
Sodium). Patients were followed up daily with blood and urine collection at inclusion and 
daily record of renal parameters, hemodynamic variables, Intake/Output, SOFA score, 
requirement of RRT for next 7 days. Final outcome was recorded from discharge 
summary as well as from electronic medical records.Urinary Neutrophil Gelatinase 
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associated Lipocalin was measured with a commercial ELISA kit (BIOPORTO) at 
Nephrology lab. 
FIG .6: STUDY ALGORITHM 
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METHODS AND DEFINITIONS 
DEFINITIONS 
 ACUTE KIDNEY INJURY : As per AKIN criteria (Table 1). 
 TRANSIENT ACUTE KIDNEY INJURY: Recovery of renal function (creatinine 
recovering to within 0.3mg% of baseline) in 72 hours. 
 PERSISTENT ACUTE KIDNEY INJURY : Non-Recovery of renal function 
within 72 hours 
1. Fractional excretion of Sodium was calculated on day 1 of inclusion in study as per 
formula – Urine Sodium X Plasma Creat/Urine creat X Plasma Sodium (Patients who 
were anuric or on diuretics were not included for fena). 
2. SOFA Score was calculated as per the scoring system for the six systems as described 
below Table 3a-f 
[190,191]
 : 
3a.Respiratory System 
PaO2/FiO2 (mmHg) SOFA score 
< 400 1 
< 300 2 
< 200 and mechanically ventilated 3 
< 100 and mechanically ventilated 4 
3b. Nervous System 
Glasgow coma scale  SOFA score 
13–14 1 
10–12 2 
6–9 3 
< 6 4 
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3c. Cardio Vascular System 
Mean Arterial Pressure  
OR administration of vasopressors required 
SOFA score 
MAP < 70 mm/Hg 1 
dop <= 5 or dob (any dose) 2 
dop > 5 OR epi <= 0.1 OR nor <= 0.1 3 
dop > 15 OR epi > 0.1 OR nor > 0.1 4 
(vasopressor drug doses are in µg/kg/min) 
Drug abbreviations: dop for dopamine, dob for dobutamine, epi for epinephrine and nor 
for norepinephrine. 
 
3d.Liver 
Bilirubin (mg/dl) [μmol/L] SOFA score 
1.2–1.9 [> 20-32] 1 
2.0–5.9 [33-101] 2 
6.0–11.9 [102-204] 3 
> 12.0 [> 204] 4 
 
3e.Coagulation 
Platelets×10
3
/µl SOFA score 
< 150 1 
< 100 2 
< 50 3 
< 20 4 
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3f.Renal System 
Creatinine (mg/dl) [μmol/L](or urine output) SOFA score 
1.2–1.9 [110-170] 1 
2.0–3.4 [171-299] 2 
3.5–4.9 [300-440] (or < 500 ml/d) 3 
> 5.0 [> 440] (or < 200 ml/d) 4 
 
3. Measurement of Urinary NGAL: 
Principle of assay: It is ELISA based test done in microwells which are coated with a 
monoclonal antibody to NGAL.NGAL from sample is captured by the bound antibody 
and is detected with horse radish peroxidise (HRP) - conjugated anti NGAL antibody 
after incubating with a chromogen containing Tetramethyl Benizidine(TMB) which acts 
as a substrate for HRP.  
Asssay Procedure:  
1. The reagents were brought to room temperature. 
2. The samples were diluted in appropriate dilutions according to the the expected 
NGAL concentrations. 
3. Fifty microlitre of HRP conjugated NGAL antibody were transferred in the coated 
microwells followed by rapid transfer of 50 μl of diluted samples, calibrator solution 
and internal controls into the corresponding wells. 
4. The wells were then covered and incubated for 30 minutes on a shaking platform set 
at 200/ min. 
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5. After incubation the microwell content was aspirated and washed three times with 300 
μl of diluted wash solution. 
6. Then 100 μl of TMB substrate was added to each microwell which were then covered 
and incubated in the dark at room temperature for exactly 15 minutes. 
7. Finally 100 μl of Stop solution was added to each well and mixed gently by shaking 
for 20 seconds and the absorbance of the wells was read at 450 nm within 30 minutes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bring Reagents to room temperature (RT) 
100 μl Stop Solution 
 
Read at 450 nm 
Dilute Samples 
100 μl TMB Substrate 
50 μl of HRP conjugated NGAL Antibody + 
50 μl of Calibrator or Diluted sample 
 
Incubate 30 min at RT then wash x3 
Incubate 15 min at RT in the dark 
Fig. 7: 
Schematic 
overview of the 
NGAL Assay 
procedure 
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Methods to minimize bias:   
 Cases were indicated with unique protocol ID and not with patient‘s name or hospital number. 
The investigator who measured the Urinary NGAL was blinded to the patient details. 
Statistical methods: 
a. Sample size calculation: 
 
Incidence of AKI in ICU during 1 month pilot study was around 50%.  
Range of AKI incidence  – 30-50% in different studies 
Hence Minimum Sample Size = 4 P*Q/d
2
 = 4*50*50/ 10
2
= 100. 
FOR NGAL it is planned to study around 50-75 patients as PILOT project 
Quantitative variables:  
SPSS software version 17 was used for all statistical analysis. Quantitative variables were 
expressed as Mean ± Standard Deviation or median with range. Categorical variables 
were expressed as frequency and percentage. 
 While doing univariate analysis categorical variables were analyzed using Chi square 
test while continuous variables were  analyzed using Student‘s ‗t‘ test/ANOVA. In case 
of skewed  data non parametric tests were used. Pearson‘s correlation was used to study 
the strength of association between two continuous variables. Multivariate analysis was 
done by using regression analysis. All P values were two tailed and less than 0.05 were 
considered as significant. 
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OBSERVATIONS AND RESULTS 
 
One hundred and three consecutive patients who had AKI at the time of ICU admission 
or who developed AKI during ICU stay were recruited in the study over a period of 6 
months as per the protocol (Fig8). 
 
 
 
 
 
 
 
 
 
 
 
Fig.8 Study Protocol 
Renal and Mortality out come at 
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STUDY POPULATION: The study population (n=103) consisted of 69 (67%) males 
and 34 (33%) females with a Male: Female ratio of 2: 1. The mean population age was 
48.2 ± 16.4 years .Mean age in both the sexes was similar being 48.6 ± 16.5 for females 
and 48.0 ± 16.5 for males. The population distribution according to the age groups is 
shown in Fig.9. 
 
 
Fig.9:Age group vs. Sex distribution of study population 
It is noteworthy that 32 (31.1%) patients belonged to the elderly age group defined as 
more than 60 years of age. This highlights the vulnerability of this age group for acute 
renal dysfunction superimposed over an already declining GFR . Of these 70 patients 
(68%) did not have any pre-ICU stay in the hospital and were directly admitted to the 
ICU form casualty. 
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BASELINE CHARACTERISTICS OF STUDY POPULATION 
CHARACTERISTICS   TOTAL N=103 PERCENTAGE (%)  
NORMAL RENAL FUNCTION 
IIIIFUNCTIONFffffFUNCTION  
74 71.8 
CKD STAGE 1 15 14.6 
CKD STAGE 2  14 13.6 
DM  31 30.1  
HYPERTENSION  27  26.2  
CAD  11  10.7  
COPD  9 8.7  
CVA  10  9.7  
CLD  9  8.7  
MALIGNANCY  8  7.8  
TUBERCULOSIS 
(PAST/PRES.) (((PAST/PRES.) 
8 7.8 
 
Table 4: Study population comorbidities 
As shown in the Table 4, Diabetes (30.1%) followed by hypertension (26.2%) were the 
most frequent comorbidities of the ICU population with AKI. Eight (7.8%) patients had 
associated malignancies of which 50% were haematological in origin. Other 
comorbidities were CAD (10.7%), COPD (8.7%), CLD (8.7%) and CVA (9.7%). 71.8% 
of patients had no prior renal dysfunction. Those who were classified as CKD stage 1or 2 
were in older age group with GFR corresponding to the age related decline. 
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CHARACTERISTICS  Mean ± SD  MEDIAN  Minimum  Maximum  
Hb (g/dl)  11.4±2.9 11.3 2.9 17.7 
TC (10
3
 per mm
3
)
 
 15.8 ±10.5 14.1 0.10 68.3 
Plt (lacs/mm
3)
  1.55±1.17 1.35 0.08 6.09 
Day-1 Urea (mg/dl)  79.6±43.6 70 17 198 
Day-1 Creat  (mg/dl)  2.3±1.3 1.8 1.1 7.3 
Protein (g/dl)  6.0±1.3 6.1 1.6 9.5 
Albumin (g/dl)  2.9±0.9 2.9 0.7 6.0 
Bilirubin (mg/dl)  2.8±5.3 1.1 0.3 39.9 
SGOT (IU/L)  501.4±2100.9 78 17 18850 
SGPT (IU/L)  137.8±506.6 35 6 4600 
Alk.phos.(U/L)  145.9±134.9 97 22 711 
Sodium (mmol/L)  137.3±7.9 137.0 113 158 
Potassium (mmol/L)  4.0 ±1.0 4.0 1.1 6.3 
Bicarbonate(mmol/L)  16.8±6.8 16.4 3.6 38 
Chloride(mmol/L) 108.8±7.8 107 84 132 
Lactate(mmol/L) 4.2±3.9 2.8 0.8 19.5 
Day 1Urine O/P (ml) 1352±953 1180 10 4850 
Day 1 SOFA score 10.7±4.3 11 2 19 
uNGAL (ng/ml) 4224.8±4586.1 (N=63) 
 
Table 5: Clinical Profile at admission 
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As seen from Table 5 most patients had high counts at admission , though a few were 
leukopenic due to presence of  aplastic anemia. Mean urea and creatinine at presentation 
were 79.6±43.6 mg% and 2.3±1.3 mg% respectively. Serum albumin and bicarbonate 
levels were on the lower side being 2.9±0.9 g% and 16.8±6.8 mmol/L respectively. 
Significant patients had high lactates at admission averaging to 4.2±3.9 mmol/L. Mean 
SOFA score at admission was 10.7±4.3. Urinary NGAL was analysed in toal of 63 
patients with mean value of 4224.8± 4586.1 ng/ml. 
AKIN STAGE at inclusion: 
At inclusion 38 patients (37 %) were in AKIN 1, 31 (30%) in AKIN 2 and 34 (33%) 
patients were already in AKIN 3 (Fig.10).  
 
Fig.10 : AKIN Stage at inclusion 
 
38, 37%
31, 30%
34, 33%
AKIN 1
AKIN 2
AKIN 3
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Table 6 : Baseline comparison between AKIN 1,2 and 3 
CHARACTERISTICS AKIN 1.00 
(N=38) 
AKIN 2.00 
(N=31) 
AKIN 3.00      
(N=34) 
P VALUE 
  Mean± SD Mean± SD Mean± SD  
AGE 48.3±15.6 47.1±16.1 49.5±17.8 0.85 
Hb (g/dl)  11.3 ±3 10.9±2.8 11.9±2.6 0.478 
TC (10
3
 per mm
3
)
 
 17.1 ±11.1 13.9± 9.2 16.7±11.9 0.410 
Plt (lacs/mm
3)
  2.1 ±1.1 1.5 ±1.3 1.0±0.7 <0.001 
Day-1 Urea (mg/dl)  52.1±27.8 78.9±38.1 108.4±45.0 <0.001 
Day-1 Creat  (mg/dl)  1.46±0.55 2.04±0.82 3.56±1.43 <0.001 
Protein (g/dl)  6.4±1.2 5.9±1.5 5.5±1.0 0.018 
Albumin (g/dl)  3.3±0.9 2.7±0.8 2.5±0.6 <0.001 
Bilirubin (mg/dl)  2.7±4.7 2.8±7.0 3.0±4.1 0.951 
AST (IU/L)  166±296 377±1337 986 ±3384 0.238 
ALT (IU/L)  63±88 122 ±414 235 ±782 0.351 
Alk.phos.(U/L)  143 ±173 142 ±92 151±119 0.96 
Sodium (mmol/L)  138±8.5 136 ±7.7 137±7.5 0.549 
Potassium (mmol/L)  3.7±0.9 4.0±1.1 4.3±0.8 0.062 
Bicarbonate(mmol/L)  18.4±7.0 16.5±7.0 15.3±6.3 0.152 
Chloride(mmol/L) 109.4±8.6 108.3±7.1 108.0±7.7 0.824 
Lactate(mmol/L) 3.7±4.5 4.4±3.1 4.7±3.9 0.547 
pH  7.31±0.13 7.31±0.14 7.23±0.15 0.023 
Day 1 SOFA score 8.3±3.6 10.7±3.7 13.4±4.1 <0.001 
Day 1Urine O/P (ml) 1701±997 1214±699 1081±1010 0.014 
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Table 6 shows the comparison of baseline parameters between different AKIN stages 
using One way ANOVA. Age , haemoglobin ,total leukocyte counts ,total bilirubin 
,AST,ALT ,Sodium , bicarbonate, chloride and lactate levels were not different between 
the three groups. However serum urea and creatinine were found to be significantly 
different between all three groups in the post hoc analysis of One way ANOVA. 
Similarly SOFA score at admission was significantly different between all three AKIN 
stages. 
Platelet count, day 1 urine output, serum protein had significant P value in ANOVA, but 
the post hoc analysis showed that the difference in their values was significant only 
between AKIN 1 and AKIN 3 stages ,while AKIN 1vs 2 and AKIN 2 vs 3 were not 
significantly different .Serum Albumin was significantly higher in AKIN 1 patients as 
compared to both AKIN 2 and AKIN 3 separately. 
Table 7 Urinary NGAL between AKIN stages 
 AKIN 1.00  
(N=19) 
AKIN2.00 
(N=22) 
AKIN 3.00      
(N=22) 
P VALUE 
UNGAL (ng/ml) 1270.2±1659.5 4865.9±4992.3 6135±4586.1 0.001 
 
Urinary NGAL (UNGAL) was compared across different AKIN stages .The mean values 
were significantly different between AKIN stage 1 and AKIN stage 2 (P= 0.024) and 
highly significant on comparing AKIN 1 and AKIN 3 (P=0.001). However there was no 
significant difference between AKIN 2 and AKIN 3.  
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A pearson correlation coefficient of 0.212 was found between UNGAL and serum 
creatinine with a two tailed p value of 0.085.  
CAUSES OF ACUTE KIDNEY INJURY: 
In most of the patients the AKI was multifactorial in nature.The most common causes 
was sepsis (58.3%) followed by drugs (17.5%),Pigment nephropathy due to 
hemolysis/rhabdomyolysis (15.5%),Scrub Typhus (15.5%), Cardio-renal syndrome 
(11.7%)  and snake envenomenation (5.8%) as depicted in Fig.11.Common drugs 
associated with AKI were aminoglycosides, NSAIDS, Colistin, ACE/ARB‘s , 
 
 
Fig.11 Causes of Acute Kidney Injury 
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Less common causes included Acute pancreatitis (3.9%),Hepatorenal syndrome 
(2.9%),Acute gastroenteritis (3.9%). There were 2 (1.9%) cases of Acute Pyelonephritis, 
Dengue Hemorrhagic fever each and one Tumour Lysis syndrome related AKI. 
Mean urine output was 1021±730 ml/day in septic AKI patients which was significantly 
lower, than those with other causes 1481±1100 (p= 0.015).Hospital stay in septic AKI 
patients was 18.23+ 29.26 while it was only 11.66+9.22 in those with other causes 
(P=0.181).The albumin levels in septic AKI patients was 2.66+0.92 while it was 
3.00+0.83 in those with other causes (P=0.040) .43.6% of patients with septic AKI 
expired as compared to 27.4% mortality in Non septic AKI ( P = 0.094).Mean urinary 
NGAL levels were 7011 ± 7025ng/ml in patients with septic AKI while they were 3806 ± 
4976 in AKI due to other causes (p=0.063). 
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TRANSIENT VERSUS PERSISTENT ACUTE KIDNEY INJURY 
 
 
Fig.12 Transient & Persistent AKI Population distribution 
As shown in Fig.12, 25% (26) patients recovered their renal function completely within 
72 hours , 8 patients expired prior to 72 hours while 69(67%) patients had persistent renal 
dysfunction .Important to note here is that except for 1 patient all of the patients with 
Transient AKI did not have any pre-ICU hospital stay and were directly admitted to the 
ICU from Emergency. 
Table 8 shows that none of the comorbidities i.e.Diabetes , hypertension, Coronary 
Artery Disease (CAD),Chronic Obstructive Pulmonary disease (COPD), Cerebro 
Vascular Disease (CVA), Chronic Liver Disease (CLD) were significantly different 
8, 8%
69, 67%
26, 25%
EXPIRED
Persistent AKI
Transient AKI
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between the Transient and Persistent AKI groups. Of note, Fractional excretion of 
Sodium (FeNa) was less than 1 in significantly greater number of patients with Transient 
AKI and none of them required Hemodialytic support. Also 72% (18) patients with 
Transient AKI were in AKIN stage 1 while only 24.3% (17) patients had AKIN 1 at 
inclusion (P<0.001). 
Characteristics TRANSIENTAKI (N=26) 
 
 
(N=25) 
Mean ±   SD 
PERSISTENTAKI (N=69) 
 
 
(N=67) 
Mean ±   SD 
p- value 
Male 17 (68%) 45 (64.3%) 0.738 
Diabetes 6 (24%) 24 (34.3%) 0.342 
Hypertension 8 (32%) 18 (25.7%) 0.545 
CAD 
(lac/mm
3
) 
2 (8%) 7 (10%) 0.769 
COPD 
(g/dl) 
2 (8%) 7 (10%) 0.769 
CLD 
(g/dl) 
3 (12%0 5 (7.1%) 0.453 
CVA 
(mg%) 
1 (4%) 7 (10%) 0.354 
AKIN 1 
(mg%) 
18 (72%) 17 (24.3%) <0.001 
Hemodialysis 0 25 (36.2%) <0.001 
FeNa<1
a
 15 (65.2%) 15 (34.9%) 0.018 
a: For FeNa N=23 for Transient and 43 for persistent AKI 
Table 8 : Baseline Characteristics of Transient and Persistent AKI 
As shown in Table  8 FeNa could be performed in a total of 66 patients ,23 in Transient 
AKI and 43 in Persistent AKI group. Of the Transient AKI group 65.2% (15) patients had 
FeNa less than 1 suggestive of Pre renal AKI. 
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Characteristics  TRANSIENTAKI(N=26) 
Mean ±   SD 
 
(N=25) 
Mean ±   SD 
PERSISTENTAKI(N=69) 
Mean ±   SD 
 
(N=67) 
Mean ±   SD 
p- 
value  
Age 43.6 ±16.3 49.1 ± 15.5 0.130  
Hb (g/dl)  12.2 ±3.2 10.9 ±2.7 0.066 
TC (10
3
 per mm
3
)
 
 19.9 ±10.7 14.5 ±10.5 0.028 
Plt (lacs/mm
3)
  2.3 ±1.3 1.3 ±1.04 <0.001  
Day-1 Urea (mg/dl)  56.4 ±27.8 89.9 ±46.1 <0.001  
Day-1 Creat  (mg/dl)  1.43 ±0.33 2.65 ±1.43 <0.001  
Protein (g/dl)  6.8 ±0.7 5.7 ±1.3 <0.001  
Albumin (g/dl)  3.4 ± 0.7 2.6± 0.9 <0.001  
Bilirubin (mg/dl)  3.0±5.2 2.9 ±5.7 0.892 
AST (IU/L)  135 ±259 673 ±2553 0.288  
ALT (IU/L)  62 ±80 171 ±613 0.370 
Alk.phos.(U/L)  123 ±131 157± 136 0.278 
.  Sodium (mmol/L)  139 ± 8.4 136 ± 8.0 0.108 
Potassium (mmol/L)  3.7  ±1.0 4.1 ± 0.9 0.031 
Bicarbonate(mmol/L)  19.3 ±6.5 15.9 ± 6.4 0.025 
Chloride(mmol/L) 110 ± 7.7 109 ± 8.0 0.302 
Lactate(mmol/L) 2.3 ± 1.9 4.7 ± 4.1 <0.001 
pH  7.37 ± 0.09 7.28 ± 0.15 <0.001 
Day 1 SOFA score 7.7 ±4.0 11.5 ±3.9 <0.001 
Day 1Urine O/P (ml) 1751± 889 1166 ± 875 0.005 
ICU stay (days) 6.4±4.6 8.0 ± 7.2 0.308 
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Characteristics  TRANSIENTAKI(N=26) 
Mean ±   SD 
PERSISTENTAKI(N=69) 
Mean ±   SD 
 
p- 
value  
UNGAL ng/ml 1078.4 ±1702.5 
(N=23) 
5292.9 ± 4913.5 
(N=40) 
<0.001 
FeNa  % 1.6 ± 2.0 
(N=23) 
6.5 ± 11.3 
(N=43) 
  0.008  
 
Table 9 Baseline Clinico-laboratory characteristics in Transient and Persistent AKI 
Table 9 shows the clinical and lab parameters of patients with Transient and Persistent 
AKI. Mean age , hemoglobin , total bilirubin ,AST,ALT ,Alkaline Phosphate ,Sodium, 
Chloride were not significantly different between the groups. Length of ICU stay was 
also not different .In comparison total leukocyte count (P=0.028), serum potassium 
(P=0.031), serum bicarbonate (P=0.025) and fractional excretion of sodium (P=0.008) 
was significantly different between the groups. 
Patients with Transient AKI had higher mean serum protein and albumin levels and lower 
mean urea and creatinine concentration than Persistent AKI patients all of which had 
highly significant P value of <0.001 on Independant ‗t‘ test. Persistent AKI patients had 
significantly more acidosis (<0.001) and higher lactate levels (<0.001) at presentation and 
a lower urine output than their counterparts (P=0.005). 
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On comparison of SOFA scores at inclusion Transient AKI patients were definitely less 
sick with mean score of 7.7 ±4.0 as compared to patients with persistent renal 
dysfunction with score of 11.5 ±3.9  (P<0.001)  
Mean urinary NGAL levels were significantly much lower in Transient AKI i.e. 1078.4 
±1702.5 ng/ml than in Persistent AKI group i.e.5292.9 ± 4913.5 ng/ml (P< 0.001).Thus 
urinary NGAL levels at inclusion were predictive of renal recovery in univariate analysis. 
OUTCOMES AT DAY 7 
1. Overall outcome: Of the total 103 patients included in the study  two patients were 
discharged against Medical advice (DAMA) while 23.3%% (23) expired before day 7.An 
additional 10 patients expired on day 7 taking the total toll to 34 ( 33%). (Fig.13) 
 
Fig.13 Overall outcome at day 7 
35, 34%
32, 31%
34, 33%
2, 2%
RECOVERED
NOT RECOVERED
EXPIRED
DAMA
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34% (35) had complete renal recovery while 31% (32) had persistence of renal 
dysfunction at day 7.Thus 52.2% of the survivors had renal recovery by day 7. 
2. Renal outcome: As mentioned above 52% of the surviving study patients recovered 
renal function completely at day 7 leaving an 48% with non recovery. Tables 10 and 11 
illustrate the characteristics of the two groups. 
Characteristics RECOVERED (N=35) 
 
 
(N=25) 
Mean ±   SD 
NOT RECOVERED(N=32) 
 
 
(N=67) 
Mean ±   SD 
p- value 
Male 24(68.6%) 18(56.3%) 0.298 
Diabetes 8 (22.9%) 16 (50.0%) 0.021 
Hypertension 11(31.4%) 10(31.3%) 0.987 
CAD 
(lac/mm
3
) 
4(11.4%) 4(12.5%) 0.893 
COPD 
(g/dl) 
2(5.7%) 4(12.5%) 0.235 
CLD 
(g/dl) 
2(5.7%) 1(3.7%) 0.944 
CVA
(mg%) 
3 (8.6%) 4(12.5%) 0.414 
AKIN 1 
(mg%) 
19 (54.3%) 8(25.0%) 0.015 
Normal baseline GFR 32 (91.4%) 18 (60.0%) 0.003 
Hemodialysis 1 (2.9%) 14 (43.8%) <0.001 
FeNa<1
a
 17(65.4%) 6 (30.0%) 0.017 
a: For FeNa, N=26 for Recovered and 20 for Not Recovered 
Table 10 : Characteristic of patients with renal recovery vs non recovery at day 7 
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As can be seen from Table 10 Diabetic patients were more likely to have persistent renal 
dysfunction even after 7 days of follow up (P=0.021).Patients who recovered renal 
function had significantly greater normal baseline renal function i.e no underlying CKD 
(P=0.003) and more number were in AKIN 1 at presentation than those who didn‘t 
recover (P=0.015).  
Characteristics  RECOVERED (N=35) 
Mean ±   SD 
 
(N=25) 
Mean ±   SD 
NOT RECOVERED (N=32) 
Mean ±   SD 
 
Mean ±   SD 
 
(N=67) 
Mean ±   SD 
p- value  
Age (years) 47±16.0 53 ± 16 0.193  
Hb (g/dl)  11.8 ±2.9 11.1 ±2.8 0.306 
TC (10
3
 per mm
3
)
 
 17.8 ±7.8 18.8 ±12.4 0.893 
Plt (lacs/mm
3)
  2.2 ±1.4 1.4 ±1.1 0.015  
Day-1 Urea (mg/dl)  66 ±35 95 ±48 0.009  
Day-1 Creat  (mg/dl)  1.76 ±0.74 2.95 ±1.59 <0.001  
Protein (g/dl)  6.4 ±0.9 5.9 ±1.1 0.084  
Albumin (g/dl)  3.1 ± 0.8 2.8± 0.8 0.115  
Bilirubin (mg/dl)  3.4±5.2 1.8 ±2.2 0.118 
AST (IU/L)  147 ±212 436 ±1321 0.237  
ALT (IU/L)  75 ±90 136 ±410 0.396 
Alk.phos.(U/L)  123 ±93 151± 142 0.340 
.  Sodium (mmol/L)  140 ± 7.5 135 ± 8.3 0.008 
Potassium (mmol/L)  3.8  ±1.0 4.4 ± 0.9 0.030 
Bicarbonate(mmol/L)  18.8 ±6.9 16.1 ± 6.4 0.105 
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Characteristics  RECOVERED 
Mean ±   SD 
NOT RECOVERED 
Mean ±   SD 
 
 
p- 
value  
Chloride(mmol/L) 112 ± 8.1 107 ± 7.8 0.008 
Lactate(mmol/L) 2.5 ± 1.7 4.4 ± 3.9 0.011 
pH  7.36 ± 0.11 7.28 ± 0.15 0.012 
Day 1 SOFA score 9.1 ±434 10.9 ±4.3 0.079 
Day 1Urine O/P (ml) 1529± 764 1151 ± 1024 0.089 
ICU stay (days) 7.8±5.8 9.3 ± 9.3 0.422 
UNGAL ng/ml 1797.6 ±2589.4 
(N=26) 
4180.1 ± 4775.4 
(N=24) 
0.037 
FeNa  % 2.0 ± 2.7 
(N=26) 
10.4 ± 15.4 
(N=20) 
0.026 
 
Table 11: Clinical and Lab parameters of patients with renal recovery vs non 
recovery at day 7 
Table 11 shows that mean serum urea and creatinine levels were 95 ±48 mg/dl and 2.95 
±1.59 mg/dl respectively in those who had persistent renal dysfunction at day 7.These 
were significantly much higher than those who completely recovered their renal function 
by day 7(P<0.01). 
Also  it can be deduced form the table that patients who did not recover renal function by 
day 7 had significantly worse acidosis (P=0.012) with greater accumulation of lactates 
(P=0.011) at presentation than those who had complete renal recovery. They also had 
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significantly lower mean serum sodium and chloride levels but higher serum potassium 
levels. 
Mean Urinary NGAL levels were 1797.6 ±2589.4 ng/ml in the group who recovered 
renal function, being significantly lower as compared to 4180.1 ± 4775.4 ng/ml in those 
who did not recover (P=0.037).Fractional excretion of sodium was also significantly 
higher in the patients who did not recover their renal function by day 7. 
 
Fig. 14 ROC curve for urinary NGAL for  prediction of renal outcome at day 7  
The performance of urinary NGAL for predicting non recovery of renal function at day 7 
revealed  the area under ROC curve of  0.713. 
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SOFA score and renal outcome : As can been seen except for SOFA score at day 1 all 
subsequent SOFA scores were significantly associated with Renal outcome at day 
7.Table 12 shows the mean SOFA scores on day 2 to day 7 compared between the 
patients with renal recovery and those with persistent renal dysfunction .Mean scores 
were significantly lower in patients who recovered renal function by day 7 (P<0.01). 
 
Table 12 SOFA score and Renal outcome at day 7 
Characteristics  RECOVERED (N=35) 
Mean ±   SD 
 
(N=25) 
Mean ±   SD 
NOTRECOVERED (N=32) 
Mean ±   SD 
 
(N=67) 
Mean ±   SD 
p- value  
SOFA 2 7.3±4.5 11.4 ± 4.6 <0.001 
SOFA 3 7.0 ±4.8 10.9 ±4.4 0.002 
SOFA 4 5.4 ±3.6 9.6 ±3.6 <0.001  
SOFA 5 4.4 ±2.9 8.6 ±3.3 <0.001  
SOFA 6 3.6 ±2.8 8.0 ±4.0 <0.001  
SOFA 7 3.0 ±2.8 7.0 ±4.6   0.001  
 
Multivariate analysis of Renal out come at Day 7: Using binary logistic regression 
with backward conditional method a model was made for predicting renal outcome at day 
7 with a predictive power of 71% (Table 13).The variables which play a significant role 
in predicting renal outcome are Diabetes Mellitus, SOFA score at day 2 and absence of 
pre-existing CKD. Serum lactate , Hemodialysis requirement and serum potassium, 
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urinary NGAL, day 1 Urea and creatinine, though significant in univariate analysis were 
not found to be independant predictors of renal outcome at day7 in multivariate analysis. 
-2 Log 
likelihood 
Cox & 
Snell R 
Square 
Nagelkerke 
R Square 
39.150
a
 0.534 0.712 
 
Table 13 : Goodness of Fit of Model 
 B SE Wald Sig Exp(B) 
DM(1) -2.659E+00 0.970 7.517 0.006 0.070 
No CKD -2.574E+00 1.070 5.785 0.016 0.076 
Lactate 0.303 0.223 1.836 0.175 1.353 
HD(1) -2.277E+01 9615.5 .000 0.998 1.287E-10 
Potassium -6.980E-01 0.510 1.875 0.171 0.498 
SOFA 
day2 
0.24 0.110 4.796 0.029 1.272 
Constant 25.3 9615.5 .000 0.998 9.731E+10 
 
Table 14: Regression model predicting Renal outcome at day 7 
 
Renal replacement Therapy requirement: Twenty nine patients (28.2%) required 
hemodialytic support. Associated comorbidities Diabetes , hypertension, Coronary Artery 
Disease (CAD),Chronic Obstructive Pulmonary disease (COPD), Cerebrovascular 
Disease (CVA), Chronic Liver Disease (CLD) were not associated with requirement of 
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RRT.AKIN stage > 1 was a significant factor predicting hemodialysis requirement in 
next 7 days. 
Table 15 shows that patients initiated on hemodialysis had significantly higher mean day 
1 Urea (P=0.032 ) and creatinine values (P<0.001).They were also having significantly 
higher potassium levels and also had significant lactic and metabolic acidosis at 
presentation. 
Characteristics No Hemodialysis (N=74) 
Mean ±   SD 
 
(N=25) 
Mean ±   SD 
Hemodialysis (N=29) 
Mean ±   SD 
 
(N=67) 
Mean ±   SD 
p- value 
Age (years) 49.7±15.9 44.9 ± 17.3 0.180 
Day-1Urea (mg/dl) 73 ±42 94 ±45 0.032 
Day-1Creat (mg/dl)  
(mg/dl) 
1.97 ±1.02 3.25 ±1.57 <0.001 
PotassiumDay 1 
(mmol/L) 
3.84±0.89 4.35±1.03 0.014 
Bicarbonate Day 1 
(mmol/L) 
18.6±6.7 12.5±5.0 <0.001 
pH Day 1 7.32±0.13 7.19±0.15 <0.001 
Lactate Day 1 
(mmol/L) 
3.6±3.6 6.1±4.4 0.005 
SOFA 1 10.0 ±4.1 12.3 ±4.3 0.014 
SOFA 2 9.8 ±4.8 13.1 ±4.4 0.002 
SOFA 3 3.0 ±2.8 7.0 ±4.6 0.002 
U NGAL( ng/ml) 3130±3814 6470±5668 0.034 
FeNa % 2.8±3.5 10.1± 14.9 0.038 
 
Table 15: Clinico-biochemical parameters associated with RRT requirement 
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Mean SOFA scores at Day 1, Day2 and Day 3 were also significantly higher for patients 
who underwent haemodialysis with P value <0.014, 0.002 and0.002 respectively. On 
evaluating urinary NGAL levels, mean values were 6470±5668 ng/ml in patients 
requiring Hemodialysis  while they were 3130±3814 in patients not requiring RRT. The 
levels were significantly different between the two groups (P=0.038).Also mean FeNa % 
was significantly higher in patients requiring RRT. 
 
 
Fig.15: ROC curve for NGAL predicting RRT requirement 
As shown in Fig.15 urinary NGAL was a good predictor of RRT requirement in ICU 
patients with AKI with an area under the ROC curve of 0.71.  
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Mortality Outcome : After censoring the two patients who went DAMA ,34 (34%) out 
of the remaining 101 patients expired within next 7 days of follow up. Fig. 16 shows the 
temporal profile of mortality .As can be seen, except for days 1 and 3 the mortality rate 
was more or less uniform in the study cohort. 
 
Fig.16 Mortality on days 1-7 
On univariate analysis age ,sex  AKIN stage >1 ,Day 1 urea and creatinine , total 
bilirubin ,albumin, AST,ALT and Alkaline Phosphatase  and comorbidities including 
CAD, COPD,CVA ,DM and hypertension were not significantly associated with 
mortality.(Table 16) 
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Characteristics  EXPIRED (N=34) 
Mean ±   SD or N% 
 
(N=25) 
Mean ±   SD 
NOT EXPIRED (N=67) 
Mean ±   SD or N% 
 
(N=67) 
Mean ±   SD 
p- value  
Age (years) 47±16.0 53 ± 16 0.193  
Male  26 (76.5%) 42(62.7%) 0.163 
CLD 6(17.6%) 3 (4.5%) 0.028 
AKIN Stage > 1 23 (67.6%) 40 (59.7%) 0.436 
FeNa<1 18 (72%) 23 (50%) 0.073 
Hemodialysis 13 (38.2%) 15 (22.4%) 0.093 
Hb (g/dl)  11.2 ±2.7 11.5 ±2.9 0.659 
TC (10
3
 per mm
3
)
 
 11.8 ±10.2 18.0 ±10.2 0.005 
Plt (lacs/mm
3)
  1.1 ±0.84 1.8 ±1.3 0.001  
Day-1Urea (mg/dl)  76 ±43 80 ±44 0.641 
Day-1Creat  
(mg/dl)  
2.28 ±1.32 2.32 ±1.35 0.884  
Protein (g/dl)  5.6 ±1.5 6.1 ±1.1 0.020  
Albumin (g/dl)  2.7 ± 0.95 2.9± 0.8 0.100  
pH  7.22 ± 0.14 7.32 ± 0.13 0.001 
Lactate(mmol/L) 5.9 ± 4.9 3.4 ± 3.1 0.011 
Day 1 SOFA score 12.2 ±3.9 9.9 ±4.4 0.013 
Day 2 SOFA score 13.2 ±3.3 9.2 ±4.9 <0.001 
Day 3 SOFA score 13.8 ±3.9 8.3 ±5.2 <0.001 
Day 4 SOFA score 15 ±4 6.9 ±4.3 <0.001 
Day 5 SOFA score 14.7 ±4.6 6.1 ±4 <0.001 
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UNGAL ng/ml 6544±5107 
(N=22) 
2539 ± 3687 
(N=41) 
0.003 
 
Table 16 Univariate analysis of Mortality outcome 
  Presence of Chronic Liver Disease was found to be significantly associated with 
mortality (P=0.028) .38.2% patients in the expired cohort as compared to 22.4% in the 
survivors were initiated on hemodialysis though the difference did not attain statistical 
significance (p=0.093). Mean lactate and pH in the patients who expired were 5.9 ± 4.9 
mmol/l and 7.22 ± 0.14 respectively and were significantly worse than the patients who 
survived. Total protein and platelet counts were also significantly lower in the the 
patients who had mortality. 
Further SOFA scores at all days had significant association with mortality 
(p<0.001).Urinary NGAL was also found to be significantly associated with mortality 
.The mean levels were  6544± 5107 ng/ml in patients who expired while the levels were 
2539 ±3687 ng/ml in survivors (P=0.003).On further analysis the area under the ROC 
curve for NGAL to predict mortality was found to be 0.81. 
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Fig.17 ROC curve for NGAL for mortality prediction 
Thirteen of the expired cohort (38.2%) as compared to 15 of survivors (22.4%) required 
Renal replacement therapy. The difference was not significant between the two with a P 
value of 0.093.Thus Hemodialysis requirement was not associated with mortality in 
univariate analysis. 
Multivariate analysis for Mortality predictors: Using stepwise backward logistic 
regression a model for prediction of mortality was generated with a predictive power of 
77.6%. In the model SOFA score at day 2 was most powerful independent predictor of 
mortality (P = 0.006), followed by pH at presentation (p=0.015) and  SOFA score at day 
1 (P=0.026 ) .Although urinary NGAL was significantly associated with mortality in 
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univariate analysis ,in multivariate model it had a borderline significance in prediction of 
mortality (P= 0.078). 
  
 
 
Table 17 Predictors of mortality in multivariate analysis 
 
 
 
 
 
 
 
 
 
 
Variable B SE Wald P 
value 
Exp (B) 
HD(1) -1.105E+00 0.884 1.563 0.211 0.331 
CLD(1) 22.436 18269.321 0.000 0.999 5.545E+09 
PH 8.342 3.428 5.923 0.015 4196.777 
Protein -1.250E-01 0.288 0.188 0.664 0.882 
UNGAL -1.358E-04 0.000 3.104 0.078 1.000 
sofa2 -4.383E-01 0.161 7.414 0.006 0.645 
sofa1 0.406 0.182 4.981 0.026 1.501 
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Discussion 
 
Acute kidney injury in the ICU is a significant contributor to morbidity and mortality. It 
is known to increase the length of hospital stay as well as predisposes to development of 
Chronic Kidney disease. Studies of biomarkers in AKI in ICU have revealed their 
capacity to detect and predict outcome at different stages of AKI.  We  planned the study 
to investigate the clinical profile and outcomes of incident and prevalent AKI patients in 
Medical ICU and study urinary NGAL as predictor of its outcome.  
Study Population characteristics: The  study population was derived from the Medical 
Intensive care unit of our hospital which admits a host of sick patients belonging to 
different medical specialities like Gastroenterology, Neurology, internal medicine, 
Nephrology etc. Thus the results of  this study are applicable to any general medical ICU 
population .There was a male predominance in the study cohort with a significant number 
of elderly patients .AKIN stage at inclusion was AKIN 1-37%,AKIN2- 30% and AKIN 3 
-33% patients .    
Causes of AKI: In our study Sepsis was the leading cause of Acute Kidney Injury 
occurring in 58.3% of patients. This is well in coherence with the fact that Sepsis and 
ARDS are the two important clinical syndromes occurring in the ICU. Our patients with 
Septic AKI had lesser mean urine out put than other AKI patients (P=0.015).Also they 
had significantly lower serum albumin levels signifying the catabolic state. Mortality and 
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length of hospital stay was also greater in patients with septic AKI patients though 
statistical significance was not reached. 
The Beginning and end supportive therapy (BEST ) kidney investigators had evaluated a 
diverse population of critically ill patients in 54 hospitals of 23 nations and inferred that 
sepsis is the leading cause of AKI in this group estimated to be responsible for 47.5% of 
burden. The septic AKI patients were also found to have greater amount of oliguria (67% 
vs 57%,P, 0.001) ,higher in hospital mortality (70.2% vs 51.8% ,P<0.001) and increased 
duration of hospital stay (37d vs 21d,P,0.001) [192]. 
Other important causes were drugs , scrub typhus ,pigment nephropathy and Cardiorenal 
syndrome. While Scrub typhus is not a very well known cause of AKI it is quite common 
in South India and is associated with renal dysfunction .In fact a study by Basu et al 
evaluated the various tropical acute febrile illnesses causing AKI.Overall 53% (80) of 
AKI was attributed to scrub typhus, other causes were malaria , Leptospirois and Dengue 
[193]
. 
There were significant number of post cardiac arrest AKI patients in the cohort who 
required prolonged inotropic support post resuscitation. Chua et al has reported that 
among the survivors of cardiac arrest the need for inotropes beyond 24 hours of return of 
spontaneous circulation predisposes to development of AKI (51.7% versus 6.4% )
[194].
 
Predictors of Renal outcome  : Important factors associated with renal outcome in 
multivariate analysis were Diabetes mellitus ,SOFA score at day 2  and a normal baseline 
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renal function .Urinary NGAL was significant in predicting renal outcome in univariate 
analysis with an area under ROC of 0.71. Of note SOFA scores were found to be 
significantly high at all days in those who did  not recover renal function. Mendonca et al  
[195]
studied the risk factors for development of AKI in ICU and its association with 
multiple organ failure (MOF) as defined by SOFA score of 3 or more for two or more 
organ systems other than the kidney. There was a strong association between Multiple 
organ dysfunction and AKI. Of 348 AKI patients 241 had MOF .Of these 65% of the 
patients developed AKI at the same time as MOF while 25% developed before AKI and 
10% after AKI. Thus it can be deduced from above discussion that coexistence of other 
organ dysfunction can further prevent renal recovery .This explains the significantly high 
SOFA scores in patients who did not recover renal function by day 7.The cause and effect 
relationship of  MOF and AKI  needs to be further looked into .  
Mortality: Overall mortality at day 7 was 34% in our study cohort. In various ICU 
studies the mortality rate in AKI patients has been variedly reported from 10.9% 
[24]
 to 
36.3% 
[20]
 to 47.5% 
[21]
.Most of these studies were done in mixed medical-surgical ICU‘s. 
The predictors of mortality in our study in multivariate logistic regression analysis were 
SOFA score at day 1 and 2 , pH at day of inclusion and a modest contribution from 
urinary NGAL ( P = 0.078). NGAL was found to have an area under ROC curve for 
mortality of 0.81. SOFA score is a validated method for outcome prediction in critically 
ill patients .Mortality rates as predicted by SOFA vary from as low as 3.2% in patients 
without failure of any organ to as high as 91.3% in patients who have failure of all six 
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organs  
[196]
. Although  RRT requirement is known to be independent risk factor for 
mortality in ICU 
[24,26]
 ,in our study it was not significantly associated with mortality 
although the P value was 0.093.This may be due to a smaller sample size. 
Urinary NGAL : The mean urinary NGAL levels in our study were 1270.2±1659.5 
ng/ml in AKIN stage 1 ,4865.9±4992.3 ng/ml in AKIN stage 2 and 6135±4586.1ng/ml in 
AKIN stage 3 patients at the time of recruitment in the study. Our levels of urinary 
NGAL were higher than those reported by de Geus et al 
[176]
 in his study of AKI patients 
in ICU .He found median urinary NGAL levels in RIFLE ‗R‘ to be 323 ng/ml, those in 
RIFLE ‗I‘ to be 523ng/ml and in RIFLE ‗F‘ to be 2013 ng/ml. The difference in 
observation can be attributed to significantly higher septic patients in our study cohort 
.The study by de Geus had only 17% of patients with septic AKI and consisted of 
significant number of post surgery and Trauma related AKI. Our trends of urinary NGAL 
seem to follow similar pattern as above study and were significantly higher in AKIN2 
and AKIN 3 stages at inclusion than AKIN 1 patients. 
Urinary NGAL was found to be significant predictor of outcomes including renal 
recovery at day 3 and day 7 in univariate analysis. In fact NGAL predicted renal outcome 
and requirement of RRT with an area under the ROC of 0.71.Supporting this observation 
is study by Singer et al 
[178]
 where  urinary NGAL predicted a composite outcome as 
defined by upgradation in RIFLE class, dialysis initiation and mortality with area under 
ROC of 0.71.In comparison, in our study NGAL was a better predictor of mortality with 
an area under ROC of 0.81.However in multivariate analysis the predictive power of 
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NGAL was subdued by concomitant addition of SOFA scores .Urinary NGAL predicted 
RRT initiation in the first week of ICU admission with an AUC of 0.89 ±0.04 in the 
study by de Geus 
[176].
However it was only a modest predictor of mortality in this study 
(AUC 0.64 ±0.06). 
Limitations of Study: Our study had significant limitations .First there was significant 
presence of sepsis and severe sepsis in our AKI patients. As already discussed the source 
of urinary NGAL can be injured tubules or it can be secondary to release from activated 
neutrophils in inflammatory states like sepsis [
156,160]
.Thus the NGAL in urine in such 
cases may actually come from extra renal sources .This condition seems to be true for our 
study where mean Urinary NGAL levels were higher than those reported by other studies.  
Also Urinary NGAL values were higher in patients with septic vs non-septic AKI 
(p=0.063).Hence there is possibility that high Urinary NGAL as found in our study 
maybe due to concomitant sepsis besides AKI. Second the sample size was small hence 
many observations like association of RRT and mortality might not have reached 
statistical significance. 
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CONCLUSIONS 
 
1. Sepsis is the most common cause of AKI followed by drug induced AKI in medical 
ICU .Patients with sepsis had a longer hospital stay and greater mortality than non 
septic AKI though statistical significance was not reached. 
2. Recovery from AKI at day 3 was 25% while 52% of surviving patients recovered 
fully by day 7. 
3. Urinary NGAL levels significantly predicted renal outcome, requirement of RRT and 
mortality in 7 days of follow up . 
4. Diabetes, SOFA score at day 2 and normal baseline renal function significantly 
predicted renal recovery at day 7.  
5. Of the study cohort 28.2% patients required renal replacement therapy within 7 days 
of diagnosis of AKI.  
6. Overall mortality at day 7 was 34%. SOFA SCORE at admission and subsequent 
days (p<0.01) but not HD requirement were significantly associated with mortality. 
In multivariate analysis SOFA score at day 1 and 2, pH at day 1 and Urinary NGAL 
significantly predicted mortality. 
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CASE 008830G SHAKUNTALA R 6 18-Jul-14 7 24-Jul-14 30-Jul-14 14 06.08.14 6-Aug-14
CASE 914177F SIVAKUMAR 0 19-Jul-14 8 19-Jul-14 26-Jul-14 9 27.7.14 27-Jul-14
CASE 914594F SIVALINGAM 0 25-Jul-14 7 25-Jul-14 31-Jul-14 11 4.8.14 4-Aug-14
CASE 865829F SOBHANRAM 18 19-May-14 13 6-Jun-14 18-Jun-14 28 3.7.14 3-Jul-14
CASE 883425F SONU TOPPO 0 13-Jun-14 9 13-Jun-14 21-Jun-14 9 21.6.14 21-Jun-14
CASE 923098F SUBBA REDDY P 0 29-Sep-14 11 29-Sep-14 9-Oct-14 12 10.10.14 10-Oct-14
CASE 932022F SUBBANA M 0 30-Nov-14 10 30-Nov-14 9-Dec-14 17 16.12.14 16-Dec-14
CASE 662171F SUDHA S 0 17-Nov-14 6 17-Nov-14 22-Nov-14 6 22.11.14 22-Nov-14
CASE 910223F SUGARANI 0 17-Jun-14 3 17-Jun-14 19-Jun-14 7 23.6.14 23-Jun-14
CASE 201236F SUGUNA D 1 24-Jul-14 7 25-Jul-14 31-Jul-14 18 11.08.14 11-Aug-14
CASE 455209F SUJI 0 4-Oct-14 4 4-Oct-14 7-Oct-14 4 7.10.14 7-Oct-14
CASE 929995F SURENDRAN AP 0 15-Nov-14 19 15-Nov-14 3-Dec-14 33 17.12.14 17-Dec-14
CASE 912024F SURESH 0 29-Jun-14 9 29-Jun-14 7-Jul-14 9 7.7.14 7-Jul-14
CASE 912057F SURESHKUMAR 0 1-Jul-14 10 1-Jul-14 10-Jul-14 10 10.7.14 10-Jul-14
CASE 922392F SYEDSHA HAMID 0 19-Sep-14 12 19-Sep-14 30-Sep-14 16 4.10.14 4-Oct-14
CASE 776472B TAMILARASI 0 19-Aug-14 2 19-Aug-14 20-Aug-14 14 1.09.14 1-Sep-14
CASE 929320F TAPAS GAIN 1 8-Nov-14 3 9-Nov-14 11-Nov-14 6 14.11.14 14-Nov-14
CASE 850718F UMAKANT TIWARI 0 30-Oct-14 4 30-Oct-14 2-Nov-14 4 2.11.14 2-Nov-14
CASE 928330F UMESH K YADAV 0 28-Oct-14 5 28-Oct-14 1-Nov-14 5 1.11.14 1-Nov-14
CASE 917357F VEERASWAMY 0 20-Aug-14 2 20-Aug-14 21-Aug-14 2 21.8.14 21-Aug-14
CASE 922027F VENKATESAN 0 14-Sep-14 12 14-Sep-14 25-Sep-14 24 7.10.14 7-Oct-14
CASE 910168F VENKATGURU 5 16-Jun-14 6 21-Jun-14 26-Jun-14 6 26.6.14 26-Jun-14
CASE 910652F VENKATREDDY 0 24-Jun-14 2 24-Jun-14 25-Jun-14 2 25.6.14 25-Jun-14
CASE 915713F VIJAYLAKSHMI 2 10-Aug-14 2 12-Aug-14 13-Aug-14 3 14.8.14 14-Aug-14
CASE 669419D VINAYGAM 2 2-Jul-14 5 4-Jul-14 8-Jul-14 5 8.7.14 8-Jul-14
CASE 929361F VISWANATHAN T 0 9-Nov-14 2 9-Nov-14 10-Nov-14 2 10.11.14 10-Nov-14
CASE 248202D YESODHA 0 1-Nov-14 4 1-Nov-14 4-Nov-14 5 5.11.14 5-Nov-14
UNGAL age AGEGROUPsex basecreat CKDSTG DM HTN CAD COPD CVA CLD MALIGNANCYHYPOTHY
47 41-50 F 0.8 2 1 0 1 0 0 0 0 0
8832.84 44 41-50 M 0.89 0 0 0 0 0 0 0 1 0
67 61-70 F 1 1 1 0 0 0 0 0
5040.44 47 41-50 F 0.68 0 0 0 0 0 0 0 0 0
2113.52 50 41-50 F 0.59 0 0 0 0 0 0 0 0 0
329.24 33 31-40 M 0.65 0 0 0 0 0 0 0 1 0
3848.29 45 41-50 F 0.67 0 1 0 0 0 0 0 0 0
52 51-60 F 0.65 0 0 0 0 0 0 0 1 0
2347.66 64 61-70 M 1 2 1 0 0 0 0 0 0 0
74.71 29 21-30 M 0.58 0 0 0 0 0 0 0 0 0
3528.38 43 41-50 M 0.9 0 0 0 0 0 0 0 0 0
31 31-40 M 0.6 0 0 0 0 0 0 0 0 0
158.55 62 61-70 M 0.87 1 1 1 1 0 1 0 0 0
62 61-70 F 0.68 0 0 0 0 1 0 0 0 0
2465.28 19 10-20 F 0.92 0 0 0 0 0 0 0 0 0
791.27 54 51-60 M 1.25 2 0 0 0 0 0 0 0 0
979.41 70 61-70 F 0.56 0 1 1 1 0 0 0 0 0
5834.31 69 61-70 M 3.13 3 0 0 0 0 0 0 0 0
8493.24 50 41-50 M 0.79 0 0 0 0 0 0 0 0 0
47 41-50 M 0.51 0 0 0 0 0 0 0 0 0
20000 20 10-20 F 0.59 0 0 0 0 0 0 0 0 0
1136.53 59 51-60 M 1 2 0 0 0 0 0 0 0 0
2327.39 80 >70 M 1.67 3 1 1 0 1 1 0 0 0
6503 68 61-70 M 0.81 0 1 1 0 1 1 0 0 0
61 61-70 F 0.65 0 0 0 0 0 0 0 0 0
50 41-50 M 1.13 2 1 0 0 0 0 0 0 0
38 31-40 M 1 0 0 0 0 0 0 0 0 0
62 61-70 M 0.6 0 0 0 0 0 0 0 0 0
199.6 79 >70 M 0.64 0 0 1 0 0 1 0 0 0
20000 72 >70 M 2.32 3 0 0 1 0 0 0 0 0
1565.65 40 31-40 M 0.61 0 0 0 0 0 0 0 0 0
4677.52 40 31-40 M 0.93 0 0 0 0 0 0 0 0 0
1144.5 22 21-30 M 0.8 0 0 0 0 0 0 0 0 0
268.37 44 41-50 M 0.62 0 1 0 0 0 0 0 0 0
7518.44 45 41-50 F 1 2 1 1 0 0 1 0 0 0
95.37 50 41-50 F 0.53 0 1 1 0 1 0 0 0 0
1233.72 51 51-60 M 1.18 2 0 1 0 1 0 0 1 1
218.22 25 21-30 F 0.97 0 0 0 0 0 0 0 0 0
792.34 38 31-40 F 0.6 0 0 0 0 0 0 0 0 0
67 61-70 M 0.49 0 0 0 0 0 0 0 0 0
47 41-50 M 0.75 0 1 0 0 1 0 1 0 0
62 61-70 F 0.64 0 1 1 0 0 0 0 0 0
17237.52 44 41-50 M 0.72 0 0 0 0 0 0 0 0 1
7819.3 75 >70 M 1.2 2 0 0 0 0 0 0 0 0
10947.74 19 10-20 M 0.65 0 0 0 0 0 0 0 0 0
42 41-50 F 0.63 0 0 0 0 0 0 0 1 0
15032.78 47 41-50 M 1.92 0 1 1 0 0 0 0 0
40 31-40 M 0.8 0 0 0 0 0 0 0 0 0
47 41-50 M 0.69 0 1 0 0 0 0 1 0 0
61 61-70 M 0.99 2 1 1 0 0 0 0 0 0
5200.13 40 31-40 M 1.1 2 1 0 0 0 0 0 0 0
2176.65 33 31-40 M 0.77 0 0 0 0 0 0 0 0 0
6594.18 30 21-30 M 0.75 0 0 0 0 0 0 0 0 0
3730.25 62 61-70 F 0.67 1 0 0 0 0 0 0 0 0
578.13 62 61-70 M 2.92 4 1 1 0 0 1 0 0 0
240.77 58 51-60 F 0.81 2 0 1 0 0 0 0 0 0
18132.24 22 21-30 M 1 0 0 0 0 0 0 0 0 0
19 10-20 M 0.51 0 0 0 0 0 0 0 1 0
48 41-50 F 1 2 0 0 0 0 0 0 0 0
1327.36 61 61-70 M 0.58 0 0 1 0 0 0 0 0 0
20000 71 >70 M 4 1 1 0 0 1 0 0 0
45 41-50 F 0 0 0 0 0 0 0 0
99.88 25 21-30 M 0.82 0 0 0 0 0 0 0 0 0
2186.8 68 61-70 F 0.97 2 1 1 0 0 0 0 0 0
10043.04 55 51-60 M 0.72 0 1 0 0 0 0 0 0 0
35 31-40 M 1.4 2 0 0 0 0 0 0 0 0
43 41-50 M 0.6 0 0 0 0 0 0 1 0 0
29 21-30 F 0.46 0 0 0 0 0 0 0 0 0
1325.26 65 61-70 M 0.65 0 0 0 0 1 0 0 0 0
24 21-30 M 0.55 0 0 0 0 0 0 0 0 0
60 51-60 F 0.78 0 0 0 0 0 0 0 0 0
62 61-70 F 1.01 2 1 0 0 0 0 0 0 0
26 21-30 M 0.76 0 0 0 0 0 0 0 0 0
3911.06 40 31-40 M 1.08 2 0 0 0 0 0 0 0 0
368.88 70 61-70 F 1.4 3 1 0 0 0 0 0 0 0
365 52 51-60 M 0.67 0 0 1 0 0 0 0 0 0
70 61-70 F 0.65 0 0 1 1 0 0 0 0 0
76.78 30 21-30 M 0.58 0 0 0 0 0 0 0 0 0
2844.68 55 51-60 M 0.64 0 0 0 0 0 0 0 0 0
1035.09 57 51-60 M 0.35 0 1 1 0 0 1 0 0 0
153.29 19 10-20 M 0.8 0 0 0 0 0 0 0 1 0
437.14 65 61-70 M 0.52 0 0 0 0 0 0 0 0 0
8924.46 70 61-70 M 0.83 0 0 0 0 0 0 0 0 0
2795.04 39 31-40 F 0.74 0 0 0 0 1 0 0 0 0
23 21-30 F 0.58 0 0 0 0 0 0 0 0 0
58 51-60 F 0.7 0 1 1 0 0 0 0 0 0
16949.64 26 21-30 F 0.66 0 0 0 0 0 0 0 0 0
808.85 61 61-70 M 0.73 0 1 1 1 0 1 0 0 0
5150.69 25 21-30 M 1 0 1 1 0 0 0 0 0 0
65.05 36 31-40 M 0.68 0 0 0 0 0 0 0 0 0
1308.58 66 61-70 M 1 2 1 1 1 1 0 0 0 0
82.02 33 31-40 F 0.44 0 0 0 0 0 0 0 0 0
72.63 32 31-40 M 0.43 0 0 0 0 0 0 0 1 0
46 41-50 M 0.53 0 0 0 0 0 0 1 0 0
5480.99 45 41-50 M 1.97 1 0 0 0 0 1 0 0
8799.54 65 61-70 M 2.02 0 0 0 0 0 0 0 0
55 51-60 M 0.6 0 0 1 0 0 0 1 0 0
7943.78 49 41-50 M 3.42 3 1 1 0 0 0 1 0 0
20000 59 51-60 M 1.2 2 0 0 0 0 1 1 0 0
9560.46 25 21-30 F 0.75 0 0 0 0 0 0 0 0 0
2996 35 31-40 M 0.78 0 0 0 0 0 0 1 0 0
10421.28 80 >70 M 0 0 1 0 0 0 0 0
761.45 72 >70 F 0.72 0 1 1 1 0 0 0 0 0
OTHERS TB VAR00003 hb TC poly lymph mono eosin BLASTS plt prot Alb sgot
0.0 0 2 7.4 12900 78 18 4 0 0 225000 6.8 3.1 51
0 0 0 8.3 100 18000 6.1 2.9 19
0 9.5 28700 90 6 4 0 0 410000 7 3.9 81
LEFT LEG FILARIASIS 0 0 12.6 8400 89 9 2 0 0 287000 5.4 2.7 77
SJOGREN'S SYNDROME0 0 11.3 36900 90 4 6 0 0 400000 7.2 2.9 30
0 0 0 13.2 12610 86 8 6 0 0 297000 7 4.4 34
0.0 0 0 13 11900 70 25 5 0 0 45000 5.9 2.4 122
DERMATOMYOSITIS 0 0 7.3 13260 85 8 7 0 0 90000 5.4 2 71
0.0 0 2 11.2 16200 91 4 5 0 0 228000 9.5 3 24
0.0 0 0 17.7 37660 81 13 4 0 0 404000 7.1 4.2 31
0.0 0 1 15.9 8920 80 17 2 0 0 60000 5.7 2.6 295
0 0 15.5 16390 84 6 10 0 0 190000 6.1 3.6 137
SLE WITH PERIPHERAL NEUROPATHY0 1 13.4 8700 84 4 12 0 0 146000 8.8 2.1 80
0.0 0 0 10.3 15700 89 7 4 0 0 130000 6.2 3 27
0.0 0 0 12.8 10500 54 36 9 1 0 70000 5.8 2.1 188
0.0 0 2 11.2 10500 92 3 4 1 0 60000 6.3 2.4 459
0 0 0 9.8 14100 73 15 12 0 0 197000 5.8 3.2 220
0.0 0 3 7 6780 46 44 10 0 0 80000 5 2.3 204
0 0 12.2 11000 85 10 4 1 0 75000 4.8 2 1031
0 0 0 12.3 10000 98 1 1 0 0 14000 5.6 2.6 45
0 0 6.5 500 10 90 0 0 0 17000 1.6 4.4 37
0.0 0 2 10 10500 68 24 7 1 0 213000 7.1 3.4 73
0 0 3 9.9 16000 96 2 2 0 0 177000 6 3.1 324
SMOKER 0 0 11 23300 77 15 8 0 0 318000 8.2 3.3 19
TAH 20 YRS.BACK 0 0 8.6 7700 81 15 4 0 0 61000 4.7 2.5 155
0.0 0 2 12.9 6100 80 9 11 0 0 369000 6.1 2.4 18
0.0 0 0 15.8 18050 91 5 4 0 0 262000 8.1 5 1301
0.0 0 0 13.1 17150 84 12 4 0 0 94000 6.6 3.8 70
CHRONICALCOHOLIC0 0 11.8 21300 83 9 8 0 0 258000 6.1 3 31
OCC ALCOHOLIC AND SMOKER1 3 15.8 4600 85 6 7 2 0 124000 6.3 2.4 80
0 0 0 10.4 13500 86 9 5 0 0 609000 7.7 3.2 19
0.0 0 1 10.3 8900 92 6 2 0 0 165000 4.2 1.5 1182
0.0 0 0 11.6 12800 88 11 1 0 0 15000 4.4 2.7 1238
RHD 0 0 10.4 25320 78 16 6 0 0 150000 7.9 3 209
0 0 2 16 19800 87 9 4 0 0 167000 8.6 3.2 182
OSA WITH BIPOLAR DISORDER0 0 11.3 24400 83 11 6 0 0 346000 7.4 4.3 59
0 2 9.7 4470 80 15 5 0 0 126000 3 6 24
0.0 0 0 13.8 21750 84 13 3 0 0 204000 6.4 3 1328
0.0 0 0 9.8 15700 75 17 8 0 0 164000 6.1 2.2 179
0.0 0 0 10.7 7480 71 27 2 0 0 21000 4.3 1.2 226
CHRONICALCOHOLIC0 0 13.8 9600 86 6 8 0 0 70000 7.1 3.6 48
0 1 1 10.2 15200 91 7 2 0 0 155000 6.1 3.1 29
1 0 10.8 2000 86 6 8 0 0 56000 4.5 1.5 88
CHRONICALCOHOLIC0 2 12.5 8400 95 1 2 2 0 20000 4.5 1.9 109
0.0 0 0 10.6 10100 64 23 9 0 0 29000 6.5 1.5 619
NONE 0 0 10.2 16400 98 1 1 0 0 197000 3.7 1.7 630
0.0 0 16.2 16400 81 12 7 1 0 164000 3.4 1.8 45
0.0 0 0 12.8 22100 84 7 9 0 0 30000 5.9 3.5 171
HCV 0 0 8 17400 91 3 4 0 0 45000 6.2 2 266
Reformed.alc. 0 2 12 13500 89 5 6 0 0 120000 7.6 3.3 51
Occ Alcoholic 0 2 8.6 57500 93 0 0 0 4 138000 7.2 2.3 44
0.0 0 0 13.3 10500 84 12 0 0 0 75000 5.3 2.3 195
0.0 0 0 17.3 27900 93 2 5 0 0 244000 6.1 3.6 66
0 1 1 8.8 21210 95 2 3 0 0 106000 5 1.9 34
PERIPHERAL VASCULAR DISEASE0 4 9.8 14900 91 7 1 1 0 206000 5.2 3 19
GITELMAN SYNDROME0 2 10.5 10420 65 25 10 0 0 308000 7 4.1 24
0.0 0 0 11.5 37900 97 1 2 0 0 67000 4.9 3.1 138
0.0 0 0 6.9 2500 46 32 8 10 4 162000 5.2 2.2 36
OVERLAP SYNDROME0 2 7.3 13000 95 2 3 0 0 124000 5.8 2
MOTOR NEURON DISEASE1 0 14.6 14120 89 3 8 0 0 119000 6.5 3.7 69
0 0 4 13.2 7990 90 5 5 0 0 28000 6.2 2 40
0.0 0 9.8 22300 74 17 9 0 0 28000 6.7 3.4 7346
.00 0 0 14.6 7500 74 19 6 1 0 179000 6.2 3.2 33
0.0 0 2 8.8 14600 87 9 4 0 0 103000 5.2 2.9 74
0.0 0 0 7.3 16200 78 15 6 1 9 110000 5.3 2.1 26
IGAN 0 2 11.3 4700 65 20 13 2 0 98000 2.2 0.7 37
0.0 0 0 6.8 18600 78 12 10 0 0 125000 7.9 2.4 97
1 0 8.3 900 20 80 0 0 0 8000 5.2 2.9 152
CHOLELITHIASIS + CHOLEDOCHO.0 0 7.5 4710 93 5 2 0 0 45000 4 1.5 139
0.0 0 0 2.9 22600 90 7 3 0 0 373000 6.5 4.2 148
MYELODYSPLASTIC SYNDROME0 0 8.5 1400 40 60 0 0 0 45000 6.2 2.4 333
PARKINSON'S 0 2 13.3 13600 84 10 6 0 0 60000 5.4 2.1 221
0.0 1 13.6 15500 84 9 7 0 0 270000 4.9 1.9 17
0.0 0 2 6.8 7800 66 20 14 0 0 60000 4.7 2.3 72
0.0 0 3 10 8600 56 39 5 0 0 66000 6.5 2.7 110
0.0 0 0 15.1 16170 91 4 5 0 0 146000 6.1 3.9 57
0 0 1 12.5 37600 95 4 1 0 0 475000 7 2.7 673
0.0 0 0 13.8 12300 78 8 14 0 0 184000 5.8 4.1 29
0 0 0 15.9 10200 85 9 5 0 0 30000 5.7 2.2 274
0 0 0 8.7 4390 76 10 7 7 0 60000 4.7 1.7 82
0 0 6.6 68300 11 16 3 0 70 42000 6.3 4 132
0.0 0 0 11.3 28300 93 4 2 1 0 53000 7.2 3.1 79
0.0 0 1 11.3 20700 91 3 2 4 0 218000 5.2 2.6 55
SCLERODERMA,ASD ( OSTEUM0 0 10.3 17400 93 3 4 0 0 371000 6.2 2.7 42
0 0 11.8 16100 69 18 13 0 0 135000 5.2 2.5 73
RHEUMATOID ARTHRITIS0 1 9 22300 88 6 6 0 0 151000 5.9 2.9 17
0.0 0 0 14.7 16400 72 14 14 0 0 16000 5.5 3 18850
0 0 0 14.9 13000 76 13 11 0 0 148000 6.7 3.4 55
0.0 0 0 12.4 27610 88 7 5 0 0 324000 7 3 26
0.0 0 0 15.9 7830 81 11 8 0 0 235000 6 3.9 439
0.0 0 2 16.7 31300 77 11 2 6 0 212000 6.2 3.2 240
0.0 0 0 9.9 21100 92 3 4 0 0 347000 7.2 4.4 75
0.0 0 0 15 19100 60 29 5 6 0 140000 7.1 3.8 32
0 0 0 12 7900 90 4 6 0 0 116000 6.7 2 118
CHRONICALCOHOLIC0 12.4 14000 78 12 6 4 0 90000 5.7 2.3 411
0 0 12 18200 75 14 8 3 0 176000 5.9 2.9 30
CHRONICALCOHOLIC0 0 7.9 18700 77 16 5 1 0 226000 5.7 2.1 156
.00 1 3 9.4 9200 92 5 3 0 0 232000 5.6 2.3 60
0 0 2 14.4 20850 93 3 4 0 0 73000 5.8 3 296
0.0 0 0 10.3 14070 88 5 1 6 0 145000 6.1 4.1 48
0.0 0 0 13.7 12610 79 9 12 0 0 60000 5.6 2.9 7178
0.0 0 13.5 25100 86 6 7 1 0 261000 6.6 3.4 31
0.0 0 0 11.9 20400 82 14 3 0 0 26000 6.2 2.8 82
sgpt alkphos SOD POT BICARB URINECULTBLDCUL CAUSEAKI1 CAUSEAKI2 CAUSEAKI3 CAUSEAKI4 DIAG1 DIAG2 DIAG3
40 90 150 3.6 30.6 YES YES SEPSIS SEPSIS - MRSA WITH PROBABLE UROSEPSIS WITH MODSPOST CARDIAC RREST - HIEDIABET S MELLITU
18 81 141 3.3 12.1 YES DRUGS SEPSIS ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASTIC RELATENEUTROPENIC FEVERGIARDIASIS
32 76 113 4.7 8 YES SEPSIS LEFT HUN WITH PYELONEPHRITISNSTEMI
37 76 138 4.1 17.7 NO NO PIGMENT NEPHROPATHYSEPSIS SNAKE ENVENOMATION WITH NEURO AND HEMATOTOXICITYSNAKE E VEN MATION WITH NEURO AND HEMATOTOXICITYRIGHT LOWER LIMB NE ROTISING FASCITISFIL RIAL L FT LOWER LI B
18 43 138 1.1 10.3 RHABDOMYOLYSIS PIGMENT NEPHROPATHY SJOGREN'S  SYNDROME.RE AL TUBULAR ACIDOSIS TYPE 1(DISTALHYPOKALEMIC PARALYSIS RESOLVED
22 75 142 3.5 16.4 NO NO RHABBOMYOLYSIS PIGMENT NEPHROPATHYSEPSIS RIGHT FRONTAL MASS LESION - PROBABLE LOW GRADE GLIS TUS EPI PTICUSASPIRATION PNEUMONIA
46 336 131 4.5 7 - NO SCRUB SCRUB TYPHUSUTI
48 229 152 4.4 17.3 - NO SEPSIS DRUGS ANTICANCER DERMATROMYOSITISLEFT BREAST CANCER ( Invasive ductal carcinoma) -FEBRILE NEUTROPENIA
9 137 135 3.4 17.7 YES SEPSIS SEPSIS
21 78 137 2.6 22.1 - - PRERENAL ORGANOPHOSPHORUS POISONINGPROBABLE ASP RATION PNEUMONIACUTE CHOLI RGIC CRISIS
91 298 133 4 16 NO SCRUB SCRUB TYPHUSREFRACTORY SEPTIC SHOCK WITH DISSEMINATED INTRAVAS
123 56 151 4.5 22.2 NO NO PRERENAL MONOCROTOPHOS POISONING-DELIBERATE SELF HARMINTERMEDIATE SYNDROMESPIRATION PN UMONIA
12 78 138 5.9 14.5 NO NO SEPSIS DRUG BILATERAL LOBAR PNEUMONIA TYPE 2 RESP FAILURESYSTEMIC L PUS ERYTHREMATOSIS WITH SECONDARY VASCUDILAT D CARDIOMY P THY
11 62 141 3 23.3 NO NO SEPSIS ILD-NSIP INFECTIVE EXACERBATION OF ILDSEPTIC SHOCK
65 174 135 5.2 10 - NO SCRUB DRUG SCRUB TYPHUSARDS COAGULOPATHY
151 333 141 5.7 17 - - SCRUB SCRUB TYPHUSRE OLVING MULTI ORGAN DYSFUNCTIO
121 88 134 3.6 15 NO NO ACUTE GASTROENTERITIS WITH PERSISTENT VOMITINGC S- STEM NON ST ELEVATION MYOCARDIAL INFARCTIONACUTE GASTROENTERITIS WITH PERSISTENT VOMITINGBIL TER KNEE OSTEOARTHRI IS
143 196 149 4.5 12 - NO SCRUB SCRUB TYPHUSARDS GI BLEED
158 44 137 4 11.1 NO NO ACUTE SEVERE NECROTIZING BILIARY PANCREATITISSEPSIS CRS CUTE SEVERE NECROTIZING INF.BIL. PANC.-S/P DRAINSEIZURES ( GTCS) PRO ABLE HYPOXIA INDUCEDPOST CARDI C ARREST RESUSCITATED
8 164 150 4.1 17.3 - YES SEPSIS DRUGS MYELODYSPLASTIC SYNDROME POST ALLOGENEIC STEM CELLG RO-INTESTINAL Graft Vs Host Disease - GRADE IVACQUIRED PURE RED CELL APLASIA POST TRANSPLANT
51 32 133 4 20 NO YES SEPSIS DRUGS AGE APLASTIC ANEMIACRO SEPSIS
42 92 137 1.8 38 YES RHABBOMYOLYSIS PIGMENT NEPHROPATHYSEPSIS S/P CARDIAC ARREST METABOLIC MYOPATHY - HYPOKALEMIA ASSOCIATEDRHABDOMYOLYSIS ASSOCIATED HYPERKALEMIASEPSIS
221 52 129 6.3 3.61 - YES SEPSIS CRS-POST ARREST ACUTE EXACERBATION OF COPDPOST CARDIAC ARREST secondary to hyperkalemia
8 80 124 4.9 20 NO NO SEPSIS COPD - INFECTIVE EXACERBRATIONTYPE 2 RESPIRATORY FAILURE
16 704 143 3.4 14.2 - YES SEPSIS DRUG HEMAOPHAGOCYTIC SYNDROMESEPSIS WITH DICPERIP RTAL LYMPHADENOPATHY
10 56 130 5 18.8 NO CRS SEPSIS ACUTE DETERIORATION OF CHRONIC CONGESTIVE HEART FAVENTRICULAR TACHYCARDIA-POST CARDIAC ARRESTVENTILATOR ASSOCIA ED PN UMONIA
168 82 141 3.5 15 - RHABBOMYOLYSIS PIGMENT NEPHROPATHY SUPER VASMOL POISONING WITH RHABDOMYOLYSIS
13 70 139 3.7 21 - - PIGMENT NEPHROPATHYSNAKE ENVENOMATION WITH NEURO AND HEMATOTOXICITYSNAKE ENV NOMATION WITH NEURO AND HEMATOTOXICITYRIGHT L WER LIMB CELLULITIS
16 57 134 3.4 19 - NO ? CARDIOGENIC SHOCK AF RELATEDSEPSIS ISCHEMIC CEREBROVASCULAR ACCIDENTASPIRATION PNEUMONIA WITH SEPSISATRI L FIBR LLATION WITH FAST VENTRICULAR RESPONSE
29 48 139 5.2 18.6 NO SEPSIS CARDIOGENIC PNEUMONIA - RIGHT MIDDLE AND LEFT LOWER LOBECUTE CORONARY SYNDROME - NON ST LEVATION MYOCARDI
19 149 151 3.7 31 NO ACUTE PANCREATITISSEPSIS ACUTE SEVERE BILIARY NECROTISING PANCREATITISSEVERE SEPSISDKA
166 711 139 4 14 - NO SEPSIS DISSEMINATED TUBERCULOSISS PTIC SHOCK
476 33 144 3.6 16.8 YES SEPSIS RHABDOMYOLYSIS MENINGOENCEPHALITISGTCS EPSIS WITH COAGULOPATHY
167 230 153 3.2 36.8 - NO SEPSIS SPONTANEOUS LEFT TEMPOROPARIETAL HAEMORRHAGERHEUMA IC VALVULAR HE RT DISEASE
67 81 130 3.4 16.4 - YES SEPSIS STAPHYLOCOCCAL SEPTICAEMIASTATUS EPIULEPTICUSIS HE IC CVA
37 104 131 4.6 24.7 NO NO ?DEHYDRATION/CRS ACUTE EXACERBATION OF OBSTRUCTIVE AIRWAY DISEASEOBSTRUCTIVE SLEEP APNOEA WITH T2 RESP. FAILURE
19 62 145 4.3 19.9 1 SEPSIS RCC OPERATEDLUNG BONE METS
328 140 146 4 20.6 NO NO ECCLAMPSIACARDIOGENIC SHOCKSEPSIS 3.STATUS POST LEFT RADICAL NEPHRECTOMYAN EPARTUM ECCLAMPSIARIGHT LOWE  LIMB DVT WITH PROBABLE PE
84 331 137 3.9 20.7 NO NO SCRUB SCRUB TYPHUSACUTE RESPIRATORY DISTRESS SYNDROMEMYOCARDITIS
412 120 148 6.3 15.6 NO NO SCRUB TYPHUSSEPSIS SCRUB TYPHUSFOURNIER'S GANGRENEHOSPITAL ACQUIRED PNEUMONIA
41 122 125 4.7 19 - YES SEPSIS LOWER RESPIRATORY TRACT INFECTION-COPDALCOHOL DEPENDENCE SY DR ME
7 47 135 3.4 14.4 NO YES SEPSIS ACUTE PYELONEPHRITIS ACUTE PYELONEPHRITIS.GRAM NEGATIVE BACILLI SEPSIS
33 91 133 2.9 13.8 - YES SEPSIS ??DISSEMINATED TB DISSEMINATED TUBERCULOSISCANDIDA SEPSIS WITH ARDS
27 155 140 4.7 10 NO SCRUB SCRUB TYPHUSARDS
139 192 123 4.3 11 - NO ?HRS SEPSIS MEDIASTINAL MASS UNDER EVALUATIONCUTE LIVER FAILURE [ T I DUCED]SEPTIC SHOCK WITH DIC
341 64 131 4.8 10 YES SEPSIS ? OBS.URO. CARCINOMA CERVIX WITH PARA AORTIC NODAL METASTASESUROSEPSIS PSEUDO INTES NAL OBSTRUCTION
13 41 143 2.9 8 NO YES SEPSIS ACUTE GASTROENTERITIS WITH PERSISTENT VOMITINGLEFT FOOT ABSCESS STATUS POST INCISION AND DRAINAGPROBABLE TOXIC SHOCK SYNDROME WITH MODS
19 52 127 3.9 17 - NO PIGMENT NEPHROPATHYSNAKE BITE-RUSSEL VIPER ENVENOMATIONSN KE BITE-RUSSEL VIPER ENVENOMATIONRIGHT LOW  LIMB CELLULITIS
62 44 129 3.9 17 - YES HRS SEPSIS DECOMPENSATED CHRONIC LIVER DISEASE HCV RELATEDPONTANE US BACTERIAL PERITONITISNECROTISING FASCII IS LEFT LOWER LIMB
22 112 129 3.5 17.9 NO NO SEPSIS ACUTE PYELO B/L ACUTE PYELONEPHRITISOST PCN
17 671 129 5.3 17 - NO SEPSIS POST CARDIAC ARREST STATUS SEPSIS WITH MULTIORGAN DYSFUNCTIONYPOXIC ISCHEMIC ENCEPHALOPATHYPOST- ARDIAC ARREST STATUS
68 119 131 3.5 13 - YES SCRUB SEPSIS SCRUB TYPHUSARDS
20 61 140 4.4 16 NO - PIGMENT NEPHROPATHYSNAKE  ENVENOMATION - RUSSELS VIPERNAKE  ENVENOMATION - RUSSELS VIPERLEFT LEG CELLULITITS
9 113 139 3.2 24.9 NO NO SEPSIS ??? 4.PROBABLE CHRONIC OBSTRUCTIVE PULMONARY DISEASEA UTE RESPIRA ORY DISTRESS SY D OMESEPSIS WITH MOD
29 128 5.3 17 NO NO SEPSIS COMMUNITY ACQUIRED PNEUMONIA - PROBABLY ATYPICALORAL CANDIDIASIS
19 65 142 2.8 27 - - ACUTE GASTROENTERITIS WITH PERSISTENT VOMITINGDRUGS PER CARDIAL EFFUSIONACUTE GASTROENTERITIS WITH PERSISTENT VOMITINGSYMPTOMATIC HIGH G ADE AV BL CK O  VVI PACING
54 30 134 3.8 13.4 - - PIGMENT NEPHROPATHYSNAKE ENVENOMATION : PROBABLE RUSSELS VIPERSNAKE ENVENOMATION : PROBABLE RUSSELS VIPERRIGHT LOWER LIM  CE LULITI
9 174 146 3.4 24 SEPSIS DRUGS PRE B CELL ACUTE LYMPHOID LEUKAEMIACANDIDA SEPSIS
10 123 5.9 9 NO NO ?VASCULITISEPSIS OVERLAP SYNDROMENSTEMI LRTI WITH SEPSIS
58 83 132 2.7 27.7 - NO ANAPHYLACTIC SHOCK MOTOR NEURON DISEASEPULMONARY TUBERCULOSISTYPE II ESPIRATORY FAILURE
14 473 133 4.3 12.7 NO YES SEPSIS E.COLI SEPSISMODS
2337 235 137 5 5 DENGUE HAEMORRHAGIC FEVER ACUTE FEBRILE ILLNESS: PROBABLE SEVERE DENGUE INFEDIC ACUTE RESPIRATORY DISTRESS SYNDROME
39 22 125 2.8 11.3 - NO ACUTE GASTROENTERITIS ACUTE GASTROENTERITIS
33 80 138 4.3 23.7 NO HAEM PIGMENT NEPHROPATHY RUSSEL VIPER SNAKE ENVENOMENATION
12 53 154 3.4 21 NO SEPSIS DRUG INFECTED PERIPANCREATIC COLLECTIONHOSPITAL ACQUIRED PNEUMONIA
15 181 133 1.7 14 NO YES SEPSIS DRUG CARBAPENEM RESISTANT E.COLI UROSEPSISPROBABLE DISSEMINATED HERPES INFECTIONCOAGULOPATHY
25 160 146 3.3 15.9 NO YES SEPSIS DECOMPENSATED CLDNFGNB SEPSISHEPATIC ENCEPHALOPATHY
61 125 137 3.8 16.2 NO - DRUGS DISSEMINATED TUBERCULOSISS PSIS DISSEMINATED TUBERCULOSISYPE 1 R SPIRATORY FAILUREMULTIORG N DYSFUNCTION SYNDROME
35 110 138 2.6 30.6 YES SEPSIS SEPSIS - VRE(vancomycin resistance enterococci)  aCHOLANGITIC ABSCESS ON PTBD
48 89 141 4.8 13 NO PIGMENT MULTIPLE BRAIN INFARCTSAUTO MMUNE HEMOLYTIC ANEMIA
122 56 130 4.1 7.3 - NO SEPSIS DRUG MYELODYSPLASTIC SYNDROME - UNCLASSIFIABLEAPENDICULAR ABSCESSREFRACTORY SEPTIC SHOCK WITH MODS
81 53 131 4.2 15.3 NO SCRUB SCRUB TYPHUS WITH MENINGOENCEPHALITISREFRACTORY SEPTIC SHOCK
12 111 136 4.2 20.3 NO TUBERCULOUS PLEURAL EFFUSIONASPIRATION PNE M IA WITH SEPSISALCOHOL W THDRAWL SEIZURE.
42 225 138 4.3 11.8 - NO SEPSIS PIGMENT NEPHROPATHYSEPTIC SHOCK DIFFUSE LARGE B CELL LYMPHOMAMACROPHAGE ACTIVATION SYNDROMEREFRACTORY SEPTIC SH CK
18 379 130 5.2 25.9 SCRUB SCRUB MENINGOENCEPHALITIS?ACS
20 47 142 2.1 13 - NO RHABBOMYOLYSIS PIGMENT NEPHROPATHYSNAKE ENVENOMATION HEMOTOXIC AND MYOTOXICSNAKE ENVEN MATION HEMOTOXIC AND MYOTOXICLEFT LEG CELLULITIS
381 72 145 3.8 18.4 - NO ??SEPSIS ?NSTEMI -CRS RIGHT MIDDLE LOBE CONSOLIDATIONPOST TBLB RIGHT PNEUMOTHORAX - POST INTERCOSTAL DRNSTEMI
15 67 139 3.8 20 - NO COMPLETE HANGINGPYRETHROID POISININGHYPOXIC ISCHAEMIC BRAIN INJURY
87 254 135 3.9 13 - NO SCRUB SCRUB TYPHUSACUTE RESPIRATORY DISTRESS SYNDROME
15 344 134 3.6 25.7 NO DRUGS TUBERCULOUS ENCEPHALO-MYELO-RADICULOPATHY WITH POLPULMONARY TUBERCULOSISAT  INDUCED HEPATITIS
48 167 146 5.4 19 NO TUMOUR LYSIS SYNDROME T - CELL ACUTE LYMPHOBLASTIC LEUKEMIAANTERIOR MEDIASTINAL MASS with SVC SYNDROMETUMOR LYSIS SYNDROME
49 281 138 4.3 15 - 0 SCRUB SCRUB TYPHUSARDS
23 97 139 4.5 15 NO NO SEPSIS NSTEMI-CRS RIGHT MIDDLE LOBE PNEUMONIA-TYPE 1 RESP FAILUREACUTE CORONARY SYNDROME - NSTEMIS PSIS
6 98 139 5.3 20 POST CARDIAC ARREST STATUS-CRS INTERSTITIAL LUNG DISEASE-iNFLUENZASC ERODERMA SPECTRUMACUTE TYPE-II RESPIRATORY FAILURE
98 353 140 5.5 12.9 ECCLAMPSIA SEVERE PRE-ECLAMPSIAACUTE FATTY LIVER OF PREGNANCY
6 238 147 4.8 12.5 NO YES SEPSIS DRUGS-ARB UROSEPSIS WITH SHOCKCRI ICAL CARE ILLNESS MYOPATHY
4600 378 128 4.9 4 NO DENGUE HAEMORRHAGIC FEVER??? DENGUE HAEMORRHAGIC FEVERMODS WITH DIC
22 46 133 3.4 21 - YES SEPSIS B/L THALAMIC INFARCT WITH HEMMORRHAGIC TRANSFORMATASPIRATION PNEUMONIAABDOMINAL PSEUDO OBSTRUCTI N
18 160 133 3 7 - DRUG DEHYDRATION DIABETIC KETO ACIDOSISRHINO OCULO CEREBRAL MUCORMYCOSIS WITH LEFT CAVERNINTRACRANIAL BLEED
261 46 147 4.3 15 - NO POST CARDIAC ARREST STATUS HYPOXIC ISCHEMIC ENCEPHALOPATHY WITH MYOCLONIC SEIPROBABLE ELECTR CU ION
111 42 131 5.2 21 - NO CRS- NSTEMISEPSIS NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION TIACUTE INFECTIVE EXACERBAT ON O  COPD
12 41 140 4.8 10 RHABDOMYOLYSIS PIGMENT NEPHROPATHY GTCS PROBABLY MITOCHONDRIAL CYTOPATHY
134 109 158 3.4 19 - NO DEHYDRATION ADENOCARCINOMA LUNG WITH PITUITARY MET3RD VENTRICLE OBSTRUCTION WITH HYDROCEPHALUS
10 163 132 3.4 10.4 YES HEPATORENAL SYNDROMESEP IS DECOMPENSATED CHRONIC LIVER DISEASE-ETHANOL RELATEPONTANE US BACTERIAL PERITONITISSEPTIC SHOCK
76 179 122 4 27 NO SCRUB SEPSIS SCRUB TYPHUSARDS
12 75 129 4.1 9.2 - NO SEPSIS POST CARDIAC ARREST STATUS ACUTE FEBRILE ILLNESS IN SEPTIC SHOCKSTATUS PO T CARDIAC ARREST
39 282 143 2.8 37 NO NO ACUTE PANCREATITIS(ETHANOL RELATED)SEPSIS ALCOHOLIC HEPATITISACUTE PANCREATITIS(ETHANOL RELATED)STATUS EPILEPTICUS
45 167 132 4.4 7 - NO DRUGS VARICELLA ZOSTER MENINGITISTUBERCULOSIS SPINE
146 98 141 3.3 7 - NO ACUTE PANCREATITIS -SEVERESEPTIC SHOCKPSIS ACUTE PANCREATITIS -SEVERE ,ALCOHOL RELATEDACUTE ALCOHOLIC HEPATITISPTIC SHOCK
11 79 133 2.6 10
496 44 154 3.6 15 - NO RHABBOMYOLYSIS PIGMENT NEPHROPATHYTHIRD S ACING PROBABLE NEUROLEPTIC MALIGNANT SYNDROMEGTCS ? ALCOHOL RELATED
10 100 139 3.3 20 NO CRS-NSTEMISEPSIS ACS-NSTEMIPROBABLE UROSEPSIS
32 170 135 4.1 17.6 - SCRUB ?CRS 1 SCRUB TYPHUSCONGESTIVE CARDIAC FAILURE
DIAG4 PH1 PCO21 P1 NA1 K1 CL1 CA1 GLU1 LAC1 HB1 BEC1 HCO31 F1
7.51 38 82 150 3.5 118 4.37 251 1.5 9.1 7.3 30.3 24
7.44 19 180 143 3 111 3.79 194 8.2 7 -11.3 12.9 100
7.3 25 322 113 4.5 84 3.81 298 5.5 9.7 -14.1 12.3 100
7.16 26 208 130 4.8 104 3.6 347 6.1 13.5 -19.4 9.3 60
7.4 20 133 151 2.4 123 3.63 138 1.5 10.3 -12.4 12.4 24
7.37 35 81 144 3.9 119 4.55 130 0.9 13 -5.1 20.2 40
7 20 127 132 5.6 111 3.33 219 7.1 12.1 -26.4 4.9 60
SEPTIC SHOCK- DISSEMINATED INTRAVASCULAR COAGULATI7.29 36 101 152 4.4 118 4.2 217 6.3 16.7 -9.3 17.3 100
7.28 34 248 151 3.1 121 4.96 236 1.8 11 -10.7 16 60
7.32 45 89 136 4.9 103 4.58 161 2.6 15 -2.9 23.2 30
7.16 30 71 138 4.5 103 3.98 257 7.5 17.2 -18 10.7 80
7.47 33 51 152 3.5 122 4.52 175 1.2 14.1 0.3 24 40
DISTAL SENSORIMOTOR AXONOPATHY- vasculitis related7.37 28 101 141 6 113 4.53 131 1.7 12.6 -9.1 16.2 100
ACUTE TYPE 2 RESPIARTORY FAILURE7.39 51 48 137 4.1 105 4.36 91 1.2 10.5 5.9 30.9 80
7.22 21 67 135 5.2 108 3.68 143 6.2 15.1 -19.1 8.6 50
7.32 29 76 142 5.2 118 4.79 260 2.9 11.2 -11.2 14.9 50
7.28 32 62 134 3.6 104 3.77 332 1.5 11.2 -11.7 15 90
7.27 23 52 143 4.5 123 4.08 188 2.7 7.6 -16.3 10.6 35
GASTRIC AND DUODENAL ULCERS-SEPTIC SHOCK7.31 22 60 137 4 107 2.83 275 5.7 12.7 -15.2 11.1 50
FEBRILE NEUTROPENIA7.43 26 71 148 3.4 116 4.46 245 4.1 12.5 -7 17.3 80
7.34 28 83 132 3.6 107 4.13 138 3.5 -10.7 15.1 30
7.34 61 77 137 1.6 101 3.29 229 2 11.9 7.1 32.9 28
7.1 37 138 126 6.7 94 4.55 632 10.7 11.1 -18.2 11.5 50
7.24 65 57 132 4 100 4.04 128 1 8.4 0.5 27.9 40
7.07 49 64 143 3.4 104 4.04 87 15 8.6 -15.9 14.2 100
RIGHT LEG CELLULITIS7.39 38 74 132 4.9 104 4.04 86 0.8 14.7 -2 23 70
7.45 33 87 138 3.6 103 4.24 187 2.6 13.5 -1.1 22.9 21
7.37 34 66 143 3.2 113 4.49 103 2.9 11.8 -5.6 19.7 21
7.34 42 50 137 3.4 103 4.34 170 1.9 14.9 -3.1 22.7 60
7.07 47 95 134 4.8 102 3.4 199 6.7 15.7 -16.5 13.6 100
7.51 37 68 155 2.7 121 4.44 218 1.1 10.2 6.5 29.5 21
7.04 17 132 143 1.9 119 2.26 128 8.2 10.3 -26 4.6 50
7.11 39 290 141 3.4 117 3.97 241 2.8 12.4 -17.1 12.4 100
7.45 53 127 158 3.2 120 4.38 226 1.5 13.6 12.8 36.8 35
7.22 33 102 138 3.5 106 3.68 455 2.8 12.2 -14.2 13.5 40
7.3 69 53 138 3.6 99 4.45 178 0.9 11.2 7.6 34 30
7.35 36 99 145 4.3 116 3.65 246 2.1 -5.7 19.9 40
SEPSIS MODS 7.42 30 93 138 5.7 113 3.61 161 3.4 14.5 -5 19.5 50
7.4 35 150 139 4 109 3.54 151 1.3 10.2 -3.1 21.7 100
BILIARY SEPSIS 7.26 37 135 150 6.1 120 3.29 106 4.8 12 -10.5 16.6 100
7.08 58 51 127 4.7 96 4.36 251 4.7 13.8 -12.8 17.2 30
7.26 32 61 135 3.4 105 4.11 259 3.5 10.9 -12.7 14.4 60
7.35 23 49 136 4.4 108 3.78 91 7.5 10.8 -12.9 12.7 25
7.17 27 42 142 3.8 118 3.61 98 3.7 11.3 -18.7 9.8 100
7.25 27 170 121 4.2 99 3.96 110 3.8 11.1 -15.4 11.8 60
7.3 29 126 131 4.3 104 3.79 128 4.4 9.1 -12.1 14.3 30
6.99 30 124 140 3.1 107 3.34 161 11.3 14.5 -24.2 7.2 100
7.41 30 105 129 3.5 101 4.05 131 4.1 9.5 -5.6 19 40
SEPSIS WITH SEPTIC SHOCK7.2 37 61 131 4 102 4.74 139 8.3 10.6 -13.5 14.5 60
7.28 32 99 134 4.1 105 4.68 189 2.8 10.7 -11.7 15 28
7.09 92 66 132 5.2 106 4.38 261 1.4 9.4 -1.9 27.9 50
7.38 25 69 134 3.6 106 3.49 98 2.8 13.7 -10.3 14.8 60
7.31 28 90 135 4.1 108 4.27 111 3 -12.2 14.1 21
7.36 44 87 139 3.2 112 3.37 196 1.8 8.7 -0.5 24.9 50
7.39 37 46 132 3.9 102 4 235 1.9 9.4 -2.6 22.4 30
HYPERTENSION 7.48 42 102 141 4.1 107 4.18 140 0.9 10.5 7.8 31.3 30
7.33 36 395 135 4.4 103 3.71 110 2.6 13.7 -6.9 19 80
7.44 36.3 110 145 3.4 112 4.1 90 2.3 9 0.4 24 80
7.13 37 38 128 5.9 105 4.56 183 1.9 9.2 -16.9 12.3 100
MRI CONTRAST INDUCED ANAPHYLAXIS7.28 59 57 132 3 102 4.02 141 1 18.6 1 27.7 30
7.11 37 68 136 4.4 106 4.2 306 5.2 17.9 -17.7 11.8 60
HEPATIC DYSFUNCTION- SHOCK LIVER7.14 16 211 134 4.7 106 3.18 276 13.2 7.5 -23.6 5.4 100
7.38 26 80 137 4.3 111 4.42 166 1.2 -9.7 15.4 21
7.33 34 56 139 4.6 110 4.57 213 1.5 13 -8 17.9 40
7.44 36 111 151 3.1 119 4.84 168 2.6 7.5 0.3 24.5 40
119
7.43 24 101 146 2.8 124 4.53 175 1.6 6 -8.4 15.9 60
7.3 33 148 137 3.8 106 3.81 166 5.6 7.2 -10.2 16.2 50
7.53 40 79 137 2.2 101 3.78 74 5.3 7.5 10.7 33.4 100
7.35 25 137 147 4.1 114 4.34 333 8.7 -11.8 13.8 40
7.16 14 308 134 3.6 98 4.66 111 19.5 8.5 -23.7 5 60
7.25 25 77 136 2.7 113 1.41 94 0.8 9.5 -16.2 11 31
7.5 26 70 136 4.2 107 4.5 150 2.4 13 -2.9 20.3 100
7.4 19 108 138 4.2 104 3.56 100 10.3 7.2 -13 11.8 25
7.44 29 140 138 4.2 108 4.35 101 3 9.8 -4.5 19.7 50
7.4 36 88 137 3.6 107 3.88 200 3.3 12.2 -2.5 22.3 28
7.26 43 86 145 3.8 112 4.6 164 2.1 14.2 -7.8 19.3 100
7.45 25 278 139 3.6 113 4.12 147 2.9 16.2 -6.6 17.4 100
7.03 56 70 131 4.6 110 3.6 151 4.2 15.7 -16 14.8 90
7.54 30 206 134 3.6 104 3.37 122 0.8 9.4 3.2 25.7 40
SEPSIS, MULTIORGAN DYSFUNCTION SYNDROME6.95 23 174 143 5.8 111 4.41 398 15.2 6.8 -27 5.1 60
7.35 38 70 141 4.2 108 4.2 158 2.9 10.8 -4.6 21 80
7.19 17 40 147 4.5 132 1.91 44 1 11.6 -21.7 6.5 60
7.2 53 52 141 6.6 111 4.65 69 4.6 10 -7.3 20.7 100
68 21
7.23 34.4 81.2 147 4.3 122 4.16 114 1.4 9.9 -12.3 13.9 21
6.88 30 73 134 5.1 104 3.92 170 17.2 10.7 -27.6 5.6 100
ATRIAL FIBRILLATION - FAST VENTRICULAR RATE7.43 32 72 133 3.5 101 4.16 143 1.4 14 -3.1 21.2 30
HYPERTENSION 7.22 12 95 147 3 124 4.95 296 0.9 14.5 -22.8 4.9 28
7.34 33 534 138 2.6 104 3.84 250 5.3 16.5 -8 17.8 100
7.21 64 51 136 3.8 100 3.95 354 4.4 15.8 -2.3 25.6 100
7.36 28 128 129 3.8 106 4 126 0.9 10.9 -9.6 15.8 30
7.42 30 125 140 2.6 113 4.2 106 2.4 -5 19.5 21
7.4 27 70 131 3.2 100 4.63 238 2.5 15.3 -8.1 16.7 30
7.09 33 78 130 4.5 101 4.69 111 8.5 14 -19.8 10 40
HYPOXIC ISCHEMIC ENCEPHALOPATHY7.55 39 145 147 3.5 108 3.95 203 3 6.8 11.7 34.1 100
7.25 23 109 129 4.1 107 4.44 102 0.8 10.5 -17.1 10.1 21
7.2 37 51 138 3.2 105 3.15 343 5.1 10.5 -13.5 14.5 60
7.15 32 59 137 3.4 114 4.3 117 1.1 12.4 -17.8 11.1 28
7.19 31 240 134 6.6 104 2.33 604 2.8 13.4 -16.4 11.8 100
7.03 34 76 145 2.2 105 4.43 314 17.5 13.5 -21.8 9 30
PF1 PF1COD PR1 SBP1 DBP1 CVS1 PLATE1 PLAT1COD GCS1 GCS11 GCS1COD vent1 BIL1 BIL1COD
341.67 1 100 130 80 0 225000 0 4T 6 3 1 0.7 0
180 2 160 106 46 4 18000 4 15 15 0 0 0.72 0
322 1 85 130 75 3 410000 0 5TS 9 3 1 0.9 0
346.67 1 110 120 80 4 105000 1 2T 3 4 1 0.97 0
554.17 0 100 110 70 4 400000 0 5T 7 3 1 0.9 0
202.5 2 110 120 70 0 297000 0 4TS 6 3 1 0.64 0
211.67 2 130 130 80 4 45000 3 4T 6 3 1 1.91 1
101 3 130 120 70 4 90000 2 4T 6 3 1 0.3 0
413.33 0 100 120 70 4 228000 0 2T 3 4 1 0.55 0
296.67 2 100 110 60 4 404000 0 2TS=4T 6 3 1 0.9 0
88.75 4 140 120 65 4 60000 2 2T 3 4 1 4.5 2
127.5 3 80 130 75 0 133000 1 2T 3 4 1 4.3 2
101 3 110 120 65 4 146000 1 7T 10 2 1 0.5 0
60 4 125 110 60 3 191000 0 3TS=5T 6 3 1 0.4 0
134 3 120 110 65 4 70000 2 3TS=5T 6 3 1 1.4 1
152 3 110 100 60 0 60000 2 3TS=5T 7 3 1 11.2 3
68.89 4 130 110 65 4 2330000 0 2TS 3 4 1 1.3 1
148.57 2 100 120 70 0 70000 2 15 15 0 0 0.9 0
120 3 100 130 80 4 75000 2 4T 6 3 1 2.3 2
88.75 4 120 130 80 0 14000 4 4TS 5 4 1 4 2
276.67 2 140 110 50 3 15000 4 15 15 0 0 1 0
275 2 70 110 65 4 213000 0 10T 13 1 1 0.5 0
276 2 100 130 55 4 177000 0 5T 7 3 1 0.4 0
142.5 3 95 120 65 4 318000 0 2TS=3T 5 4 1 0.5 0
64 4 120 120 75 3 61000 2 4TS=5T 7 3 1 6.3 3
105.71 3 100 120 80 0 369000 0 6T 9 3 1 0.27 0
414.29 0 80 150 90 0 262000 0 15 15 0 0 1.3 1
314.29 1 100 100 60 3 94000 2 15 15 0 0 4 2
83.33 4 100 130 70 3 185000 0 4TS=6T 9 3 1 2 2
95 4 115 115 65 4 124000 1 2T 3 4 1 1.4 1
323.81 1 110 140 75 0 400000 0 15 15 0 0 0.53 0
264 2 120 100 65 4 165000 0 2TS=3T 4 4 1 0.88 0
290 2 130 140 80 4 15000 4 2T 3 4 1 1.6 1
362.86 1 120 110 70 0 150000 1 7T 10 2 1 0.6 0
255 2 90 110 70 4 167000 0 2TS 3 4 1 0.45 0
176.67 2 105 130 70 0 346000 0 15 15 0 0 0.66 0
247.5 2 110 130 80 0 126000 1 6T 8 3 1 0.7 0
186 2 100 120 70 0 204000 0 15 15 0 0 0.7 0
150 2 80 120 70 4 190000 0 15 15 0 0 7 3
135 3 126 110 70 4 21000 3 5T 7 3 1 1.33 1
170 3 90 100 50 4 66000 2 2TS=5T 7 3 1 2.4 2
101.67 3 115 110 65 4 155000 0 2TS 6 3 1 0.3 0
196 2 120 120 80 0 60000 2 15 15 0 0 0.9 0
42 4 118 140 70 3 60000 2 3TS=5T 7 3 1 1.87 1
283.33 2 100 110 70 4 32000 3 4T 6 3 1 18.9 4
420 0 110 130 70 4 150000 1 15 15 0 0 1 0
124 3 120 105 70 4 164000 0 6TS=9T 11 2 1 1.4 1
262.5 2 80 130 80 4 30000 3 2TS 4 4 1 2.4 2
101.67 2 120 100 70 4 45000 3 15 15 0 0 5 2
353.57 1 110 120 70 3 90000 2 15 15 0 0 1.1 0
132 3 140 100 70 4 138000 1 3TS=5T 7 3 1 3.7 2
115 2 112 110 70 0 75000 2 15 15 0 0 2.3 2
428.57 0 110 120 65 0 150000 1 15 15 0 0 2.5 2
174 3 100 115 70 4 118000 1 9TS=10T 10 2 1 1.9 1
153.33 3 80 140 90 0 143000 1 7T 10 2 1 0.4 0
340 1 50 140 60 0 300000 0 15 15 0 0 0.8 0
493.75 0 105 130 60 3 67000 2 6TS=8T 9 3 1 10 3
137.5 2 110 100 70 2 162000 0 13 13 1 0 0.7 0
38 4 100 110 80 0 124000 1 3TS 7 3 1 0.6 0
190 3 100 120 70 4 119000 1 10T 12 2 1 1.3 1
113.33 3 121 75 55 4 28000 3 2T 3 4 1 3.3 2
211 2 120 120 65 2 28000 3 5TS 7 3 1 3 2
380.95 1 92 120 60 2 179000 0 15 15 0 0 0.6 0
140 2 90 130 70 0 90000 2 15 15 0 0 0.6 0
277.5 2 81 100 60 4 75000 2 5T 7 3 1 0.8 0
410 0 90 110 60 4 98000 2 12 12 2 0 0.4 0
168.33 3 120 130 70 0 110000 1 8TS 11 2 1 24 4
296 2 155 125 75 4 6000 4 7TS=8T 9 3 1 1.5 1
79 2 115 105 60 0 45000 3 13 13 1 0 7.6 3
342.5 1 120 120 65 2 373000 0 5TS=7T 10 2 1 14 4
513.33 0 105 115 60 4 45000 3 5TS=6T 9 3 1 1.06 0
248.39 2 100 130 65 0 60000 2 12 12 2 0 0.54 0
70 4 130 110 60 4 270000 0 3TS 7 3 1 1.4 1
432 0 115 110 65 0 60000 2 15 15 0 0 39.9 4
280 2 80 110 70 0 66000 2 2TS 4 4 1 1.3 1
314.29 1 95 120 70 0 146000 1 15 15 0 0 4.8 2
86 4 110 116 64 3 475000 0 10TS 12 2 1 0.4 0
278 2 94 120 80 0 184000 0 3TS 5 4 1 0.9 0
77.78 4 120 110 70 4 30000 3 4T 6 3 1 3.4 2
515 0 80 122 80 0 30000 3 15 15 0 0 1.8 1
290 2 130 120 70 4 35000 3 10T 13 1 1 0.4 0
87.5 4 95 125 70 4 53000 2 2T 3 4 1 3 2
66.67 4 110 110 60 4 218000 0 2TS 4 4 1 0.5 0
52 2 105 110 70 4 272000 0 3TS 6 3 0 1.3 1
323.81 1 115 140 80 0 135000 1 15 15 0 0 15.7 4
386.67 1 120 130 70 4 151000 0 4TS=5T 7 3 1 0.4 0
73 4 120 100 60 4 16000 4 2TS 4 4 1 2.78 2
240 2 80 120 70 0 148000 1 2T 3 4 1 1.9 1
339.29 1 90 150 90 0 324000 0 15 15 0 0 0.4 0
534 0 120 110 70 3 235000 0 2T 3 4 1 0.4 0
51 4 120 100 60 4 212000 0 2TS=4T 6 3 1 0.7 0
426.67 0 115 122 70 0 327000 0 10TS 12 2 1 0.4 0
595.24 0 80 110 75 0 140000 1 14 14 1 0 0.4 0
1 130 120 60 3 116000 1 12 12 2 0 2.46 2
233.33 2 105 115 70 4 90000 2 9T 12 2 1 2.1 2
195 2 115 130 70 4 208000 0 15 15 0 0 0.72 0
145 3 106 120 60 3 226000 0 2T 3 4 1 6.6 3
519.05 0 130 100 70 0 190000 0 3T 4 4 1 0.47 0
85 4 130 100 60 4 73000 2 6T 8 3 1 3.2 2
210.71 2 90 110 60 4 145000 1 2TS 5 4 1 0.4 0
240 2 90 130 60 4 30000 3 2TS 4 4 1 0.67 0
253.33 2 85 115 60 4 261000 0 2TS 4 4 1 1.3 1
2 80 140 75 4 27000 3 14 14 1 0 2 2
creat1 CREAT1CODurea1 sofa1 intake1 output1 RIFLE1 AKIN1 sofa2 intake2 output2 creat2 CREAT2CODurea2
1.5 1 104 5 1855 1475 1 1 3 3465 1272 1.17 0 87
1.9 1 69 11 5852 2030 2 2 14 2.61 2 109
1.99 2 34 9 1926 750 1 10 1398 1355 2.11 2 65
3.6 3 70 13 4425 735 3 3 13 2677 365 3.78 3 90
1.63 1 73 8 3534 1295 2 2 1 2970 1330 1.15 0 45
1.46 1 31 6 3250 865 1 1 2 4075 2095 1.25 1 30
6.06 4 159 17 10557 1430 3 3 16 6980 1290 3.91 3 114
1.12 0 60 12 6658 1485 1 1 15 4475 645 1.5 1 90
1.62 1 91 9 3330 1820 1 10 3640 1035 2.2 2 110
1.08 0 23 9 3198 770 1 1 5 3785 2880 0.95 0 25
2.27 2 107 18 7958 177 2 3 18 3997 825 2.56 2 112
1.14 0 60 10 4015 870 1 1 8 3925 1060 0.8 0 41
3.61 3 155 13 2010 620 3 3 10 3960 470 3.12 2 102
1.4 1 41 11 4419 1575 1 1 14 3664 685 2.79 2 70
1.88 1 78 14 11853 3000 2 2 13 5708 1680 1.54 1 69
2.08 2 119 13 2640 1115 1 1 9 2353 1455 1.86 1 93
2.09 2 71 15 4322 1740 3 3 8 1573 2525 1.92 1 55
3.76 3 154 7 3 3 7 4.03 3 168
3.33 2 78 16 5620 1845 3 3 15 4602 5130 2.32 2 59
1.41 1 198 15 3456 2195 2 2 12 4775 3445 1.42 1 181
1.75 1 61 10 5768 360 2 2 11 7039 1210 2.48 2 63
1.1 0 27 7 4178 3360 1 1 13 3181 1505 1.36 1 28
3.72 3 95 12 967 460 2 2 13 2590 1020 3.62 3 66
1.6 1 90 12 3500 1500 1 1 12 4043 1235 1.49 1 94
1.01 0 17 15 2113 757 1 1 13 4287 442 1.43 1 34
1.5 1 28 7 1632 1020 1 1 9 3379 1153 2.63 2 57
2.16 2 33 3 4060 1865 2 2 2 1035 40 3 2 38
1.05 0 46 8 5395 2350 1 1 8 4335 2647 1 0 40
1.35 1 55 13 4016 1720 2 2 9 1742 1420 0.94 0 38
2.36 2 77 16 4295 125 3 3 16 1000 65 2.32 2 47
2.09 2 86 3 4808 2225 2 2 2 1775 1880 0.8 0 34
1.69 1 65 11 5207 1135 1 1 12 2480 1055 1.86 1 70
3.98 3 80 18 8051 3475 3 3 18 3000 1800 3.79 3 88
1.6 1 110 5 2500 555 2 2 3 5074 1145 1.09 0 107
2.4 2 68 12 5732 500 2 2 12 5034 1230 3.22 2 80
1.28 1 45 3 1520 1665 1 1 2 1850 4430 0.66 0 30
2.1 2 81 8 2986 1020 1 1 9 2688 1015 2.32 2 110
1.55 1 101 3 3300 880 1 1 2 1545 1795 1.73 1 114
1.71 1 78 10 1866 1290 2 2 10 1974 1415 1.08 0 66
2.89 2 183 16 6494 475 3 3 17 4578 1050 2.99 2 215
1.63 1 50 15 4715 400 2 2 16 2480 562 2.86 2 75
1.51 1 61 11 3663 722 2 2 9 3354 1110 1.27 1 60
1.68 1 54 5 4620 1155 2 2 16 3884 380 1.84 1 67
4.54 3 184 16 4527 690 3 3 17 5677 890 3.86 3 213
1.09 0 61 16 10000 275 3 3 17 4502 375 1.32 1 50
2.67 2 71 7 6895 250 3 3 11 1675 411 3.24 2 94
1.92 1 37 11 7125 365 3 3 20 3495 102 4.97 4 109
4.94 4 116 19 3450 10 3 3 18 1516 5 5.87 4 106
3.15 2 60 13 3537 670 3 3 15 1756 750 2.88 2 75
3.28 2 95 8 3293 850 3 3 11 3025 720 3.88 3 110
1.56 1 77 14 2181 2340 1 1 9 1840 2470 1.34 1 84
2.3 2 120 8 3060 1250 3 3 8 2400 1170 2.43 2 123
4.51 3 121 6 7785 895 3 3 8 3845 1130 5 4 130
1 0 49 11 1954 465 1 1 10 2099 410 1.07 0 50
5.36 4 129 10 2853 2265 2 2 6 1094 2050 5.4 4 130
1.25 1 20 2 1820 205 1 1 0 1440 785 0.99 0 20
5.78 4 145 15 2566 65 3 3 17 2218 85 5.46 4 125
1.28 1 69 6 2455 1125 2 2 7 2765 1235 1.31 1 70
2.59 2 81 10 1265 595 2 2 10 1815 20 2.87 2 68
1.06 0 32 11 4650 3570 1 1 9 2067 1247 0.77 0 22
3.12 2 111 18 3000 400 3 3
1.91 1 68 13 7337 345 2 2 15 3450 290 3.04 2 91
1.52 1 50 4 5041 1698 1 1 0 2028 2710 0.98 0 31
5.8 4 132 8 1814 127 3 3 9 1351 580 5.11 4 97
1.53 1 124 12 6672 1290 2 2 13 4168 1010 1.31 1 128
3.05 2 98 10 7095 410 2 2 9 3159 615 2.85 2 90
1.1 0 48 10 5110 2410 1 1 11 4599 2135 1.04 0 48
1.3 1 51 15 4756 1490 2 2 17 3957 675 2.6 2 85
1.2 0 95 9 5710 1575 1 1 18 6740 2295 0.87 0 77
1.47 1 73 10 3806 3395 1 1 8 6158 2760 0.85 0 90
1.58 1 55 11 3359 560 1 1 16 4406 595 1.47 1 73
5.45 4 187 10 7138 1085 3 3 12 2042 1185 5.22 4 193
1.52 1 44 13 7568 1142 2 2 11 4391 940 1.19 0 44
2.5 2 150 8 2740 1340 2 2 16 4060 750 3.34 2 191
2.54 2 143 11 1856 685 2 2 15 6125 690 2.04 2 133
1.46 1 28 5 7148 2225 1 1 7 5700 3875 1.27 1 31
1.34 1 48 10 1656 1465 1 1 6 1585 965 1.27 1 55
1.1 0 25 6 2813 1635 1 1 5 2710 2399 0.75 0 30
1.71 1 85 17 8932 1990 2 2 15 2945 1350 1.72 1 98
2.37 2 78 6 1220 3328 3 3 7 1508 3595 2.02 2 57
3.46 3 179 13 5938 2970 3 3 12 4288 2633 2.3 2 140
1.65 1 56 17 2720 1035 2 2 17 2297 1150 1.84 1 147
4.05 3 94 15 5864 1995 3 3 15 3360 385 3.28 2 109
1.84 1 61 11 3991 790 2 2 15 2841 390 2.67 2 83
3.43 3 82 9 1250 50 3 3 6 2830 540 3.59 3 90
2.67 2 69 10 3223 2675 3 3 9 2064 1348 2.59 2 90
1.57 1 46 19 9293 30 3 3 18 5901 60 1.51 1 29
1.38 1 48 9 880 1205 1 1 8 2596 1220 1.05 0 56
1.77 1 45 2 8780 4850 1 1 1 5544 2985 1.49 1 43
1.4 1 28 8 7864 2575 1 1 7 4719 2460 0.91 0 40
2.03 2 60 13 4502 1305 2 2 11 2628 1217 1.71 1 67
1.06 0 27 2 2945 2825 1 1 2 3206 2515 0.61 0 30
1.1 0 31 2 4100 1625 1 1 3 5030 1440 0.49 0 30
1.71 1 12 10 2000 400 2 2 14 1800 200 3.17 2 20
4.82 3 183 15 13250 2705 3 3 14 6203 1215 2.49 2 148
2.36 2 46 8 3574 1675 2 2 13 876 130 2.02 2 60
2.06 2 59 15 5066 1585 3 3 9 3344 1950 1.57 1 50
4.26 3 103 7 4120 2025 1 9 3195 1040 4.58 3 102
4.33 3 70 18 8307 530 3 3 18 2.98 2 58
1.29 1 45 12 7585 2820 1 1 13 4095 1690 1.5 1 58
7.27 4 149 17 11724 1411 3 3 15 2135 305 5.98 4 105
1.58 1 27 12 6880 760 1 1 12 2146 290 2.3 2 37
2.39 2 104 14 2480 840 3 3 9 2700 1315 1.83 1 102
PH2 PCO22 P2 NA2 K2 CL2 CA2 GLU2 LAC2 HB2 BEC2 HCO32 F2 PF2
7.53 34 91 147 3.3 115 4.76 241 1.5 6.1 5.7 28.4 21 433.33
7.46 28 150 147 2.7 115 4.08 151 2.6 8.5 -3.9 19.9 30 500
7.57 16 108 119 3.5 90 3.94 176 1.5 10 -7.3 14.7 45 240
7.42 31 63 134 4.5 105 3.9 241 4.3 12.4 -4.4 20.1 25 252
7.4 18 138 146 3.1 126 4.09 134 1 8.8 -13.7 11.1 24 575
7.41 37 79 141 3 108 4.54 165 0.9 12.3 -1.1 23.5 24 329.17
7.21 19 131 139 2.9 105 3.58 81 12.3 10.7 -20.3 7.6 40 327.5
7.43 36 55 146 3.6 117 4.22 101 3.4 6.9 -0.4 23.9 50 110
7.01 42 259 150 3.5 118 4.58 537 3.5 10 -20.5 10.6 60 431.67
7.38 42 236 134 3.5 101 4.41 109 1.2 -0.3 24.8 40 590
7.23 31 65 141 4.4 103 4.12 166 10.7 8.2 -14.6 13 100 65
7.41 43 74 144 3.4 111 4.61 142 1.5 15.7 2.7 27.3 30 246.67
7.38 30 73 136 3.7 110 4.51 189 1.5 10.4 -7.4 17.7 24 304.17
6.96 145 76 154 4 117 4.81 271 1.2 10.9 0.7 32.6 80 95
7.2 34 70 138 3.9 108 3.92 150 9.8 13.3 -14.7 13.3 44 159.09
7.52 30 100 147 4.4 119 4.61 145 1.5 9.5 1.6 24.5 30 333.33
7.36 34 143 147 3.8 118 3.95 157 1 10 -6.2 19.2 40 357.5
7.29 26 67 132 3 123 3.96 199 1.6 6.3 -14.1 12.5 60 111.67
7.5 31 73 146 3.6 115 3.67 198 1.8 11.8 1 24.2 40 182.5
7.43 32 88 151 4 123 4.81 186 2 12.3 -3.1 21.2 75 117.33
7.21 33 78 138 4 112 4.43 145 3.2 7.6 -10.7 13.2 28 278.57
7.27 42 71 155 5.8 114 2.5 158 3 12.2 -7.6 19.3 100 71
7.41 39 55 137 4.3 107 4.29 222 1.5 9.6 0.1 24.7 40 137.5
7.39 52 50 137 2.9 102 3.92 233 2.2 8.4 6.5 31.5 40 125
7.43 28 104 143 3.1 110 3.91 128 7.4 8.9 -5.7 18.6 30 346.67
7.39 38 74 132 4.9 104 4.04 86 0.8 14.7 -2 23 70 105.71
7.51 30 111 137 3.6 105 4.05 131 2.1 12.9 0.9 23.9 21 528.57
7.4 32 70 142 3.7 112 4.42 109 2.6 11 -5 19.8 21 333.33
7.52 30 49 143 3.6 114 4.32 159 1.1 11.8 1.6 24.5 30 163.33
6.83 32 56 132 8.6 103 3.66 593 18.7 6.6 -28.7 5.3 100 56
7.55 35 59 151 3.3 119 4.29 246 2 10.1 8.2 30.6 21 280.95
7.4 25 105 146 3.1 107 4.3 173 14.8 8.4 -9.3 15.5 30 350
250
7.45 47 114 162 3.1 126 4.85 59 2.1 10.9 8.7 32.7 30 380
7.46 18 72 141 2.9 113 3.67 118 3.5 14.4 -11 12.8 21 342.86
7.39 62 44 139 4.1 106 4.31 192 1.2 11.1 12.5 37.5 30 146.67
7.09 70 50 139 4.6 108 3.5 259 2.4 -8.6 21.2 30 166.67
7.46 33 95 141 4.7 115 4.36 107 1.5 14.5 -0.3 23.5 31 306.45
7.4 40 265 140 4.1 111 3.64 168 1.6 11.1 0 24.8 100 265
7.44 30 71 150 4.9 119 3.61 206 4.7 11.4 -3.8 20.4 55 129.09
7.25 25 117 127 3.3 98 3.77 276 5.7 11 -16.2 11 40 292.5
7.49 28 189 148 3.1 116 3.94 215 3.3 9.5 -2 21.3 50 378
7.57 92 36 179 3.8 119 2.96 112 8.1 8.5 62.3 84.3 70 51.43
7.24 48 138 145 3.3 117 3.34 208 3.1 11.4 -6.8 20.6 50 276
7.31 26 82 129 3.3 102 3.81 143 5.3 6.7 -13.2 13.1 30 273.33
7.26 32.9 120 131 5.5 106 0.98 101 4.2 6.5 -4.5 19.5 100 120
7.42 33 54 144 3.2 107 4.15 135 9.4 14.5 -3.1 21.4 80 67.5
7.62 38 67 140 3.5 99 4.11 205 4.6 8 17.9 39.1 40 167.5
7.48 35 64 133 3.5 101 4.08 135 3.4 8.5 2.6 26.1 40 160
7.24 37 71 132 3.8 100 4.51 183 3.7 11 -11.5 15.9 24 295.83
7.64 23 172 144 3.2 116 4.29 170 1.3 7.6 3.9 24.8 35 491.43
7.4 30 80 131 3.4 107 3.91 101 1.3 12.2 -6.2 18.6 40 200
7.38 30 70 137 4.2 109 4.36 126 1.5 12.5 -7.4 17.7 21 333.33
7.36 44 81 143 3.6 112 3.31 172 1.7 9 -0.5 24.9 35 231.43
179 140 4 30 596.67
7.34 40 82 134 4 104 4.04 118 1.5 9.1 -4.2 21.6 80 102.5
7.5 31.5 122 144 4 110 4 100 2 8.3 1.7 26.2 60 203.33
7.44 31 203 130 4.3 103 4.32 187 0.9 6.3 -3.1 21.1 80 253.75
7.38 49 67 141 3.7 109 4.29 134 1 13.3 3.9 29 30 223.33
7.43 28 64 142 3.9 112 4.24 174 4.5 7 -5.7 18.6 40 160
7.36 42 145 138 4.3 107 4.6 97 0.5 10 -1.7 23.7 60 241.67
7.44 34 68 148 3.4 115 4.63 153 1.9 11.1 -1.1 23.1 35 194.29
7.27 18 211 136 2.9 119 3.81 119 3.7 14.7 -18.6 8.3 31 680.65
7.34 29 39 147 4.3 121 4.35 148 3.4 7.5 -10.2 15.6 25 156
7.28 36 49 131 4.2 104 3.54 147 2.8 11.3 -9.8 16.9 30 163.33
7.51 38 46 138 4.6 107 3.92 139 4.4 9.4 7.3 30.3 40 115
7.48 31 103 150 4 121 4.71 181 1.1 5.2 -0.4 23.1 21 490.48
7.47 31 103 138 3.3 105 4.24 146 4.8 7.3 -1.1 22.6 35 294.29
7.47 26 182 130 3.7 100 3.96 151 3.4 12.1 -4.8 18.9 30 606.67
7.38 29 60 135 3.6 110 3.97 596 1.7 -7.9 17.2 100 60
7.42 18 205 144 5.1 108 3.11 101 10.7 6.7 -12.8 11.7 80 256.25
7.36 33 76 140 4.3 112 4.47 143 1.7 8.1 -6.8 18.6 30 253.33
7.43 42 56 137 3.9 104 4.08 140 1.1 11.9 3.6 27.9 21 266.67
7.44 39 69 148 2.3 116 4.58 116 0.9 9.4 2.3 26.5 30 230
7.39 37 90 138 3.3 106 4.35 169 1 15.4 -2.6 22.4 30 300
7.34 33 61 137 3.3 105 4.36 163 4.3 13.8 -8 17.8 30 203.33
7.52 32 97 136 4.6 103 3.15 95 0.9 12.5 3.2 26.1 31 312.9
7.3 45 144 139 6.3 106 4.72 135 0.6 8.1 -4.3 22.1 25 576
7.35 43 62 140 4.1 108 3.88 116 2.1 10.1 -1.9 23.7 70 88.57
7.45 27 67 148 4.1 115 3.81 294 3.5 10.7 -5.2 18.8 60 111.67
7.31 62 50 144 3.3 109 5.03 136 2 7.5 4.9 31.2 85 58.82
7.48 24 87 135 3.7 110 4.14 100 2.6 10.8 -5.6 17.9 21 414.29
7.33 15 133 150 3.4 114 3.63 265 3.1 8.8 -18 7.9 30 443.33
7.26 33 64 143 3 107 4.24 86 13.1 8.4 -12.3 14.8 100 64
7.43 37 50 136 4.4 102 4.48 212 1.7 14 0.3 24.6 30 166.67
7.32 32.4 248 147 3.6 123 1.03 309 1.9 10.4 -8.5 16.4 60 413.33
7.28 40 99 136 3.8 109 4.06 144 2.7 16 -7.9 18.8 21 471.43
7.52 39 70 144 3.4 106 4.37 230 2.3 14.4 8.9 31.8 80 87.5
7.45 32 103 144 2.9 114 3.68 106 1.3 -1.8 22.2 21 490.48
7.05 26 171 132 4.6 104 3.68 92 13.6 10.2 -23.3 7.2
7.36 39 86 137 4.1 106 4.46 211 1.5 15.3 -3.4 22 40 215
7 28 102 139 8.6 109 4.06 326 17.7 9.4 -24.4 6.9 75 136
7.58 32 98 141 3.1 107 3.7 106 2.1 7.7 8.1 30 25 392
7.22 38 47 136 4.2 109 4.73 305 1.2 12 -12.1 15.6 21 223.81
7.1 35 70 145 3.8 115 3.58 42 13.5 7.8 -18.8 10.9 60 116.67
6.93 36 72 147 2.7 114 3.29 300 9.2 11.5 -24.8 7.6 90 80
7.38 25 138 137 5.8 104 2.72 144 4.8 16.5 -10.3 14.8 40 345
7.31 43 50 140 4.5 108 3.77 95 5.4 11.9 -4.6 21.7 40 125
7.38 38 83 139 3.6 111 4.18 149 1.7 10.5 -2.6 22.5 40 207.5
PF2COD GCS2 GCS22 GCS2COD vent2 PLATE2 PLAT2COD BIL2 BIL2COD PR2 SBP2 DBP2 CVS2 SOFA3
0 5T 7 3 1 180000 0 0.6 0 94 140 90 0 4
0 5TS=6T 9 3 1 15000 4 1.5 1 145 85 50 4 16
2 9T 12 2 1 336000 0 0.9 0 95 110 65 4 7
2 4T 6 3 1 60000 2 0.9 0 96 110 70 3 14
0 10T 13 1 1 250000 0 0.9 0 90 100 60 0 1
1 15 15 0 1 167000 0 0.7 0 100 120 74 0 1
1 2TS=4T 6 3 1 45000 3 2.2 2 126 120 76 4 18
3 2T 3 4 1 30000 3 0.5 0 130 120 70 4 16
0 2T 3 4 1 175000 0 0.7 0 120 120 80 4 12
0 7TS=8T 11 2 1 241000 0 0.6 0 116 130 80 3 3
4 2t 3 4 1 81000 2 4.8 2 140 120 60 4 20
2 4T 6 3 1 130000 1 3.3 2 75 145 85 0 6
1 12 12 2 0 117000 1 0.6 0 100 125 65 4 9
4 2TS=4T 6 3 1 127000 1 0.6 0 120 105 60 4 16
3 2TS=4T 6 3 1 56000 2 0.58 0 115 120 70 4 13
1 7T 10 2 1 75000 2 9.7 3 95 110 70 0 9
1 7T 10 2 1 197000 0 0.9 0 120 120 65 4 8
2 15 15 0 0 70000 2 1.1 0 100 130 60 0
3 10T 13 1 1 45000 3 2 2 100 120 65 4 8
3 4TS 7 3 1 50000 3 3.97 2 110 120 80 0 13
2 15 15 0 0 15000 4 1 0 145 107 45 3 12
4 2T 3 4 1 200000 0 0.5 0 110 90 50 4
3 9T 12 2 1 140000 1 0.5 0 110 140 60 4 14
3 3T 4 4 1 200000 0 0.6 0 90 120 70 4 6
1 5TS=6T 9 3 1 60000 2 8 3 115 120 75 3 10
3 7T 10 2 1 303000 0 0.4 0 100 130 65 2 8
0 15 15 0 0 243000 0 1.2 0 72 140 90 0 2
1 15 15 0 0 64000 2 2 2 90 100 60 3 5
3 5TS=8T 12 2 1 170000 0 2 2 90 140 80 2 8
4 2T 3 4 1 60000 2 1.2 0 90 100 65 4
2 15 15 0 0 394000 0 0.5 0 100 150 80 0 1
1 7TS 9 3 1 60000 2 1.4 1 110 100 65 4 11
2 2T 3 4 1 17000 4 1.8 1 120 90 50 4
1 8T 11 2 1 160000 0 0.6 0 130 110 70 0 4
1 2T 3 4 1 100000 2 0.9 0 90 120 70 3 12
2 15 15 0 0 275000 0 0.6 0 100 140 75 0 1
3 6T 9 3 1 120000 1 0.7 0 120 160 100 0 11
1 15 15 0 0 200000 0 0.8 0 105 110 70 0 2
2 6TS 9 3 1 200000 0 2.6 2 70 120 70 3 8
3 4TS=5T 7 3 1 18000 4 1.8 1 120 100 60 4 18
2 2TS=4T 6 3 1 30000 3 2.6 2 95 130 70 4 12
1 6TS 10 2 1 118000 1 0.4 0 100 140 70 4 7
4 2TS 4 4 1 30000 3 0.9 0 100 110 65 4 18
2 3T 4 4 1 30000 3 2 2 100 120 70 3 17
2 10T 12 2 1 18000 4 18 4 70 140 80 4 18
2 13 13 1 0 100000 2 1 0 120 120 70 4 14
4 4TS=6T 9 3 1 36000 3 4 2 135 100 60 4 18
3 5TS=6T 9 3 1 46000 3 2 2 80 130 75 3 15
2 15 15 0 0 17000 4 6 3 120 110 70 4 14
2 15 15 0 0 43000 3 0.9 0 110 115 60 3 6
0 4T 6 3 1 120000 1 3.5 2 120 130 80 2 8
2 15 15 0 0 133000 1 4.3 2 96 90 45 1 6
1 15 15 0 0 110000 1 2 2 110 135 70 0 7
2 9TS=9T 12 2 1 106000 1 1.9 1 95 100 60 4 9
1 10T 14 1 1 150000 1 0.5 0 90 130 80 0
0 15 15 0 0 200000 0 0.8 0 60 170 80 0 0
3 7T 10 2 1 30000 3 7 3 100 110 60 2 12
2 12 12 2 0 153000 0 0.7 0 100 120 75 2 7
2 7T 10 2 1 120000 1 0.7 0 70 120 70 3 7
2 10T 12 2 1 88000 2 1.1 0 100 140 80 3 11
3 3TS 6 3 1 34000 3 5.9 2 105 135 60 2 15
0 15 15 0 0 207000 0 0.6 0 90 130 74 0 0
2 15 15 0 0 90000 2 1.5 1 90 130 70 0 10
3 5T 7 3 1 46000 3 0.4 0 90 100 60 3
0 13 13 1 0 70000 2 0.5 0 90 110 80 4 9
3 8TS 12 2 1 90000 2 25 4 120 120 70 0 20
3 9TS=9T 12 2 1 4000 4 2.7 2 135 120 75 4 17
3 2TS=3 4 4 1 16000 4 7.7 3 115 120 70 4 18
0 7T 9 3 1 121000 1 12 4 125 115 60 0 12
2 4TS=6T 9 3 1 10000 4 3 2 125 100 50 4 16
0 3T 4 4 1 15000 4 0.5 0 110 130 70 0 12
4 9T 11 2 1 247000 0 1.7 1 95 120 75 4 6
2 7TS=9T 12 2 1 62000 2 34 4 110 110 65 4 18
2 2T 4 4 1 45000 3 1.4 1 100 130 60 3 12
2 15 15 0 0 78000 2 2.5 2 80 135 80 0 4
2 10T 13 1 1 382000 0 0.4 0 110 120 70 2 3
1 3T 6 3 1 135000 1 0.8 0 110 130 90 0 7
2 4TS=5T 7 3 1 30000 3 3 2 90 110 65 4 14
1 15 15 0 0 45000 3 1.7 1 90 150 100 0 6
0 8TS 12 2 1 15000 4 0.6 0 133 105 50 4 9
4 2TS 3 4 1 45000 3 4 2 85 100 70 3 15
3 2TS 4 4 1 95000 2 0.5 0 105 120 75 4 13
4 3T 4 4 1 200000 0 1.5 1 100 115 65 4
0 15 15 0 0 162000 0 11.4 3 118 130 80 0 8
0 5TS 7 3 1 163000 0 0.5 0 110 120 65 4 10
4 3TS 6 3 1 16000 4 3.5 2 115 100 60 4 13
3 6T 9 3 1 130000 1 1.7 1 80 125 75 0 5
0 15 15 0 0 319000 0 0.6 0 73 130 90 0 2
0 2T 3 4 1 264000 0 0.2 0 130 120 70 3 8
4 7TS=8T 11 2 1 166000 0 0.7 0 125 110 70 4 13
0 12 12 2 0 210000 0 0.5 0 90 120 70 0 0
0 13 13 1 0 90000 2 0.3 0 70 105 70 0 1
1 2T 3 4 1 80000 2 3.5 2 140 120 55 3 20
2 5TS=6T 9 3 1 110000 1 2.1 2 90 105 60 4 14
3 2TS 4 4 1 208000 0 0.8 0 80 120 60 4
1 2T 3 4 1 212000 0 7 3 100 124 75 0 9
2 2T 3 4 1 232000 0 0.4 0 84 116 72 0 6
3 2T 3 4 1 42000 3 3.5 2 120 50 30 4
4 2T 3 4 1 211000 0 0.6 0 120 90 50 4
1 2T 3 4 1 60000 2 0.6 0 120 100 70 4 15
3 3TS 6 3 1 200000 0 0.8 0 90 120 60 4
2 15 15 0 0 27000 3 1.2 0 85 105 70 3 8
intake3 output3 creat3 CREAT3CODurea3 PH3 PCO23 P3 NA3 K3 CL3 CA3 GLU3 LAC3
2732 1355 1.42 1 72 7.52 36 157 136 3.4 107 4.54 252 1.6
2.9 2 120 7.24 30 172 147 3 117 3.54 146 6.2
1145 865 2.33 2 75 7.28 30 91 132 4.4 98 4.16 255 2
2355 325 3.71 3 119 7.37 38.4 130 134 4.1 106 4.07 1.4
2970 1330 0.88 0 22 7.41 19 94 142 3.7 119 4.29 122 0.7
3000 2000 0.89 0 19 80
2604 1325 4.07 3 138 7.46 36 78 145 3.2 110 5.68 200 3
2929 810 1.71 1 110 7.38 35 53 136 4 108 3.94 142 2.7
2207 980 3.34 2 157 7.34 31 166 147 5.2 120 3.86 346 1.5
3640 1975 0.83 0 25 7.57 20 76 135 2.8 103 4.19 126 1.1
4340 700 5.1 4 144 7.24 31 61 142 4.9 104 4.02 109 12.8
2490 1295 0.62 0 32 7.46 41 95 138 3.7 105 4.42 160 0.7
1591 1155 2.57 2 101 7.37 31 58 135 4.7 108 4.44 115 1.8
5528 160 4.05 3 95 7 85 44 144 3.3 106 4.57 149 3.7
4577 1280 1.23 0 55 7.47 31 90 143 3.8 105 3.68 238 9.2
2947 1585 1.74 1 85 7.51 29 64 138 5 113 4.53 161 1.2
1195 1680 1.53 1 50 7.43 31 91 154 3.7 124 4.23 186 0.9
4.61 3 194 7.37 22 147 140 4.2 117 4 140 1.8
4507 4160 1.34 1 41 7.47 32 55 141 3.1 112 3.98 90 1.3
6590 5340 1.02 0 140 7.43 45 157 148 3.6 115 4.44 169 1.7
4498 830 3.1 2 75 7.11 23 86 142 4.2 108 4.13 159 13
1849 1335 5.06 4 88 7.29 34 73 131 5.9 100 4.88 402 3.9
2364 1385 1.2 0 79 7.51 39 85 138 4 105 4.21 173 1.9
2532 1080 1.58 1 42 7.5 24 90 139 3.3 110 3.84 91 6.5
3178 1345 3.06 2 68 7.37 38 96 138 3.9 110 4.09 100 0.5
1385 120 3.3 2 40
3500 2000 0.6 0 30 7.46 33 72 139 3.2 110 4.68 130 1.2
2200 940 0.82 0 41 7.51 33 62 140 3.5 111 4.21 138 1
2825 2450 0.78 0 40
3340 1035 1.86 1 80 7.47 34 185 139 3.6 108 4.29 100 3.4
4003 1355 0.69 0 63
5392 1125 3.78 3 95 7.52 19 104 148 3.7 117 3.8 120 5.1
2100 1740 0.65 0 30 7.38 44 76 149 4.8 118 4.56 207 1.7
1550 1250 2.5 2 120 6.87 99 68 131 5.3 104 3.52 96 4.7
1520 1670 1.03 0 71 7.45 35 69 139 4.4 108 4.13 98 1.4
1885 1630 0.82 0 71 7.39 49 89 147 4.2 115 4.18 161 1.2
2037 2340 2.18 2 228 7.47 32 57 148 4.4 119 3.73 220 2.9
2475 940 3.41 2 112 7.34 25 78 132 4.6 102 3.76 279 2.2
3992 607 0.98 0 79 7.48 33 71 151 2.7 119 4.19 152 1.4
3140 145 2.5 2 80 7.1 39 94 138 4.6 111 4.24 114 11.7
2451 1100 4.01 3 237 7.36 36 79 142 3.3 112 3.23 159 1.8
3282 765 1.5 1 60 7.1 41 89 131 4.3 99 3.87 168 10.6
2660 785 3.02 2 82 7.28 51 72 139 3.8 110 4.28 118 3.4
2022 30 4.83 3 128 7.37 43 86 140 4.2 103 3.83 170 4.4
1008 60 8.24 4 149 7.43 32 52 134 3.6 104 4.24 95 0.9
1878 740 2.7 2 93 7.43 42 39 138 3.2 105 4.26 215 2.4
1962 1985 4.21 3 139 7.34 34 104 133 3.3 101 4.55 208 2.2
1270 3110 1.14 0 61 7.52 32 73 144 4.1 113 4.17 316 1.3
2321 2880 1.92 1 118 7.41 34 76 135 3.8 107 4.16 92 1.1
1540 1025 6.89 4 161 7.39 28 79 132 4.1 106 4.2 124 0.9
1761 580 1.01 0 53 7.38 41 88 142 3.8 113 3.38 191 1.8
1150 1100
1260 765 0.96 0 16 7.5 41 145 138 2.6 104 3.8 144 1
1350 130 7.2 4 240 7.35 36 86 135 3.6 104 4.41 97 0.7
2450 1100 1.47 1 83 7.46 34 145 145 3.9 114 3.99 80 2.1
2090 204 3.55 3 84 7.41 27 100 128 4.1 101 4.14 146 2
4076 742 0.83 0 22 6.99 136 249 142 3.5 109 4.37 197 0.7
3230 250 3.24 2 100 7.44 21 86 144 2.1 123 5.11 76 1.5
3000 3950 0.9 0 30
1210 280 5.88 4 120 7.4 35 123 136 4.3 108 4.4 80 0.7
5164 892 1.29 128 7.43 33 101 145 3.4 112 4.62 195 3.4
2378 350 2.76 2 109 7.41 22 105 144 2.8 114 2.77 125 3.6
3659 2070 0.77 0 35 7.38 31 70 148 4.2 123 4.49 146 1.7
2700 2590 3.6 3 150 7.41 31 285 135 3.4 105 3.34 161 2.6
4197 1095 0.99 0 94 7.51 38 46 138 4.6 107 3.92 139 4.4
5699 3120 0.84 0 82 7.42 34 46 146 3.7 114 4.21 310 3.7
2163 260 2.14 2 88 7.37 20 93 140 3.9 102 4.15 130 16.8
3490 3050 5.58 4 230 7.53 25 79 139 4.5 112 4.08 147 2
2158 2765 1.35 1 45 7.45 31 89 141 3 108 4.9 112 1.8
5559 310 3.54 3 180 7.36 22 192 145 5 112 3.01 207 10.2
3525 1060 1.73 1 119 7.39 27 79 146 4.4 120 4.56 161 1.8
3190 2575 1.1 0 26
1782 878 1.02 0 58 7.42 40 147 147 3.7 119 4.56 103 1.5
3432 2580 0.74 0 35 7.48 22 54 130 7 112 3.93 183 2.3
2921 1765 1.17 0 67 7.38 40 73 140 4 115 4.21 106 1.3
1728 1987 2.06 2 47 7.51 32 110 136 3.9 105 3.3 126 1.2
3513 3204 1.43 1 64 7.45 42 189 137 4 106 4.44 149 0.7
1954 1455 1.57 1 130 7.35 45 89 141 4.4 109 4.22 124 1.7
2039 585 1.81 1 68 7.53 27 83 139 3.7 108 4.32 206 2.2
2655 170 7.31 50 46 146 3.2 113 4.42 124 1.9
2405 850 1.62 1 78 7.45 28 50 135 3.4 107 4.37 66 2.4
4257 1348 1.98 2 91 7.3 30 143 139 4 109 3.73 287 5.7
2810 10 2.82 2 57 7.42 33 149 138 3.4 103 3.75 158 6.5
3046 2530 1.09 0 43 7.44 39 113 136 4.2 102 4.87 208 1.3
5319 3105 1.39 1 33 7.41 26 89 146 3.1 117 3.97 131 2.7
3919 1405 0.43 0 21 7.41 33 84 131 4.8 103 3.96 140 2
2847 2320 1.92 1 73 7.5 41 60 146 3.3 109 4.39 239 2.4
2950 1500 0.5 0 26
2170 1798 0.43 0 25
3411 20 3.5 3 20 7.15 41 72 137 4.5 105 4.71 47 13.3
8068 1730 1.97 2 148 7.34 42 108 144 3.9 113 4.05 192 1.1
3450 2080 1.39 1 46 7.57 28 78 139 3.9 104 4.01 109 2
4157 865 4.04 3 106 7.4 32 129 152 3.3 124 4.76 193 1.6
2631 90 7.76 4 131 7.35 30 98 134 5.7 98 3.27 160 6.3
3061 1275 1.4 1 76
HB3 BEC3 HCO33 F3 PF3 PF3COD GCS3 GCS33 GCS3COD vent3 PLATE3 PLAT3COD BIL3 BIL3COD
7.6 6.5 29.4 30 523.33 0 6T 9 3 1 180000 0 0.6 0
8.9 -14.5 12.9 100 172 3 6TS=7T 10 2 1 8000 4 1.5 1
8.6 -12.6 14.1 30 303.33 1 15 15 0 0 250000 0 0.8 0
8.4 -2.8 22.1 50 260 2 2T 3 4 1 75000 2 0.9 0
10.5 -12.6 12 21 447.62 0 10T 14 1 1 200000 0 0.8 0
24 333.33 1 15 15 0 0 200000 0 0.9 0
7.7 1.8 25.6 35 222.86 2 2T 3 4 1 29000 3 2.7 2
7.8 -4.4 20.7 40 132.5 3 2T 3 4 1 19000 4 0.7 0
9.4 -9.1 16.7 30 553.33 0 2T 3 4 1 75000 2 0.8 0
14.6 -3.7 18.3 30 253.33 2 10T 13 1 1 200000 0 0.6 0
16 -14.1 13.3 100 61 4 2TS=2T 3 4 1 70000 2 4.8 2
15 5.4 29.2 30 316.67 1 10T 12 2 1 118000 1 2.5 2
10.6 -7.4 17.9 21 276.19 2 14 14 1 0 120000 1 0.7 0
11.5 -10.3 21 100 44 4 2T 3 4 1 110000 1 0.8 0
11.1 -1.1 22.6 50 180 3 2TS=4T 6 3 1 30000 3 0.6 0
10.3 0.1 23.1 30 213.33 2 7TS=9T 12 2 1 107000 1 11.4 3
8.8 -3.7 20.6 30 303.33 1 6T 9 3 1 185000 0 0.5 0
7.2 -12.6 12.7 40 367.5 60000 2 1.1 0
11.6 -0.4 23.3 21 261.9 2 10T 13 1 1 45000 3 1.8 1
8.8 5.6 29.9 100 157 3 6TS 9 3 1 4000 4 6 3
5.9 -22.2 7.3 40 215 2 15 15 0 0 11000 4 1 0
10.4 -10.3 16.3 100 73 4 8T 12 2 1 131000 1 0.5 0
8.5 8.1 31.1 30 283.33 2 6TS=7T 10 2 1 243000 0 0.7 0
7.2 -4.5 18.7 25 360 1 7T 10 2 1 44000 3 9.5 3
10.3 -3.3 22 40 240 2 2TS=3T 4 4 1 335000 0 0.4 0
0 15 15 0 0 240000 0 0.9 0
11.7 -0.3 23.5 21 342.86 1 15 15 0 0 60000 2 1.2 0
12.2 3.3 26.3 35 177.14 3 3T 4 4 1 166000 0 1.5 1
1 15 15 0 0 355000 0 0.7 0
9.8 1 24.7 30 616.67 0 10TS 12 2 1 45000 3 1.65 1
1 7T 11 2 1 150000 1 0.7 0
10.8 -7.4 15.5 30 346.67 1 2TS 4 4 1 130000 1 1.4 1
11.4 0.9 26 21 361.9 1 15 15 0 0 220000 0 0.6 0
-15.3 18.1 100 68 4 2T 3 4 1 120000 1 0.5 0
14.8 0.3 24.3 31 222.58 2 15 15 0 0 180000 0 0.8 0
8.3 4.7 29.7 35 254.29 2 10TS 12 2 1 250000 0 2.3 2
10.6 -0.4 23.3 40 142.5 3 5T 7 3 1 11000 4 2.8 2
10 -12.3 13.5 21 371.43 1 7T 10 2 1 30000 3 2.9 2
9.3 1.1 24.6 30 236.67 2 8T 11 2 1 107000 1 0.5 0
9.8 -17.6 12.1 100 94 4 2TS 4 4 1 30000 3 1.3 1
11.6 -5.1 20.3 30 263.33 2 3T 4 4 1 30000 3 2.4 2
6.3 -17 12.7 50 178 3 2T 3 4 1 75000 2 17 4
5.1 -2.7 24 30 240 2 2T 3 4 1 60000 2 1 0
11.1 -0.4 24.9 75 114.67 3 2TS=4T 6 3 1 30000 3 5 2
7 -3.1 21.2 21 247.62 2 7TS 10 2 1 30000 3 1.8 1
8.2 3.6 27.9 31 125.81 2 15 15 0 0 20000 4 7 3
11.9 -7.5 18.3 31 335.48 1 15 15 0 0 60000 2 0.8 0
8.1 3.2 26.1 35 208.57 2 5T 7 3 1 110000 1 3 2
12 -3 21.6 60 126.67 2 15 15 0 0 119000 1 3 2
12 -8.1 16.9 21 376.19 1 15 15 0 0 110000 1 1.7 1
8.4 -0.8 24.3 30 293.33 2 9T 12 2 1 110000 1 1.8 1
0 15 15 0 0 153000 0 0.4 0
9.9 8.8 32 30 483.33 0 15 15 0 0 200000 0 0.8 0
8.9 -5.7 19.9 35 245.71 2 8T 11 2 1 30000 3 1.5 1
8.9 0.4 24.2 50 290 2 12 12 2 0 155000 0 0.7 0
8 -7.5 17.1 30 333.33 1 10T 12 2 1 120000 1 0.9 0
12.8 1.4 32.8 100 249 2 2T 3 4 1 108000 1 1 0
10 -9.9 14.3 30 286.67 2 3TS 5 4 1 55000 2 6.5 3
0 15 15 0 0 200000 0 0.6 0
9.5 -3.1 21.7 60 205 2 15 15 0 0 45000 3 1.6 1
7.5 -2.4 21.9 40 252.5 2 9T 12 2 1 90000 2 0.4 0
13.8 -10.7 13.9 24 437.5 0 13 13 1 0 60000 2 0.7 0
7.8 -6.8 18.3 25 280 2 10T 13 13 1 120000 1 25 4
10.2 -5 19.6 100 285 2 2TS=4T 6 3 1 8000 4 3 2
9.4 7.3 30.3 40 115 3 3T 4 4 1 7000 4 7.9 3
5.6 -2.4 22.1 30 153.33 3 5T 7 3 1 105000 1 11 3
7.2 -13.7 11.6 28 332.14 1 4TS=6T 9 3 1 15000 4 4 2
12.1 -1.8 20.9 25 316 1 3T 4 4 1 45000 3 0.44 0
12.2 -2.5 21.5 30 296.67 2 10T 13 1 1 267000 0 1.8 1
7 -13 12.4 50 384 1 3T 4 4 1 60000 2 34 4
6.8 -8.7 16.3 21 376.19 1 3T 4 4 1 60000 2 1.4 1
1 15 15 0 0 90000 2 1.4 1
10.2 1.4 25.9 25 588 0 9TS 13 1 1 300000 0 0.6 0
14.3 -7.1 16.4 30 180 3 4T 7 3 1 140000 1 0.7 0
11.3 -1.4 23.7 40 182.5 3 4TS=5T 7 3 1 26000 3 2.5 2
9.7 2.5 25.5 24 458.33 0 15 15 0 0 35000 3 1.5 1
8 5.2 29.2 25 756 0 9TS 13 1 1 30000 3 0.6 0
10.3 -0.8 24.8 50 178 3 2TS 4 4 1 30000 3 4.1 2
9.7 -0.1 22.6 80 103.75 3 5T 7 3 1 90000 2 0.5 0
8.5 -1.1 25.2 100 46 4 6T 9 3 1 108000 1 2 2
11.1 -4.5 19.5 21 238.1 2 15 15 0 0 90000 2 11 3
9.6 -11.6 14.8 25 572 0 5T 7 3 1 150000 1 0.5 0
8.3 -3.1 21.4 70 212.86 2 3TS=5 7 3 1 58000 2 5.9 2
13 2.3 26.5 30 376.67 1 7T 10 2 1 128000 1 1.5 1
9.8 -8.1 16.5 28 317.86 1 15 15 0 0 280000 0 0.6 0
15.5 -3.7 20.9 21 400 0 3T 4 4 1 194000 0 0.4 0
14.3 8.8 32 50 120 3 4T 6 3 1 132000 1 1.4 1
0 15 15 0 0 180000 0 0.6 0
0 15 15 0 0 110000 1 0.3 0
7.8 -14.6 14.3 100 72 4 2T 3 4 1 25000 3 3.5 2
8 -3.1 22.7 100 108 3 6TS=8T 11 2 1 105000 1 2.7 2
7.9 3.7 25.7 21 371.43 1 2T 3 4 1 200000 0 8 3
10 -5 19.8 25 516 0 4T 6 3 1 220000 0 0.4 0
15.4 -9 16.6 40 245 2 3T 4 4 1 60000 2 0.8 0
2 15 15 0 0 25000 3 1.2 0
PR3 SBP3 DBP3 CVS3 sofa4 intake4 output4 creat4 CREAT4CODurea4 PH4 PCO24 P4 NA4
80 110 70 0 7 2138 1595 1.26 1 61 7.35 50 40 139
150 80 50 4
110 110 70 4 7 1323 885 2.76 2 87 7.5 28 101 139
90 110 70 3 12 1875 500 4.84 3 155 7.33 41.1 61.7 133
90 110 70 0 1 2200 2145 0.73 0 15 7.36 20 113 142
100 130 80 0 1 2075 1200 0.8 0 20 80
130 130 80 4 13 3516 995 4.09 3 159 7.48 34 107 143
110 130 80 4 12 2222 935 1.95 1 119 7.32 35 65 129
100 130 70 4 15 1482 1280 3.7 3 170
96 140 80 0 1 2310 2120 0.58 0 30 7.38 33 93 134
140 100 70 4 200 100
85 130 80 0 9 2250 2405 0.64 0 40 7.37 58 66 138
110 120 60 3 8 2161 1090 2.06 2 89 7.42 26 84 132
120 110 65 4 18 1732 20 5.5 4 90 7.08 70 29 140
120 120 75 4 15 5275 2025 0.92 0 71 7.49 24 51 140
90 120 80 0 6 1830 1950 1.76 1 1.62 76 34 168 138
110 120 70 3 9 1811 1215 1.47 1 45 7.47 27 50 147
90 120 70 0 9 3610 565 5.6 4 217 7.22 21 185 138
105 130 80 0 7 4120 3265 0.95 0 25 7.5 26 82 138
120 130 80 0 15 4735 2835 0.89 0 135 7.32 63 75 147
150 120 43 4 17 7223 175 4.1 3 91 7.26 67 141
110 110 65 3 10 1284 2580 6.27 4 116 7.42 32 65 133
85 130 70 2 4 2913 3745 0.89 0 59 7.54 38 72 133
120 120 70 0 11 2923 1895 1.87 1 51 7.5 27 77 141
100 130 70 0 8 1960 1283 3 2 85 7.31 39 83 138
80 150 90 0 3 1350 65 4.5 3 60
80 100 70 2 3 3000 1800 0.67 0 28 72
100 140 80 0 7 2000 1155 0.67 0 35 7.5 33 79 140
110 150 80 0 1 1045 1300 0.65 0 35
110 100 60 4 13 3710 1155 1.76 1 85 7.48 33 98 138
100 110 70 0 2 1535 1540 0.6 0 60
90 120 70 2 10 1000 300 3.98 3 100 7.45 28 89 147
100 140 90 0 0 1288 1750 0.66 0 29 7.38 48 114 153
140 100 50 0
100 120 80 0 2 1790 1550 0.97 0 50
86 120 60 2 4 1700 1895 0.65 0 55 7.52 34 77 140
104 110 70 4 15 2950 6580 1.5 1 195 7.52 34 52 153
90 115 75 2 13 1930 2225 3.82 3 126 7.29 35 99 133
90 120 70 2 7 3062 2261 1.09 0 86 7.44 40 24 150
125 110 65 4 19 1200 75 3 2 90 7.15 49 61 146
90 130 70 3 15 2155 1910 4.22 3 268 7.36 40 79 145
70 120 80 4 16 4365 20 1.51 1 52 7.29 32 137 133
100 120 70 4 15 1507 440 3.59 3 111 7.37 42 85 141
130 100 55 4 19 1639 15 5.84 4 161 7.42 36 139 135
90 135 70 3 14 1440 30 8.5 4 155 7.43 37 93 140
110 110 80 3 14 2346 1900 2.64 2 119 7.44 38 67 142
106 120 66 0 5 2568 3525 3.36 2 134 7.44 36 73 135
120 120 70 0 9 2690 2175 1.1 0 56 80
100 120 70 0 4 2732 5136 1.53 1 104 7.42 36.6 61.7 134
95 140 80 0 7 1520 1975 8.23 4 137
90 100 72 3 1684 1495 1.09 0 48 7.27 50 66 147
90 130 70 0 4 1500 3250 5.8 4 133 7.41 35 154 131
60 110 70 0 0 800 600 0.9 0 20
100 125 70 0 8 1258 230 4.9 3 150 7.41 39 124 132
105 110 70 2 9 2566 910 1.55 1 85 7.44 33 77 145
50 150 80 0 5 1651 320 2.45 2 56 7.4 29 88 127
100 140 80 4 5 4525 2225 0.7 0 20 7.45 39 62 134
120 110 70 2 14 2500 200 3.11 2 58 7.47 32 76 133
92 120 70 0 0 2950 3400 0.85 0 28
100 160 100 0 9 2600 235 5.78 4 134
90 100 60 0 7 2622 1295 1.27 1 119 7.48 28 78 143
80 110 60 4 13 3473 195 3.19 2 123 7.31 23 111 140
120 120 70 0 3483 1290 0.85 0 28 7.33 37 45 148
120 90 60 3 20 4.48 3 186 7.11 45 61 143
120 120 70 4 16 5616 1233 1.22 0 111 7.52 38 55 144
120 120 60 2 9 3642 3270 0.55 0 68 7.45 38 41 142
130 115 55 4 17 3570 295 2.14 2 88 7.45 31 85 141
100 130 80 0 10 4710 2400 5.39 4 234 7.47 27 169 141
105 125 75 1 3 1410 2395 1.2 0 40 7.48 31 101 143
120 110 65 4 19 500 50 3.8 3 190 6.79 23.3 95.2 143
110 135 80 3 9 1791 3715 1.9 1 125 7.44 29 89 142
80 140 70 0 2 1200 1150 0.83 0 26
110 140 70 2 4 2065 2355 0.98 0 41 7.43 43 139 140
120 120 90 0 4 2765 2125 0.74 0 38 7.45 30 172 137
70 110 60 3 11 3402 2555 1.12 0 42 7.49 33 57 138
95 119 85 0 4 2402 1909 1.75 1 45 7.51 27 119 138
116 130 77 4 7 4687 3330 1.27 1 49 7.36 40 87 133
85 120 70 2 12 2417 2085 1.29 1 160 7.53 31 113 146
105 130 65 4 10 1329 830 1.4 1 80 7.51 30 76 143
95 100 65 3 16 2087 60 4.2 3 124 7.37 46 49 142
130 150 90 0 7 1980 1140 1.45 1 70
104 100 60 4 8 3353 910 1.39 1 76 7.42 31 108 136
110 125 75 2 20 1210 5 3 2 65 7.25 30 55 134
90 130 80 0 5 2680 2085 1 0 40 7.45 37 98 135
80 140 80 0 3 4354 3955 1.01 0 29 7.5 26 79 141
130 110 70 4 8 3033 2240 0.97 0 32 7.5 29 91 131
120 120 75 4 9 2161 2885 1.68 1 89 7.47 46 77 148
100 120 80 0 0 1750 2050 0.44 0 25
70 110 70 0 2 1275 4845 0.45 0 30
150 130 55 4 19 250 5 2.68 2 18 7.13 29 40 135
85 120 70 4 17 4609 1425 2.1 2 138 7.21 44 72 145
95 130 80 0 8 2664 3030 1.33 1 42 7.57 27 89 136
90 110 70 0 10 4428 595 4.15 3 123 7.32 34.5 76.5 151
90 110 70 3 11 2150 126 7 4 123 7.46 33 129 129
90 100 65 2 6 1250 800 0.99 0 74
K4 CL4 CA4 GLU4 LAC4 HB4 BEC4 HCO34 F4 PF4 PF4COD GCS4 GCS44 GCS4COD
3.8 106 4.56 227 1.4 9 2 27.6 25 160 3 6T 9 3
3.9 105 4.12 102 1.6 8 -1.4 21.8 31 325.81 1 15 15 0
4.6 107 1.08 1.3 9.1 -4.2 20.8 50 123.4 3 5T 7 3
3.7 122 4.49 119 0.6 10.2 -14.1 11.3 31 364.52 1 15 15 0
25 320 1 15 15 0
3.7 111 4.84 168 1.7 6.9 1.8 25.3 25 428 0 4T 6 3
4.7 96 3.88 136 3.8 20.6 -8.1 18 30 216.67 2 2T 3 4
2T 3 4
3.5 104 4.58 101 0.8 14.6 -5.6 19.5 21 442.86 0 10T 13 1
2T 3 4
3.4 101 4.59 195 1.2 16.4 8.2 33.5 80 82.5 4 6TS=8T 12 2
4.7 109 4.21 163 1.9 9.9 -7.6 16.9 40 210 2 14 14 1
4 105 4.33 56 4 11.2 -9.2 20.8 40 72.5 4 2T 3 4
3.9 109 3.36 108 12.1 8.1 -5 18.3 100 51 4 2TS=3T 4 4
4.7 111 4.87 161 0.9 10 -2.4 22.1 40 420 0 7TS=9T 12 2
3.8 121 4.23 180 1.6 9.3 -4 19.7 50 100 3 6T 9 3
4.4 111 3.76 131 4.7 9.6 -19.1 8.6 40 462.5 0 4T 6 3
3.4 108 3.96 147 1.2 12.3 -2.9 20.3 30 273.33 2 10T 13 1
3.3 115 4.46 148 1.2 8.2 6.4 32.5 100 75 4 2TS 3 4
4.3 105 3.89 159 14.7 7.9 -14.5 12.6 30 223.33 2 2T 3 4
4.4 101 4.37 180 1.3 10.4 -3.7 20.8 24 270.83 2 10T 14 1
3.6 97 4.2 291 1.7 8.6 10 32.5 30 240 2 9T 12 2
2.5 107 4.18 149 4 -2.1 21.1 21 366.67 1 7T 10 2
4.6 109 4.33 142 0.6 10.2 -6.7 19.6 30 276.67 2 2T 3 4
0 15 15 0
21 342.86 1 15 15 0
3 110 4.04 143 0.7 10.7 2.5 25.7 30 263.33 2 5T 7 3
1 15 15 0
3.4 107 4.1 132 3 7.2 1.1 24.6 40 245 2 10T 12 2
0 8T 12 2
4.1 114 4 183 2.1 11.4 -4.5 19.5 28 317.86 1 5T 7 3
3.8 121 4.74 154 0.8 11.2 3.3 28.4 21 542.86 0 15 15 0
14 2 15 15 0
3.9 109 3.98 185 1 7.9 4.9 27.8 21 366.67 1 10T 14 1
4 121 4.22 159 1.6 10.4 4.9 27.8 35 148.57 3 5T 7 3
4.4 100 4 79 1.3 11 -9.8 16.8 31 319.35 1 9T 12 2
3.3 117 4.27 191 1.8 9.6 3 27.2 30 80 4 8T 12 2
4.3 113 4.63 112 11.5 8.7 -11.8 17.1 90 67.78 4 2T 4 4
3.7 113 4.63 123 1 8.8 -2.8 22.6 30 263.33 2 5T 7 3
3.5 98 5.48 137 9.3 8.3 -11.2 15.4 30 456.67 0 2T 3 4
4 110 4.33 94 3.1 6.1 -1 24.3 30 283.33 2 8T 11 2
3.9 103 3.39 201 3 10.8 -1.1 23.4 70 198.57 3 2TS=4T 6 3
3.4 107 4.49 115 1 6.4 0.3 24.6 25 372 1 8TS 12 2
3 113 4.39 169 2.2 8 1.6 25.8 31 216.13 2 15 15 0
3.4 106 4.61 214 1.2 10.3 0.3 24.5 21 347.62 1 15 15 0
35 228.57 2 5T 7 3
3.5 107 1.07 2 11.6 -0.4 23.5 24 257.08 2 15 15 0
11.6 0 15 15 0
3.3 117 3.55 181 2.1 9.9 -3.9 23 35 188.57 3 9T 12 2
3.5 101 3.79 140 0.6 9 -2.4 22.2 24 641.67 0 15 15 0
10 0 15 15 0
4.5 102 6.99 91 1 9.2 0.1 24.7 35 354.29 1 15 15 0
4.2 114 4.33 85 2.8 8.7 -1.8 22.4 60 128.33 2 11 11 2
3.6 105 4.24 142 0.5 9.1 -6.8 18 21 419.05 0 10T 12 2
3.2 98 4.17 69 2.2 14.1 3.1 27.1 30 206.67 2 10T 13 1
3.5 101 3.64 210 3.2 9.5 -0.4 23.3 30 253.33 2 3TS 6 3
0 15 15 0
1 15 15 0
3.2 110 4.42 202 3.2 9.5 -2.6 20.9 30 260 2 9T 12 2
3.6 110 2.8 227 4.9 15 -14.7 11.6 35 317.14 1 2T 3 4
3.9 122 4.65 146 2.2 7.2 -6.4 19.5 24 187.5 2 13 13
5.3 106 3.71 25 12.4 6 -15.2 14.3 95 64.21 4 4T 6 3
4.3 110 4.33 110 3.4 7.6 8.1 31 50 110 3 5T 7 3
3.9 117 4.35 170 1.4 5.7 2.4 26.4 31 132.26 3 10T 13 1
4.2 105 3.96 92 11.9 7.7 -2.5 21.5 30 283.33 2 5TS=7T 10 2
3.4 111 4.23 198 2.5 10 -4 19.7 25 676 0 4T 6 3
3.3 110 4.87 106 1.5 11.9 -0.4 23.1 40 252.5 2 15 15 0
6.7 118 1.06 26 3.8 -27.4 3.4 40 238 2 2T 3 4
4 115 4.79 222 1.7 7 -4.5 19.7 21 423.81 0 5T 7 3
1 15 15 0
3.6 106 4.25 101 1.9 12.6 4.2 28.5 35 397.14 1 10T 13 1
4 110 4.27 123 1.5 15.9 -3.1 20.9 50 344 1 4T 7 3
4.2 111 4.48 98 1.2 10.5 1.8 25.1 30 190 3 5T 7 3
4.1 110 3.24 107 1.6 7.6 -1.5 21.5 21 566.67 0 15 15 0
4.1 100 4.24 299 2.1 7.9 -2.8 22.6 25 348 1 10T 13 1
3.9 112 4.35 187 2 10.5 3.2 25.9 40 282.5 2 2TS 4 4
3.5 110 3.97 142 1.1 9 0.9 23.9 35 217.14 2 6T 9 3
3.2 108 4.51 252 1.7 7 1.3 26.6 90 54.44 4 5T 7 3
1 15 15 0
4.3 110 3.89 251 2.2 8.7 -4.4 20.1 25 432 0 4T 7 3
3.2 99 3.62 101 13.6 10.9 -14 13.2 100 55 4 2T 3 4
3.8 101 4.75 253 1.4 13.8 1.7 25.7 30 326.67 1 8T 12 2
3.1 110 4.13 181 2.1 10.3 -2.9 20.3 31 254.84 2 13 13 1
4.2 105 3.98 124 1.5 14.1 -0.6 22.6 21 433.33 0 2T 3 4
3 109 3.96 244 1.4 14.3 9.8 33.5 40 192.5 3 6T 9 3
0 15 15 0
0 13 13 1
8.6 101 4.62 4 18.6 6.8 -19.6 9.6 100 40 4 2T 3 4
4 111 3.75 150 5.6 13.7 -10.3 17.6 100 72 4 2T 3 4
4 105 3.87 118 2.2 2.7 24.7 21 423.81 0 2T 3 4
3 125 1.26 3 9.5 -7.7 18.1 21 364.29 1 5T 7 3
5.1 93 3.39 103 2 11.8 -0.3 23.5 60 215 2 9T 12 2
2 15 15 0
vent4 PLATE4 PLAT4COD BIL4 BIL4COD PR4 SBP4 DBP4 CVS4 sofa5 intake5 output5 creat5 CREAT5COD
1 180000 0 0.6 0 70 120 70 0 7 2390 1965 1.31 1
0 230000 0 0.9 0 110 110 70 4 4 900 450 3.27 2
1 50000 3 1 0 90 140 80 0 8 1786 460 3.5 3
0 200000 0 0.6 0 80 100 70 0 0 2305 1417 0.7 0
0 200000 0 0.8 0 80 120 80 0 0 3100 1400 0.77 0
1 35000 3 1.9 1 90 110 80 3 9 1957 780 3.83 3
1 33000 3 0.7 0 100 150 90 2 10 1511 3260 1.79 1
1 58000 2 0.9 0 75 130 75 4
1 180000 0 0.5 0 86 140 80 0 0 2180 2410 0.6 0
1 55000 2 5.5 2 120 110 60 4 200 100
1 120000 1 2.5 2 95 150 90 0 7 2080 1405 0.6 0
0 110000 1 0.7 0 125 110 50 2 5 1800 1055 1.66 1
1 90000 2 1 0 130 80 60 4 18 500 10 6 4
1 30000 3 0.6 0 120 115 70 4 15 39744 1415 0.92 0
1 163000 0 10 3 95 115 75 0 6 2520 2260 1.6 1
1 217000 0 0.5 0 120 120 70 2 7 2620 1770 1.63 1
1 90000 2 1.1 0 90 120 60 0 10 3214 660 4.3 3
1 45000 3 1.5 1 96 150 85 0 5 3438 2040 1.12 0
1 20000 4 6.7 3 120 140 80 0 14 4947 2920 0.83 0
1 10000 4 1 0 140 85 50 4
1 131000 1 0.6 0 110 110 65 2 7 1700 3500 6 4
1 243000 0 0.6 0 90 140 80 0 1 1860 3875 0.88 0
1 44000 3 12 4 120 130 80 0 12 2351 3170 1.62 1
1 330000 0 0.5 0 90 145 75 0 8 2745 2731 2.96 2
0 200000 0 0.6 0 85 140 80 0 4 900 100 6.76 4
0 60000 2 1 0 80 100 70 0
1 188000 0 2 2 100 150 80 0 6 1930 1815 0.64 0
0 345000 0 0.7 0 105 135 80 0 0 1450 1560 0.64 0
1 22000 3 1.9 1 100 95 65 4 19 3261 1520 2.12 2
1 160000 0 0.8 0 100 120 70 0 3 2650 1400 0.54 0
1 136000 1 2 2 120 125 75 0
0 211000 0 0.7 0 80 160 70 0 1 3050 1530 0.66 0
0 180000 0 1.2 0 82 90 60 0 1 1500 1200 0.98 0
1 200000 0 2 2 80 120 60 0 2 1975 1510 0.64 0
1 9000 4 2.8 2 90 140 80 2 9 5448 4500 1.1 0
1 30000 3 3.3 2 85 120 70 2 12 1774 3525 4.38 3
1 101000 1 0.6 0 95 120 65 0 6 2824 5150 1 0
1 20000 4 1.3 1 110 90 50 4
1 60000 2 3 2 100 130 80 3 13 1629 1120 4.17 3
1 43000 3 17 4 80 100 70 4 18 3500 30 0.85 0
1 16000 4 1 0 105 140 70 4 10 890 360 3.59 3
1 30000 3 5.6 2 105 105 55 4 20 1336 67 6.51 4
1 45000 3 1.5 1 85 120 85 3 14 1550 10 9.67 4
0 13000 4 8.17 3 90 110 70 3 11 1940 1055 2.51 2
0 75000 2 0.9 0 106 150 76 0 5 2518 3560 2.9 2
1 90000 2 2.5 2 120 125 70 0 7 2690 2175 1.2 0
0 170000 0 1.74 1 82 120 70 0 1 2530 2175 1.19 0
0 80000 2 1.4 1 90 130 85 0 7 1530 1800 8.55 4
1 105000 1 1.91 95 120 80 0 16 3738 390 1.29 1
0 155000 0 0.5 0 85 120 70 0 4 1300 1650 5.69 4
0 180000 0 1 0 60 130 70 0 0 1000 800 0.97 0
0 30000 3 1.5 1 90 140 80 0 6 1818 445 4.9 3
0 150000 1 0.7 0 100 110 70 3 10 3817 1050 1.56 1
1 120000 1 1 0 80 150 90 0 7 2441 302 3.18 2
1 87000 2 1 0 90 140 80 0 5 2405 3510 0.63 0
1 60000 2 7 3 120 110 65 2 17 2050 150 4.04 3
0 180000 0 0.5 0 105 120 80 0 0 2500 1940 0.8 0
0 40000 3 1.3 1 90 170 90 0 9 1000 450 6.3 4
1 60000 2 0.4 0 90 120 60 0 4 3026 3670 1.16 0
1 75000 2 0.7 0 90 110 60 4 16 3413 190 3.5 4
0 136000 1 24 4 110 120 80 0 4 2130 1350 0.8 0
1 5000 4 3.5 2 160 70 50 4
1 15000 4 9 3 105 110 65 3 13 5515 1830 1.28 1
1 59000 2 9.8 3 110 130 70 0 8 2970 1877 0.6 0
1 15000 4 8 3 10.1 115 65 4 19 2.5 2
1 35000 3 0.7 0 95 130 80 0 8 2040 2170 3.92 3
0 250000 0 1.7 1 130 140 95 0 2 2860 2050 1 0
1 60000 2 35 4 120 70 50 4
0 75000 2 1.4 1 105 140 60 2 8 1299 4550 1.86 1
0 113000 1 1.2 0 80 130 80 0
1 153000 0 0.7 0 110 130 70 2 6 1952 1215 0.82 0
1 160000 0 0.6 0 120 140 90 0 4 2325 1855 0.89 0
1 25000 3 2 2 85 120 70 0 9 2680 2081 1.02 0
0 35000 3 1.2 0 101 140 82 0 4 2020 1600 1.9 1
1 18000 4 0.8 0 140 135 75 0 7 2780 3230 1.68 1
1 45000 3 3.2 2 85 110 65 0 11 1953 2325 1.1 0
1 69000 2 0.6 0 100 140 65 2 9 1490 1535 1.05 0
1 113000 1 2.6 2 90 105 60 3 17 886 30 6.44 4
0 78000 2 10.1 3 124 140 90 0 6 1785 1450 1.36 1
1 165000 0 0.4 0 96 110 60 4 7 3296 1125 1.12 0
1 50000 3 6 3 130 70 50 4
1 128000 1 1.4 1 90 135 80 0 4 2895 1925 0.9 0
0 180000 0 0.4 0 103 110 70 0 5 3457 3770 1.18 0
1 180000 0 0.7 0 130 120 70 4 5 3741 1235 0.78 0
1 160000 0 1.2 0 110 110 70 2 10 2443 2120 1.87 1
0 185000 0 0.7 0 100 110 80 0 0 2500 1800 0.45 0
0 110000 1 0.4 0 70 110 70 0 3 3150 1675 0.5 0
1 25000 3 3 2 150 80 40 4
1 103000 1 2.7 2 130 110 60 4 18 1200 650 2.3 2
1 200000 0 8.5 3 90 120 75 0 8 2842 3015 1.33 1
1 180000 0 0.6 0 120 133 70 3 13 6617 440 3.92 3
1 45000 3 1 0 90 130 70 0
0 30000 3 1 0 90 100 50 1 4 1200 850 0.85 0
urea5 PH5 PCO25 P5 NA5 K5 CL5 CA5 GLU5 LAC5 HB5 BEC5 HCO351 F5
59 7.37 39 41 139 3.6 104 4.83 233 2.1 13 -2.8 22.5 25
103 7.52 30 167 136 3.8 105 3.88 112 1.7 8 1.6 24.5 21
128 7.44 35 112 139 3.8 107 4.44 127 1 9.7 -0.4 23.8 30
26
25 90 21
170 7.49 32 106 141 3.4 108 4.53 117 1.2 10.4 1.1 24.4 25
129 7.42 36 61 133 3.3 107 4.3 133 1.7 10.3 -1.1 23.4 30
30 7.47 27 107 131 4.1 103 4.24 94 0.6 15 -4 19.7 25
35 7.45 46 58 137 3.9 104 4.48 169 0.8 15.2 8 32 40
108 7.41 28 88 130 4.4 108 4.2 100 0.9 10.3 -6.9 17.7 31
120 7.03 68 34 139 4.3 105 4.07 86 5.3 11.5 -12.8 18 45
70 7.4 28 87 138 4.3 107 4.17 87 12.6 7.4 -7.5 17.3 100
65 7.46 30 189 134 4.8 107 4.7 164 1 9.9 -2.5 21.3 30
50 7.45 26 68 149 3.1 118 4.56 218 1.1 9.4 -5.9 18.1 50
138 7.53 24 62 137 3.6 110 3.56 106 2.4 9.9 -2.6 20.1 25
25 7.51 27 73 137 3.9 105 3.71 134 1.9 11.9 -1.5 21.5 30
133
7.01 36 70 142 4.2 99 3.61 41 20 7.5 -22 9.1 40
140 7.41 33 69 133 4.5 102 4.21 197 1 9.6 -3.7 20.9 28
45 7.51 41 169 128 2.9 96 4.14 197 1.2 9.2 9.7 32.7 30
57 7.54 27 69 145 2.6 110 4.35 116 3.1 9.7 0.6 23.1
86 7.35 34 78 139 4.4 109 4.28 246 0.7 11.7 -6.8 18.8 30
82
32 7.49 34 60 143 3.3 109 4.25 141 0.6 10.3 2.6 25.9 30
34
98 7.05 82 74 137 3.7 104 5.62 96 2.9 8.9 -7.8 22.7 90
25
21 7.35 55 87 149 3.4 118 4.57 173 1 11.8 4.8 30.4 28
50
45 7.5 36 79 138 3.5 106 4.05 130 1.3 8 4.9 28.1 24
140 7.56 33 166 145 2.6 113 3.91 200 2.4 12.3 7.3 29.5 40
135 7.29 35 99 133 4.4 100 4 79 1.3 11 -9.8 16.8 31
70 7.58 33 56 140 2.9 106 3.8 273 2.2 10.1 9 30.9 30
296 7.29 46 71 143 4.8 112 3.81 106 2.4 11.4 -4.5 22.1 30
35 7.12 45 17 137 2.9 105 5.12 83 12 6.4 -14.7 14.6 100
111
228 7.39 36 98 136 5.2 103 4.04 194 1.5 9.6 -3.2 21.8 40
160 7.41 32 76 138 3.3 107 4.12 116 1 8.9 -4.3 20.3 30
103 7.41 39 55 148 2.8 117 4.42 163 2.1 7.1 0.1 24.7 31
115
55 7.48 26 86 134 4 107 4.24 163 0.7 8.1 -4.1 19.4 21
69 7.5 32 109 130 4 102 4.06 133 1.7 11.7 1.8 25 24
147 11.5
53 7.37 40 88 148 3.7 117 3.91 114 3 7.7 -2.2 23.1 80
124
25
150
80 7.34 38 87 140 3.9 109 4.37 103 3.1 7.7 -5.3 20.5 40
68 7.5 29 74 134 2.7 109 4.21 120 1.1 8.1 -0.6 22.6 25
20 7.51 38 48 135 3.4 102 4.23 134 1.3 12.5 7.3 30.3 40
84 75 30
30
145
120 7.51 32 75 145 2.3 110 4.25 147 2.3 9.9 2.5 25.5 21
134 7.32 14 123 138 3.7 109 3.28 153 7.7 12.7 -18.9 7.2 35
35 7.35 37 84 147 3.6 123 4.78 103 1.4 7.2 -5.2 20.4 21
116 7.54 31 76 144 3.9 110 4.32 98 3.8 7.6 4 26.5 60
55
90 7.42 25 86 142 4.6 106 4.05 48 15.8 5.5 -8.3 16.2 30
204 7.53 25 157 138 3.7 110 4.3 141 1.5 10.1 -1.8 20.9 21
35
117 7.48 31 124 139 3.8 110 4.72 165 1 8.8 -0.4 23.1 40
45 7.42 50 49 150 3.5 107 4.35 105 0.8 10.9 7.9 32.4 30
40 7.55 21 120 142 6 119 4.12 101 1.8 14.1 -4 18.4 31
36 7.46 34 86 134 3.5 108 4.55 126 1.4 8.9 0.4 24.2 30
50
87 7.53 30 77 139 3.7 106 3.72 138 1.5 7.5 2.4 25.1 40
120 7.45 42 59 147 4.1 115 4.34 138 1.2 10.5 5.2 29.2 30
79 7.52 31 62 141 3.1 107 3.87 199 1.3 8.5 2.4 25.3 35
166 7.35 47 49 142 4.1 108 4.88 125 2.2 7.6 0.3 25.9 70
50
55 7.42 30 91 140 3.2 112 3.94 59 2.2 9.8 -5 19.5 21
39 7.49 33 90 136 4.2 102 4.52 232 1.6 15 1.8 25.1 30
37 7.52 30 153 138 4.6 106 4.24 261 1.1 9.5 1.6 24.5 60
30 7.52 27 71 132 4.7 104 4.21 117 1.4 14.6 -0.9 22 21
104 7.52 37 53 152 2.8 110 4.17 292 1.9 12.2 7.3 30.2 30
25
30
140 6.8 150 36 143 5.6 110 3.7 25 5.4 10.9 40
42 7.53 26 92 133 4.1 101 3.78 108 2.2 7.4 -1 21.7 21
129 7.3 30 73 147 3.3 115 4.34 176 4.4 9.6 -11.6 14.8 40
14
6.89 75 46 128 6.7 85 4.54 651 13.3 9.1 -18.7 14.4 60
60
PF5 PF5COD GCS5 GCS55 GCS5COD vent5 PLATE5 PLAT5COD BIL5 BIL5COD PR5 SBP5 DBP5 CVS5
164 3 6T 9 3 1 200000 0 0.6 0 90 140 80 0
795.24 0 15 15 0 0 227000 0 0.7 0 100 100 60 2
373.33 1 8T 11 2 1 90000 2 0.9 0 90 140 80 0
15 15 0 0 0 0.6 0 70 100 60 0
428.57 0 15 15 0 0 180000 0 0.8 0 70 130 80 0
424 0 9T 12 2 1 39000 3 1.8 1 80 110 70 0
203.33 2 6T 9 3 1 31000 3 0.8 0 100 140 80 1
428 0 15 15 0 0 160000 0 0.6 0 85 140 80 0
145 3 10TS=10T 13 1 1 116000 1 2.6 2 90 140 80 0
283.87 2 13 13 1 0 101000 1 0.7 0 115 115 65 0
75.56 4 2T 3 4 1 75000 2 1 0 55 60 40 4
87 4 2T 3 4 1 30000 3 0.8 0 120 110 65 4
630 0 8T 12 2 1 160000 0 9 3 90 135 80 0
136 3 10T 13 1 1 200000 0 0.7 0 110 120 70 2
248 2 4T 6 3 1 61000 2 1.1 0 100 130 70 0
243.33 2 10T 13 1 1 120000 1 1.4 1 120 130 80 0
6TS 9 3 1 9000 4 6.7 3 120 140 80 0
175 3 2T 3 4 1 10000 4 1 0 140 70 50 4
246.43 2 15 15 0 0 130000 1 0.4 0 100 140 70 0
563.33 0 10T 13 1 1 250000 0 0.6 0 100 150 85 0
7T 10 2 1 45000 3 15.7 4 130 110 75 0
260 2 3T 4 4 1 330000 0 0.4 0 90 170 90 0
0 15 15 0 0 160000 0 0.6 0 80 130 80 0
200 2 5T 7 3 1 175000 0 1.5 1 90 150 80 0
15 15 0 0 300000 0 0.8 0 98 130 80 0
82.22 4 2TS 3 4 1 30000 3 2 2 110 100 60 4
0 8T 12 2 1 150000 1 0.6 0 100 110 70 0
310.71 1 15 15 0 0 200000 0 0.6 0 96 150 80 0
1
1 15 1 0 0 180000 0 1.2 0 90 90 60 0
329.17 1 15 15 0 0 165000 0 1.8 1 80 130 70 0
415 0 4T 6 3 1 9000 4 2.8 2 100 140 80 0
319.35 1 13 13 1 0 25000 3 3.2 2 80 135 70 2
186.67 3 8T 12 2 1 136000 1 0.6 0 85 125 60 0
236.67 2 5T 7 3 1 36000 3 4 2 90 120 80 0
17 4 2T 3 4 1 62000 2 16 4 80 100 50 4
1 8T 12 2 1 16000 4 1 0 95 140 80 0
245 2 2T 3 4 1 22000 3 7.2 3 110 110 65 4
253.33 2 8T 12 2 1 75000 2 1.3 1 85 115 65 3
177.42 2 15 15 0 0 14000 4 8.5 3 90 110 60 0
1 15 15 0 0 80000 2 0.7 0 100 150 80 0
409.52 0 5T 7 3 1 90000 2 2 2 120 120 70 0
454.17 0 15 15 0 0 200000 0 1.7 1 80 110 70 0
0 15 0 0 90000 2 1.3 1 85 130 80 0
110 3 2T 3 4 1 90000 2 2.5 2 100 122 80 4
0 15 15 0 0 160000 0 0.6 0 85 130 80 0
0 15 15 0 0 200000 0 1 0 66 130 70 0
0 15 15 0 0 35000 3 1 0 80 150 85 0
217.5 2 11 11 2 0 120000 1 0.6 0 100 120 60 4
296 2 10T 13 1 1 120000 1 1.3 1 106 160 80 0
120 3 10T 13 1 1 110000 1 0.9 0 95 140 80 0
250 2TS 5 4 75000 2 7.5 3 125 105 60 2
0 15 15 0 0 179000 0 0.6 0 100 110 80 0
1 15 15 0 0 45000 3 1.3 1 90 160 90 0
357.14 1 10T 13 1 1 90000 2 0.6 0 90 120 60 0
351.43 1 2T 3 4 1 45000 3 0.9 0 100 84 50 4
400 0 15 15 0 0 155000 0 24 4 110 130 80 0
126.67 3 7T 10 2 1 11000 4 10 3 110 115 60 0
2 13 13 1 0 90000 2 8.5 3 105 120 70 0
286.67 2 2T 3 4 1 15000 4 11 3 120 90 15 4
747.62 0 5T 7 3 1 75000 2 0.9 0 90 130 80 0
1 15 15 0 0 250000 0 1.6 1 120 130 90 0
310 1 7T 10 2 1 60000 2 0.9 0 110 160 70 2
163.33 3 10T 14 1 1 160000 0 0.7 0 94 140 70 2
387.1 1 4T 7 3 1 160000 0 0.6 0 120 120 70 0
286.67 2 6T 9 3 1 21000 3 1.5 1 80 120 65 0
0 15 15 0 0 30000 3 1.1 0 90 130 80 0
192.5 2 15 15 0 0 15000 4 1.2 0 135 140 70 0
196.67 3 2T 3 4 1 94000 2 2.5 2 90 120 70 0
177.14 3 7T 10 2 1 90000 2 0.6 0 100 140 70 2
70 4 5T 7 3 1 115000 1 2.6 2 95 105 60 3
0 15 15 0 0 57000 2 10.1 3 128 140 90 0
433.33 0 5TS 8 3 1 180000 0 0.31 0 106 115 60 4
300 1 8T 12 2 1 181000 0 1.3 1 105 140 90 0
255 2 6T 9 3 1 200000 0 0.6 0 100 140 80 0
338.1 1 2T 3 4 1 180000 0 0.7 0 130 120 70 0
176.67 3 6T 9 3 1 140000 1 1.1 0 110 110 70 2
0 15 15 0 0 170000 0 0.8 0 100 110 70 0
1 14 14 1 0 110000 1 0.3 0 75 110 80 0
90 4 2T 3 4 1 90000 2 2.8 2 120 90 50 4
438.1 0 3T 4 4 1 233000 0 10.7 3 90 140 80 0
182.5 3 5T 7 3 1 180000 0 0.8 0 130 110 60 4
76.67 4 3T 4 4 1 40000 3 1.4 1 120 80 40 4
1 15 15 0 0 35000 3 0.9 0 82 110 60 0
sofa6 intake6 output6 creat6 CREAT6CODurea6 PH6 PCO26 P6 NA6 K6 CL6 CA6 GLU6
3 2000 1450 1.17 0 56 7.47 30 91 137 3.3 107 4.93 316
6 1129 190 3.69 3 138 7.53 23 80 131 4.5 99 3.79 201
7 1880 2165 3.52 3 164 7.38 34 72 137 3.9 104 4.19 131
0 2550 1685
2875 1450 0.7 0 30 80
11 1534 1750 3.48 3 169 7.46 36 75 143 2.7 110 4.43 125
10 1863 2375 1.33 1 122 7.51 32 58 143 2.6 112 4.44 185
0 3140 1875 0.65 0 25
7 2550 1315 0.65 0 38 7.39 54 60 144 3.9 107 4.82 186
5 2430 2230 1.88 1 80 7.4 27 100 131 5.3 108 4.29 93
14 2427 1300 1 0 91 7.55 30 134 148 2.8 113 4.22 132
6 2250 2000 1.49 1 52 7.41 32 112 130 4.5 99 4.59 136
7 1898 2165 1.3 1 45 7.44 34 55 147 3.9 115 4.43 201
3 2910 1310 0.95 0 29 7.45 24 91 134 4.2 106 4.24 185
14 5013 3200 1.14 0 139 7.47 41 57 150 4.4 112 4.41 156
5 2090 2300 5.98 4 138
2 1145 2895 0.85 0 42 7.43 47 71.3 131 3.6 100 4.04
14 3790 2682 1.73 1 62 7.52 27 57 142 3.4 111 4.27 101
8 3136 3875 2.82 2 91 7.45 31 77 142 3.6 111 4.6 210
4 875 70 6.52 4 71
4 2052 2007 0.77 0 32 7.4 44 100 138 3.2 106 4.08 121
0 2400 1900 0.65 0 25
20 2277 1305 2.55 2 95 7.14 55 64 129 4.2 100 4.08 85
2 2700 1100 0.5 0 30
2 2260 1445 0.6 0 25 7.4 46 61 146 3.6 112 4.64 179
2 1450 1000 1.2 0 60
3 2125 2405 0.65 0 35
12 3194 4610 0.85 0 95 7.6 34 54 147 2 110 4.02 134
10 1034 2950 4.1 3 120 7.41 35 96 139 3.2 102 3.85 96
4 1757 3795 0.89 0 66 7.51 40 39 139 3.7 106 3.96 106
13 1328 1740 4.16 3 298 7.34 45 26 143 4.7 109 3.31 166
8 932 1200 3.87 3 156 7.33 46 165 142 3.5 110 4.25 88
19 1445 60 5.41 4 197 7.44 30 100 133 6.1 103 4.01 202
13 1245 50 9.33 4 155 7.43 32 68 138 3.5 104 4.13 113
2770 1095 2.2 2 7.41 39 45 148 2.8 117 4.42 163
4 1997 2600 2.55 2 107
9 2460 2470 1.2 0 45 7.48 26 86 134 4 107 4.24 163
650 1100 0.77 0 42
6 2000 1950 11 4 183
17 200 1.57 1 67 7.27 43 78 147 3.8 111 4.29 152
4 2230 1750 5.9 4 130
1200 900 0.87 0 20
6 2815 1145 5.2 4 145
11 4562 115 1.6 1 83 7.3 35 104 138 4.4 109 4.39 118
3 2150 730 3.27 2 74 7.44 27 134 134 3 110 4.31 90
5 890 1950 0.58 0 20 7.46 42 59 139 3.4 104 4.66 125
16 2000 100 2.96 2 57 60
0 2390 1960 0.8 0 27
7 1425 250 5.7 4 129
4 3316 3950 1.25 1 113 7.43 43 37 146 2.2 108 4.18 154
14 1000 50 2.31 2 94 7.42 20 119 140 4.6 111 5.18 50
2450 1460 0.79 0 30
13 3162 2540 1.59 1 129 7.51 33 98 138 2.5 103 4.14 98
5 1950 4750 0.6 0 50
6 2440 2500 3.45 3 192 7.55 24 142 138 3.6 109 4.41 109
2 1600 1350 0.9 0 30
3 2165 755 1.42 1 100
1 2000 2080 0.65 0 35 7.51 35 72 134 3 103 4.33 116
4 3389 1770 0.62 0 30 7.46 36 94 150 3.1 115 4.59 142
5 1320 2540 0.64 0 35 7.48 34 69 135 3.5 108 4.6 114
5 1625 1250 2.12 2 55
6 3877 2370 1 0 51 7.57 27 85 143 2.6 112 3.92 91
7 2673 3700 0.84 0 78 7.49 40 85 159 3.9 113 4.45 188
6 1847 2110 0.92 0 68 7.48 45 53 145 3.4 109 3.94 113
19 400 5 7 4 180 7.3 52 49 138 4.7 107 4.82 117
5 1750 850 1.03 0 40
5 1425 1620 0.96 0 35 7.5 32 69 140 2.8 107 3.69 174
3 2906 1320 1.07 0 48 7.45 36 109 139 3.3 105 4.52 247
4 4910 2660 1.29 1 44 7.46 40.3 278 139 4.3 110 1.14
5 2870 930 0.73 0 69 7.42 35 77 143 4.1 107 4.46 152
6 1892 2365 1.53 1 97 7.45 51 66 154 2.9 114 4.03 219
0 2200 1000 0.45 0 25
0.5 0 25
7 1580 2605 1.16 0 38 7.51 29 84 133 3.4 102 3.91 96
12 4.75 3 139 7.32 30 125 145 3.7 111 4.23 164

LAC6 HB6 BEC6 HCO36 F6 PF6 PF6COD GCS6 GCS66 GCS6COD vent6 PLATE6 PLAT6COD BIL6
1.3 9.4 -1.9 21.8 21 433.33 0 6T 9 3 1 200000 0 0.8
2.5 7.8 -3.5 19.2 21 380.95 1 15 15 0 0 220000 0 0.5
1.5 13.7 -5 20.1 21 342.86 1 10T 13 1 1 120000 1 1.3
15 15 0 0 0.5
21 380.95 1 15 15 0 0 200000 0 0.8
1.1 8.7 1.8 25.6 50 150 3 10T 13 1 1 39000 3 1.4
1.6 9.9 2.5 25.5 30 193.33 3 4T 6 3 1 30000 3 0.8
0 15 15 0 0 180000 0 0.6
0.9 14.8 7.7 32.7 60 100 3 10TS=11T 14 1 1 120000 1 2.2
1.4 10.7 -8.1 16.7 80 125 2 13 13 1 0 101000 1 0.8
5.2 5.1 3.8 26.2 50 268 2 2T 3 4 1 15000 4 1
0.9 10.3 -4.3 20.3 30 373.33 1 9TS=10T 13 1 1 160000 0 8.7
1.1 9.3 -1.1 23.1 40 137.5 3 10T 13 1 1 230000 0 0.7
1.2 10.5 -7.3 16.7 25 364 1 10T 13 1 1 155000 0 1.3
4.2 11.3 6.1 29.8 90 63.33 4 4TS 7 3 1 20000 4 7
1 15 15 0 0 160000 0 0.4
1.6 9.1 6.4 30 24 297.08 2 15 15 0 0 250000 0 0.6
4 -0.9 22 25 228 2 8T 11 2 1 42000 3 17.5
0.6 11 -2.5 21.5 30 256.67 2 3T 4 4 1 405000 0 0.4
15 15 0 0 180000 0 0.6
0.9 9.8 2.5 27.3 50 200 2 8T 12 2 1 180000 0 1.2
0 15 15 0 0 294000 0 0.7
4.3 9.2 -10.3 18.7 100 64 4 2TS 3 4 1 16000 4 2
0 8T 13 1 1 150000 1 0.7
1.9 10.9 3.7 28.5 21 290.48 2 15 15 0 0 200000 0 0.6
14.5 15 15 0 214000 0 1.2
1 15 15 0 0 146000 1 1.5
2.1 9.5 11.8 33.4 30 180 3 6T 9 3 1 8000 4 2.9
1 11.3 -2.4 22.2 21 457.14 0 15 15 0 0 40000 3 2.8
0.8 10 8.9 31.9 24 162.5 3 10T 13 1 1 168000 0 0.7
0.9 8.6 -1.5 24.3 25 104 3 4T 6 3 1 72000 2 5
0.9 8.3 -1.6 24.3 40 412.5 0 10T 13 1 1 16000 4 1
2 8.8 -3.8 20.4 30.51 327.76 1 2T 3 4 1 30000 3 7.5
1.7 8 -3.1 21.2 30 226.67 2 6T 9 3 1 133000 1 1.1
2.1 7.1 0.1 24.7 31 145.16 15 15 0 15000 4 9
0 15 15 0 0 80000 2 0.8
0.7 8.1 -4.1 19.4 21 409.52 0 5T 7 3 1 10000 4 2.3
241000 0 1.7
0 15 15 0 0 100000 2 1.2
6.5 6.4 -7.2 19.7 90 86.67 4 2T 3 4 1 66000 2 5.9
0 15 15 0 0 165000 0 0.4
0 15 15 0 0 200000 0 1
15 15 0 0 60000 2 0.8
5.2 11.4 -9.2 17.2 50 208 2 6T 8 3 1 101000 1 0.6
0.7 7.5 -5.9 18.3 24 558.33 0 15 15 0 0 120000 1 1
0.6 13.4 6.1 29.9 21 280.95 2 8T 11 2 1 110000 1 1
40 150 3 2TS 5 4 1 45000 3 8.4
0 15 15 0 0 175000 0 0.6
1 15 15 0 0 65000 2 1.1
2.3 11.1 4.2 28.5 21 176.19 2 15 15 0 0 101000 1 0.6
8 7.5 -11.5 13 35 340 1 2T 3 4 1 45000 3 0.8
0 15 15 0 175000 0 23.5
5.5 7 3.3 26.3 45 217.78 2 7T 10 2 1 8000 4 12.6
1 15 15 0 0 101000 1 8
1.1 9.8 -1.4 21 21 676.19 0 9T 12 2 1 101000 1 0.9
1 15 15 0 0 250000 0 1.8
0 15 15 0 0 59000 2 0.7
1.6 10.4 4.9 27.9 21 342.86 1 15 15 0 0 165000 0 0.5
1.2 13.8 1.8 25.6 30 313.33 1 3T 6 3 1 184000 0 0.6
0.7 9.1 1.8 25.3 30 230 2 10T 13 1 1 75000 2 1.2
0 15 15 0 0 35000 3 1.1
1.2 8.8 2.7 24.7 40 212.5 2 15 15 0 0 20000 4 1.2
1.7 9.8 7.2 30.5 30 283.33 2 8T 12 2 1 110000 1 2
2 9.2 10 33.5 40 132.5 3 7T 10 2 1 120000 1 0.8
1.6 -0.8 25.6 75 65.33 4 3T 4 4 1 108000 1 2.8
0 15 15 0 0 59000 2 9
1.1 8.3 1.8 25 21 328.57 1 10T 13 1 1 184000 0 0.4
1.8 12.9 1 25 30 363.33 1 8T 11 2 1 183000 0 1.1
1.1 8.2 4.8 28.8 50 556 0 6T 9 3 1 247000 0 0.6
3.6 17.7 -1.8 22.7 21 366.67 1 4T 6 3 1 150000 1 0.9
1.6 13.6 11.4 35.4 31 212.9 2 10T 13 1 1 160000 0 1.1
0 15 15 0 0 180000 0 0.7
0 14 14 1 0 110000 1 0.4
1.5 9.1 0.1 23.1 21 400 0 2T 3 4 1 230000 0 10
4.6 10.8 -10.6 15.5 60 208.33 2 4T 6 3 1 180000 0 1

BIL6COD PR6 SBP6 DBP6 CVS6 sofa7 intake7 output7 creat7 CREAT7CODurea7 PH7 PCO27 P7
0 110 150 90 0 2 2500 2000 1.05 0 54 7.5 32 159
0 100 100 60 2 4 992 180 4.07 3 165 7.5 23 81
1 95 150 90 0 7 1886 1260 4.16 3 198 7.31 39 94
0 80 110 70 0 0 2560 1000
0
1 80 120 75 0 7 2010 4100 2.58 2 115
0 110 140 80 0 1994 1050 0.93 0 99 7.43 43 180
0 80 140 80 0 0 2150 1450 0.8 0 30
2 90 150 90 0 7 2530 1335 0.67 0 35 7.32 57 56
0 120 110 70 0 4 2000 900 1.77 1 95
0 120 120 70 4
3 100 130 70 0 4 1800 1600 1.45 1 45
0 115 125 70 2 5 1251 2180 1.31 1 35 7.56 28 70
1 115 110 66 0 3 1942 2325 0.89 0 28 7.38 20 100
3 110 140 90 0
0 100 130 80 0 5 1295 2400 5.36 4 108
0 100 140 90 0 0 1500 1900 0.85 0 40
4 135 125 75 2 14 1638 2355 1.55 1 70 7.48 33 63
0 96 170 90 0 5 2343 3675 2.5 2 91 7.43 36 82
0 80 130 80 0 4 1050 20 7.61 4 99
0 95 130 70 0 2000 1700 0.7 0 32 7.49 37 78
0 92 130 80 0 0 2450 2000 0.62 0 25
2 80 80 55 4
0 100 120 80 0 1 2850 1650 0.44 0 25
0 90 110 60 0 1 2340 1560 0.65 0 26
0 95 90 60 0 8 2613 300 1.52 1 62 7.34 20 226
1 80 120 70 0 1 2324 2080 0.64 0 30
2 90 150 90 0 10 2376 3320 0.68 0 65 7.37 26 84
2 85 130 75 2 7 1550 1700 3.5 3 120
0 90 120 60 0 0 2160 2020 0.76 0 55 7.5 32 103
2 90 130 80 0 12 1500 1250 3.91 3 323 7.42 37 76
0 100 140 80 0 4 1656 1365 2.53 2 139 7.43 38 97
3 115 110 65 4 20 1329 50 7.5 4 210 7.38 30 67
0 85 130 80 3 12 753 35 10 4 160 7.49 27 52
3 80 120 60 0 2.27 2 7.34 39 49
0 90 140 80 0 3 2950 2300 1.82 1 85
2 120 120 75 0 900 400 70
1 80 130 80 0 1 900 1000 0.75 0 40
0 85 140 80 0 6 1800 1350 9.5 4 146
2 4 1.63 1 73 7.3 53 80
0 90 130 80 0 4 2200 1600 5.57 4 120
0 1 1700 1500 0.85 0 22
0 80 130 80 0 5 1300 600 5.2 4 155
0 70 140 60 4 14 1400 50 1.68 1 75 7.08 28 69
0 120 150 75 0 4 1130 940 3.85 3 85
0 80 140 80 0
3 130 100 60 1 20 2300 100 6.34 4 106 7.38 34 42
0 90 110 70 0 0 2525 1956 0.82 0 25
0 90 150 90 0 7 1750 235 6.38 4 107
0 100 130 70 0 4 2903 1600 1.02 0 96 7.46 38 55
0 110 90 70 4
4 105 120 70 0 4 1600 1450 0.7 0 25
4 105 110 60 0 15 3665 2728 1.56 1 118 7.49 35 51
3 110 120 70 0 6 745 2600 0.65 0 45
0 90 140 80 0 5 2300 2100 2.29 2 158 7.51 13 157
1 105 130 90 0 2 1400 950 0.8 0 35
0 95 150 70 0 2 750 1300 1.42 1 90
0 90 140 70 0 1 1600 1800 0.65 0 35
0 110 130 70 0 4 2345 1765 0.58 0 28 7.44 36 116
0 65 120 70 0 4 1800 2420 0.65 0 30 7.47 35 92
0 85 140 80 0 5 2000 2650 2.02 2 60
0 130 150 80 0 9 3500 3250 2.27 2 176 7.14 52 60
2 95 135 75 0 4 1729 2480 0.74 0 64 7.48 42 91
0 85 140 70 0 7 1610 2135 0.9 0 67 7.58 37 67
2 100 100 50 4
3 106 140 90 0 5 2000 1050 0.58 0 35
0 95 110 55 3 2 1413 1080 0.81 0 42 7.4 46 45
0 95 150 85 0 4 2320 1170 1 0 43 7.42 43 87
0 90 130 70 0 7 4922 4665 1.34 1 41 7.62 27 70
0 125 130 90 0 5 2000 1000 0.68 0 58 7.48 35 69
0 120 120 80 2 3 3217 3100 1.5 1 71 7.48 49 81
0 85 110 70 0 0 2000 1500 0.45 0 25
0 80 110 80
3 100 130 80 0 7 2264 2445 0.94 0 38 7.6 19 118
0 110 50 30 4

NA7 K7 CL7 CA7 GLU7 LAC7 HB7 BEC7 HCO37 F7 PF7 PF7COD GCS7 GCS77
136 3.3 107 4.75 214 1.5 9.6 1.8 25 21 757.14 0 7T 10
130 4.5 99 3.74 133 1.8 7.8 -5.3 17.9 21 385.71 1 15 15
136 3.9 105 4.56 85 1.9 8.7 -6.7 19.6 30 313.33 1 10T 13
15 15
10T 13
152 4.4 121 4.48 197 2.2 9.1 4.2 28.5 100 180 3 2T
0 15 15
144 3.6 103 4.72 172 4.3 21.8 3.3 29.4 35 160 3 10TS=11T 14
14 14
2T 3
0 15 15
145 2.7 109 3.93 199 1.6 9.7 2.9 25.1 60 116.67 2 15 15
135 4.4 104 4.25 287 1.5 10.2 -13.3 11.8 60 166.67 2 15 15
1 15 15
0 15 15
147 2.9 111 4.36 138 3.4 1.1 24.6 35 180 3 10T 14
142 3.6 107 4.6 210 0.7 15.5 -0.4 23.9 35 234.29 2 9T 13
15 15
135 2.9 103 3.89 142 1 12.1 4.9 28.2 40 195 3 8T 12
410 0 15 15
0 8T 13
1 15 15
134 5.5 102 3.93 51 10.4 14 -15 10.8 100 226 2 15 15
0 15 15
141 6.2 116 4.55 163 7.6 12.8 -10.3 15 40 210 2 10 10
15 15
136 4 108 3.98 229 1.2 9.7 1.8 25 24 429.17 0 15 15
147 3.9 111 3.92 124 0.8 8 -0.5 24 25 304 1 4T 6
142 3.7 111 4.27 114 1.1 7.9 0.9 25.2 21 461.9 0 15 15
134 6.8 103 4.07 119 3.5 8.5 -7.4 17.7 30 223.33 2 2T 3
140 3.2 105 4.17 128 1 7.5 -2.7 20.6 30 173.33 3 7T 10
150 2.9 122 4.51 213 2.9 8.1 -4.8 21 31 158.06 2 12 12
0 15 15
30 233.33 2 4T 6
15 15
0 15 15
143 3.2 110 4.64 108 2.3 8.7 -0.3 26.1 60 133.33
0 15 15
0 15 15
0 15 15
133 5.1 108 4.38 222 12.7 9.6 -21.7 8.3 50 138 3 2T 3
0 15 15
131 3.7 104 4.09 83 0.9 7 -5 20.1 50 84 4 2T 3
0 25 15
1 15 15
147 3.1 112 4.47 177 1.5 10.3 3.2 27 21 261.9 2 15 15
0 15 15
138 3.2 103 4.09 120 5.3 8 3.4 26.7 45 113.33 3 9T 13
1 13 13
145 1.7 125 2.69 69 0.6 5.5 -12.6 10.4 21 747.62 0 8T 12
1 15 15
0 15 15
1 15 15
144 3.4 111 4.48 216 2.6 13.2 0.3 24.5 31 374.19 1 3T 6
134 3.5 107 4.52 98 0.7 9.2 1.8 25.5 35 262.86 2 15 15
0 15 15
149 3.3 119 3.09 80 2 7.1 -11.3 17.7 100 60 2 15 15
139 3 105 4.52 94 1.3 9.9 7.8 31.3 30 303.33 1 9T 13
143 2.8 106 3.98 127 1 9.2 12.8 34.7 35 191.43 3 6T 9
0 15 15
139 3.6 105 3.78 234 1.4 9.2 3.7 28.5 28 160.71 2 15 15
139 3.5 102 4.67 212 1.8 12.8 3.4 27.9 30 290 2 8T 11
142 4.5 111 4.36 164 2.1 8.8 6.6 27.8 30 233.33 2 3T 4
140 3.4 107 4.57 121 1.1 12.6 2.6 26.1 21 328.57 1 4T 6
154 3.2 115 3.92 205 1.5 13.6 13 36.5 31 261.29 2 15 15
0 15 15
134 3.7 102 3.94 118 2.4 8.8 -2.9 18.7 21 561.9 0 3T 4

GCS7COD vent7 PLATE7 PLAT7COD PLATE7CODBIL7 BIL7COD PR7 SBP7 DP CVS7 AKINEXP RIFLE7 AKIN7
2 1 225000 0 0.7 0 100 140 90 0 0 0
3
0 0 250000 0 0 0.6 0 90 110 55 0 3 3
1 1 132000 1 1 1.3 1 110 150 85 0 3 3
0 0 0.3 0 80 110 70 0 0 0
0 0
1 1 52000 2 1.2 0 90 140 80 0 3 3
1 45000 3 1 0 110 130 70 4 1 1
3
0 0 178000 0 0.7 0 76 120 70 0 0 0
3
1 1 120000 1 2.2 2 80 150 90 0 0 0
1 0 110000 1 0.8 0 115 120 70 0 2 2
3
4 1 100000 2 1 0 4 0 0
0 0 156000 0 6 3 95 125 80 0 0 0
0 0 230000 0 0.7 0 120 115 65 2 2 2
3
0 0 264000 0 1.3 1 110 130 80 0 0 0
1 1
0 0 160000 0 0.3 0 90 130 80 0 3 3
0 0 250000 0 0.6 0 90 130 80 0 0 0
1 1 40000 3 19.5 4 125 125 70 2 2 2
1 1 400000 0 0.4 0 96 150 80 0 2 2
0 0 200000 0 0.6 0 80 120 70 0 3 3
0 0
2 1 191000 0 1.1 0 82 130 66 0 0
0 0 285000 0 0.6 0 90 140 80 0 0 0
3 3 3
31 1 160000 0 0 0.6 0 110 120 90 0 0 0
3
0 0 210000 0 0.6 0 90 130 80 0 0 0
0 0 150000 1 1.2 0 116 97 60 4 1 1
0 0 160000 0 1.4 1 74 130 70 0 0 0
2 0 11000 4 2.9 2 100 140 80 0 0 0
0 0 75000 2 2 2 85 130 70 0 3 3
0 0 170000 0 0.8 0 85 120 60 0 0 0
3
3 1 55000 2 6.31 3 100 140 80 0 3 3
3
0 0 60000 2 1 0 90 145 80 0 3 3
4 1 37000 3 8 3 125 100 50 4 3 3
2 1 144000 1 1 0 90 120 70 2 3 3
2 0 22000 3 9 3 3 3
0 0 80000 2 0.7 0 90 160 80 0 1 1
3 1 80000 2 2 2 130 120 70 0 0 0
0 0 246000 0 1.7 1 80 120 80 0 0 0
0 0 100000 2 1.2 0 80 140 80 0 3 3
60000 2 6 3 2 2
0 0 160000 0 0.6 0 90 130 80 0 2 2
0 0 150000 1 0.8 0 70 130 80 0 0 0
0 0 107000 1 0.8 0 90 130 80 0 3 3
4 1 90000 2 0.8 0 50 150 70 4 3
0 0 105000 1 0.8 0 105 160 90 0 3 3
0 0
4 1 36000 3 9.2 3 130 110 70 2 3 3
0 0 185000 0 0.6 0 85 120 80 0 0 0
0 0 80000 2 1 0 90 140 90 0 3 3
0 0 75000 2 0.7 0 120 110 60 0 1 1
3 3
0 0 215000 0 24 4 100 120 80 0 0 0
3
1 1 8000 4 12.9 4 115 124 62 2 2 2
1 0 110000 1 7 3 110 120 70 0 0 0
3
2 1 110000 1 0.9 0 90 170 100 0 2 2
0 0 250000 0 0 1.6 1 85 135 80 0 0 0
3
0 0 126000 1 0.6 0 95 150 80 0 1 1
0 0
0 0 170000 0 0.8 0 90 150 75 0 0 0
3 1 185000 0 0.6 0 100 120 80 0 0 0
0 0 75000 2 0.94 0 70 125 60 0 0 0
0 0 50000 3 1 0 80 130 90 0 3 3
0 0 6000 4 1.4 1 125 135 75 0 3 3
1 1 120000 1 1.3 1 95 115 70 0 0 0
3 1 148000 1 0.8 0 85 140 65 0 0 0
3
0 0 53000 2 8.2 3 100 140 90 0 0 0
0 0 185000 0 0.6 0 100 120 70 0 0 0
3
2 1 180000 0 1 0 90 150 85 0 0 0
4 1 200000 0 0.6 0 80 120 80 0 1 1
3 1 150000 1 0.9 0 120 110 70 0 0 0
0 0 166000 0 1.1 0 105 120 75 0 1 1
0 0 160000 0 0.7 0 85 110 70 0 0 0
0 0
3
3
2 2
4 1 230000 0 9.6 3 100 130 80 0 0 0
2
0 0
PREATN UNa Ucreat SNA SCR FeNa FENALESS1 TAKIPAKI TAKIPAKINUMHD RENALOCAT7MORTALITYoutcomeat7
?PRE PAKI 1 0 RECOVEREDNOT EXPIREDNOTIMPROVED
ATN/PRE 3 63.43 147 2.61 0.08 0 PAKI 1 0 EXPIRED EARLIER WITHOUT RECOVERYEXPI ED EXPIRED
ATN PAKI 1 1 PAKI NOT EXPIREDIMPROVED
ATN 5 41.65 138 3.78 0.33 0 PAKI 1 1 PAKI NOT EXPIREDNOTIMPROVED
PRE 64 107.12 146 1.15 0.47 0 TAKI 0 0 RECOVEREDNOT EXPIREDIMPROVED
?PRE 122 146 144 1.25 0.73 0 TAKI 0 0 RECOVEREDNOT EXPIREDIMPROVED
?ATN 91 42.6 132 6.06 9.81 1 PAKI 1 1 PAKI WITH IMPROVING RENAL FUNCTIONNOT EXPIREDIMPROVED
?PRE PAKI 1 0 PAKI WITH IMPROVING RENAL FUNCTIONNOT EXPIREDNOTIMPROVED
ATN 5 40.3 152 2.5 0.2 0 PAKI 1 0 EXPIRED EARLIER WITHOUT RECOVERYEXPI ED EXPIRED
PRE 91 108.16 134 0.95 0.6 0 TAKI 0 0 RECOVEREDNOT EXPIREDIMPROVED
ATN 82 103.73 141 2.56 1.44 1 PAKI 1 1 EXPIRED EXPIRED EXPIRED
PRE 189 170 153 0.92 0.67 0 TAKI 0 0 RECOVEREDNOT EXPIREDNOTIMPROVED
?ATN 31 113.16 140 3.6 0.7 0 PAKI 1 1 PAKI WITH IMPROVING RENAL FUNCTIONNOT EXPIREDNOTIMPROVED
ATN PAKI 1 0 EXPIRED WITHOUT RECOVERYEXPIRED EXPI ED
?PRE 169 30.47 138 1.54 6.19 1 TAKI 0 0 IMPROVED WITH EXPIRY AT DAY 7EXPIRED EXPIRED
?PRE 78 45.57 141 2.13 2.59 1 PAKI 1 0 RECOVEREDNOT EXPIREDIMPROVED
?PRE 87 36.95 143 2.09 3.44 1 PAKI 1 0 PAKI NOT EXPIREDIMPROVED
ATN 69 45.26 139 5.6 6.14 1 PAKI 1 1 DAMA
?PRE 104 35.73 147 2.32 4.59 1 PAKI 1 0 RECOVEREDNOT EXPIREDNOTIMPROVED
PAKI 1 0 IMPROVED WITH EXPIRY AT DAY 7EXPIRED EXPIRED
94 49.14 138 4 5.54 1 PAKI 1 0 EXPIRED EXPIRED EXPIRED
?ATN 105 12.69 141 1.1 6.46 1 EXPIRED 2 0 EXPIRED EXPIRED EXPIRED
ATN 130 15.93 137 3.62 21.56 1 PAKI 1 1 PAKI NOT EXPIREDIMPROVED
PRE 16 75.15 131 1.61 0.26 0 TAKI 0 0 RECOVEREDNOT EXPIREDIMPROVED
ATN PAKI 1 0 PAKI NOT EXPIREDNOTIMPROVED
ATN PAKI 1 0 PAKI NOT EXPIREDNOTIMPROVED
ATN 105 5.24 138 2.16 31.36 1 PAKI 1 1 PAKI NOT EXPIREDIMPROVED
PRE 151 24.9 143 1.05 4.45 1 TAKI 0 0 RECOVEREDNOT EXPIREDIMPROVED
PRE 35 71.93 140 1.09 0.38 0 TAKI 0 0 RECOVEREDNOT EXPIREDNOTIMPROVED
?ATN 83 48.09 144 2.32 2.78 1 EXPIRED 2 1 EXPIRED EXPIRED EXPIRED
PRE TAKI 0 0 RECOVEREDNOT EXPIREDIMPROVED
ATN 60 35.54 139 1.86 2.26 1 PAKI 1 0 PAKI WITH EXP AT7IRED EXPIRED
ATN 107 29.72 144 3.79 9.48 1 EXPIRED 2 0 EXPIRED EXPIRED EXPIRED
PRE 114 76.33 150 0.69 0.69 0 TAKI 0 0 RECOVEREDNOT EXPIREDNOTIMPROVED
ATN 121 42.83 141 3.22 6.45 1 PAKI 1 0 DAMA DAMA DAMA
PRE 69 52.61 139 0.66 0.62 0 TAKI 0 0 RECOVEREDNOT EXPIREDIMPROVED
5 104.43 136 2.1 0.07 0 PAKI 1 0 EXPIRED EARLIER WITHOUT RECOVERYEXPI ED EXPIRED
ATN 9.5 100.59 140 1.73 0.12 0 TAKI 0 0 RECAKI NOT EXPIREDNOTIMPROVED
?ATN 24 71.26 142 1.44 0.34 0 TAKI 0 0 RECOVEREDNOT EXPIREDIMPROVED
PRE 5 29.52 148 2.89 0.33 0 PAKI 1 0 RECOVEREDNOT EXPIREDNOTIMPROVED
ATN PAKI 1 0 PAKI NOT EXPIREDIMPROVED
?ATN PAKI 1 0 RECOVEREDNOT EXPIREDIMPROVED
ATN 25 49.9 138 1.84 0.67 0 PAKI 1 0 EXPIRED EXPIRED EXPIRED
ATN 109 79.54 145 3.28 3.1 1 PAKI 1 0 PAKI NOT EXPIREDNOT EXPIRED
?ATN 39 74.55 131 1.32 0.53 0 PAKI 1 1 EXPIRED EXPIRED EXPIRED
PAKI 1 1 PAKI WITH IMPROVING RENAL FUNCTIONNOT EXPIREDNOTIMPROVED
ATN 149 13.53 144 1.92 14.68 1 PAKI 1 1 PAKI WITH EXP AT7IRED EXPIRED
ATN PAKI 1 1 PAKI NOT EXPIREDNOTIMPROVED
PAKI 1 0 PAKI WITH EXP AT7IRED EXPIRED
ATN PAKI 1 0 PAKI WITH IMPROVING RENAL FUNCTIONNOT EXPIREDIMPROVED
PRE 80 36.42 137 1.56 2.5 1 TAKI 0 0 IMPROVED WITH EXPIRY AT DAY 7EXPIRED EXPIRED
?PRE 27 92.23 131 1.92 0.43 0 PAKI 1 0 RECOVEREDNOT EXPIREDIMPROVED
ATN 71 51.43 136 4.51 4.58 1 PAKI 1 1 PAKI NOT EXPIREDIMPROVED
?ATN 57 27.21 143 1.07 1.57 1 PAKI 1 0 PAKI NOT EXPIREDNOTIMPROVED
ATN PAKI 1 0 PAKI NOT EXPIREDIMPROVED
?PRE 150 174 141 1.25 0.76 0 TAKI 0 0 RECOVEREDNOT EXPIREDIMPROVED
ATN 92 80.26 135 5.78 4.91 1 PAKI 1 1 PAKI NOT EXPIREDIMPROVED
ATN PAKI 1 0 PAKI WITH EXP AT7IRED EXPIRED
ATN+ AGN PAKI 1 1 PAKI NOT EXPIREDIMPROVED
PRE 116 35.3 132 0.69 1.72 1 TAKI 0 0 IMPROVED WITH EXPIRY AT DAY 7EXPIRED EXPIRED
EXPIRED 2 1 EXPIRED EXPIRED EXPIRED
ATN PAKI 1 1 PAKI NOT EXPIREDNOTIMPROVED
PRE 137 131.55 138 0.98 0.74 0 TAKI 0 0 RECOVEREDNOT EXPIREDIMPROVED
ATN 125 14.71 134 5.8 36.78 1 PAKI 1 1 PAKI NOT EXPIREDNOTIMPROVED
?ATN 5 75.17 151 1.53 0.07 0 PAKI 1 0 PAKI NOT EXPIREDNOTIMPROVED
ATN PAKI 1 1 PAKI WITH EXP AT7IRED EXPIRED
PRE TAKI 0 0 RECOVEREDNOT EXPIREDIMPROVED
ATN 14 81.66 131 2.6 0.34 0 PAKI 1 0 EXPIRED EARLIER WITHOUT RECOVERYEXPI ED EXPIRED
ATN 102 13.4 137 1.2 6.67 1 PAKI 1 0 PAKI NOT EXPIREDNOTIMPROVED
PRE TAKI 0 0 RECOVEREDNOT EXPIREDIMPROVED
ATN PAKI 1 0 EXPIRED EXPIRED EXPIRED
ATN PAKI 1 0 PAKI WITH IMPROVING RENAL FUNCTIONNOT EXPIREDNOTIMPROVED
PRE PAKI 1 0 RECOVEREDNOT EXPIREDIMPROVED
ATN 13 44.35 138 2.5 0.53 0 PAKI 1 1 EXPIRED WITHOUT RECOVERYEXPIRED EXPI ED
ATN 112 35 137 2.04 4.76 1 PAKI 1 0 PAKI WITH IMPROVING RENAL FUNCTIONNOT EXPIREDIMPROVED
?PRE 21 191.5 137 1.29 0.1 0 TAKI 0 0 RECOVEREDNOT EXPIREDIMPROVED
?PRE PAKI 1 0 RECOVEREDNOT EXPIREDIMPROVED
PRE 209 136.24 138 1.07 1.19 1 TAKI 0 0 RECOVEREDNOT EXPIREDNOTIMPROVED
?PRE 110 25.32 135 1.71 5.5 1 PAKI 1 0 RECOVEREDNOT EXPIREDIMPROVED
ATN 114 11.26 134 2.37 17.91 1 PAKI 1 0 PAKI NOT EXPIREDIMPROVED
ATN 44 1.46 138 2.64 57.65 1 PAKI 1 1 PAKI NOT EXPIREDNOTIMPROVED
?ATN 6 156.35 141 1.84 0.05 0 PAKI 1 0 IMPROVED NOT EXPIREDNOTIMPROVED
ATN 120 23.42 141 3.08 11.19 1 PAKI 1 0 RECOVEREDNOT EXPIREDNOTIMPROVED
ATN 36 85.69 139 3.84 1.16 1 PAKI 1 1 EXPIRED EXPIRED EXPIRED
?ATN 5 148.16 135 3.59 0.09 0 PAKI 1 1 RECOVEREDNOT EXPIREDIMPROVED
ATN PAKI 1 0 RECOVEREDNOT EXPIREDIMPROVED
ATN 85 53.09 140 1.51 1.73 1 PAKI 1 1 EXPIRED EXPIRED EXPIRED
PRE 112 110.08 136 1.05 0.79 0 TAKI 0 0 RECOVEREDNOT EXPIREDNOTIMPROVED
?ATN 133 66 145 1.39 1.93 1 PAKI 1 0 PAKI NOT EXPIREDNOTIMPROVED
PRE 146 17.8 143 0.91 5.22 1 TAKI 0 0 RECOVEREDNOT EXPIREDNOTIMPROVED
?ATN 40 95.96 142 1.99 0.58 0 PAKI 1 0 PAKI NOT EXPIREDIMPROVED
PRE 131 27.55 135 0.61 2.15 1 TAKI 0 0 RECOVEREDNOT EXPIREDIMPROVED
PRE 4 17.29 150 1.1 0.17 0 TAKI 0 0 RECOVEREDNOT EXPIREDIMPROVED
?ATN PAKI 1 1 EXPIRED EARLIER WITHOUT RECOVERYEXPI ED EXPIRED
?ATN 65 46.89 134 3.2 3.31 1 PAKI 1 0 EXPIRED EXPIRED EXPIRED
?ATN 49 38.4 132 2.02 1.95 1 EXPIRED 2 0 EXPIRED EXPIRED EXPIRED
?PRE PAKI 1 0 RECOVEREDNOT EXPIREDNOTIMPROVED
PAKI 1 0 PAKI WITH EXP AT7IRED EXPIRED
ATN 112 84.26 141 5 4.71 1 EXPIRED 2 1 EXPIRED EXPIRED EXPIRED
109 14.69 147 1.5 7.57 1 EXPIRED 2 1 EXPIRED EARLIER WITHOUT RECOVERYEXPI ED EXPIRED
ATN 84 117.86 138 7.27 3.75 1 PAKI 1 1 EXPIRED WITHOUT RECOVERYEXPIRED EXPI ED
117 24.12 145 2.3 7.69 1 EXPIRED 2 0 EXPIRED EARLIER WITHOUT RECOVERYEXPI ED EXPIRED
PRE 108 25.25 135 2.2 6.97 1 TAKI 0 0 RECOVEREDNOT EXPIREDIMPROVED
